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Healthy pregnancy requires a tightly regulated materno-fetal dialogue for processes 
such as embryo implantation, endometrial decidualisation (in the mouse), placentation 
and maternal adaptation to occur. Disruption of placental development as well as 
maternal adaptation can lead to fetal intrauterine growth restriction (IUGR) which 
increases the risk of late miscarriage/stillbirth (e.g. 53% of preterm stillbirth and 26% 
of term stillbirth are found to be IUGR). Furthermore, IUGR is a risk factor for 
neurodevelopmental conditions in childhood and for a spectrum of related adult health 
disorders such as cardiovascular disease and type II diabetes, often termed metabolic 
syndrome. Despite these pregnancy disorders being common (e.g. 1 in 200 pregnancies 
results in stillbirth in the UK) the molecular lesion(s) underlying their pathophysiology 
are poorly understood and in particular those with placental and/or maternal 
aetiologies most frequently remain unexplained.  
Here we investigate the hypothesis that poly(A)-binding protein 4 (PABP4) is required 
for healthy pregnancy in mice. PABP4 is an RNA-binding protein and a member of 
the PABP family which are central regulators of mRNA translation and stability. Using 
all four permutations of wild-type and knock-out crosses, we find that maternal 
PABP4-deficiency results in a reduced litter size and IUGR. The number of 
implantations at e8.5 were not reduced in Pabp4-/- females, implying that the reduced 
litter size was not a consequence of decreased ovulation, fertilisation or implantation 
frequency. Further longitudinal analysis (at e13.5, e15.5 and e18.5) reveals that fetal 
death primarily occurred between e18.5 and birth, suggesting these mice may provide 
a unique opportunity to inform on the maternal causes of stillbirth. The onset of IUGR, 
which was found to be symmetrical in nature, was established by e15.5 preceding the 
majority of fetal death.  
During pregnancy, a materno-fetal dialogue directs and responds to changes in gene 
expression to give rise to the placenta and adapt the maternal physiology. Defects in 
these processes may result in reduced growth and/or fetal death and were examined in 
Pabp4-/- mice to shed light on the mechanistic basis of these related phenotypes. Fetal 
to placental (F:P) weight ratio, whose changes can be indicative of placental 
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insufficiency or placental  adaptation in an attempt to aid fetal growth, was found to 
be increased in Pabp4-/- dams at e15.5 and e18.5 due to the presence of IUGR fetuses 
with placentas of normal weight. Consistent with this observation, placental volume 
was unchanged at e18.5. Total placental weight and volume alone fails to discriminate 
potential differences in the individual placental zones which include the labyrinth 
zone, where materno-fetal gas and nutrient exchange occur; the junctional zone, which 
has endocrine functions including those that promote maternal adaptation; and the 
decidua basalis, derived from the maternal endometrium and is the site of trophoblast 
invasion and maternal vascular remodelling in early pregnancy. Therefore, volumetric 
analysis of these zones and the maternal blood spaces, which transcend the decidua 
basalis and junctional zone, was undertaken. This showed no change in the maternal 
blood spaces or the labyrinth, the latter being the zone whose size is most frequently 
altered in IUGR. Critically however, the size of the maternally-derived decidua basalis 
was increased with a concurrent decrease in the size of the junctional zone. These 
morphological changes may play a causative role either through directly affecting 
placental function and/or by the reduced junctional zone failing to promote appropriate 
maternal adaptation. Alternatively, they may reflect compensatory adaptations to a 
primary defect elsewhere in the mother.  
Complementing these morphological studies, functional studies were undertaken: 
remodelling of maternal vasculature and the resistance index of vessels delivering 
blood to the fetus were assessed; as was delivery of nutrients to the fetus (measured by 
fetal glucose); and systemic maternal adaptations (maternal hormonal profile, 
circulating glucose levels and organ weights). Uterine, umbilical and decidual spiral 
arteries were examined, but displayed no apparent differences suggestive of normal 
blood supply to the fetus. However fetal blood glucose was reduced suggesting a 
reduced delivery of nutrients important for fetal growth. This was not due to lower 
circulating maternal blood glucose levels, and mRNA levels of the placental glucose 
transporters Glut-1 and Glut-3 were not reduced but upregulated, suggestive of an 
attempt to compensate for reduced fetal glucose. Furthermore, upregulation of at least 
one system A amino acid transporter mRNA, Snat-2, was observed. The maternal 
physiological state of PABP4-deficient dams showed deviations in some organ 
weights (e.g. spleen weight is reduced at e13.5 and e15.5) and the levels of some 
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circulating hormones (e.g. estradiol is deceased whereas progesterone is increased at 
e18.5). However, future work will be required to determine which, if any, of these 
changes are primary defects rather than downstream consequences and to identify 
which mis-regulated mRNAs/pathways within in the materno-fetal dialogue underlie 
the phenotype.  
Taken together, my results suggest that the regulation of mRNA translation/stability 
by PABP4 is critical to achieving the correct pattern of gene expression within the 
materno-fetal dialogue to enable appropriate placentation and maternal adaptation. 
Furthermore, my results suggest that Pabp4-/- mice provide a unique opportunity to 
further understand the maternal causes of a spectrum of related pregnancy 






In the UK, approximately 1/200 babies are stillborn, making it more common than 
both Down’s syndrome (1/1000) and Sudden Infant Death syndrome (1/2000). 
Stillbirth refers to a loss of pregnancy from 24 weeks till birth and often occurs without 
warning. Despite its frequency, relatively little is heard about this devastating 
condition as often parents find it hard to talk about what has happened. Surprisingly, 
UK stillbirth rates have only decreased by 5% (2000 to 2008). One barrier to progress 
in tackling stillbirth is our lack of knowledge about why it happens, with roughly 60% 
of cases being “unexplained” as both mother and baby (also known as a fetus) appeared 
healthy. Interestingly, another complication of pregnancy, intrauterine growth 
restriction (IUGR), is present in many of these unexplained cases and therefore IUGR 
is considered a “risk-factor” for stillbirth, being present in 26% of cases. IUGR refers 
to a condition where a baby’s growth pace is slow-downed in the womb, meaning they 
are smaller than would normally be expected. This occurs in 3-7% of pregnancies. 
Importantly, IUGR is not only a risk factor for stillbirth and death within the first 
weeks after birth, but also for developmental problems in childhood and adult health 
conditions such as heart disease and diabetes.  
Currently, they only way to protect growth restricted babies from the risk of stillbirth 
is early delivery. However this is fraught with problems as many of these babies would 
have survived and pre-term (early) birth is associated with its own health and 
developmental complications. Moreover, to prevent stillbirth of babies that aren’t 
small, this approach would need to be applied to all pregnancies presenting social, 
ethical and medical problems. Therefore, it is important that we gain more knowledge 
of how such pregnancy complications arise, as this is the first step towards being able 
to better identify at risk pregnancies and to developing better clinical interventions. 
Where investigated, many cases of IUGR and stillbirth have been found to be 
associated with problems with the placenta, an organ which develops during 
pregnancy. Thus these studies highlight this pregnancy-specific organ, which provides 
oxygen and nutrients which are critical for the growing baby, as an important factor in 
these pregnancy complications.  
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Animal models are key to understanding the basis of human disease as they allow for 
detailed investigations which can uncover underlying problems and ascertain whether, 
and how, they lead to disease. Importantly in this regard, we have developed a mouse 
model that mirrors critical aspects of this spectrum of human pregnancy complications, 
in which we observe IUGR and some, but not all, fetuses die in late pregnancy. Using 
this model my studies have already shown that the development of the placenta is 
affected, resulting in a change in its structure rather than size and indicate that its 
ability to transfer nutrients to fetuses may also be compromised. In addition to 
providing oxygen and nutrients, the placenta also plays an important role in directing 
the numerous changes that have to happen in the female body to support pregnancy. 
We find that several aspects of “maternal adaptation” including changes in organ 
weights and hormone levels don’t appear to have occurred correctly. Finally, we have 
found that even before pregnancy the red blood cells of the adult female mice, which 
carry oxygen around the body, are smaller than normal and contain less haemoglobin 
(the red blood cell component that carries oxygen). The extra “strain” of pregnancy 
can result in such “pre-existing” conditions becoming problematic. Importantly, each 
of these observations has the potential to explain the poor fetal growth and survival. 
Thus, future work will aim to identify which of them may be causative and to provide 
a detailed understanding of the series of events that lead to these abnormalities, with 
the long term aim of providing better diagnostic tools and interventions to improve 
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Although international definitions vary, in the UK late miscarriage is defined as a 
pregnancy loss between 12-24 weeks of pregnancy, with stillbirth occurring after 24 
weeks (Smith and Fretts, 2007). In the UK, around 5/1000 babies are stillborn each 
year (Downe et al., 2012). Comparatively, for every 1,000 babies born, only 1 will 
have Down’s syndrome (Down’s syndrome association) and stillbirth is 10 times more 
common than Sudden Infant Death Syndrome (Information and Statistics Division 
NHS Scotland. Scottish perinatal and infant mortality report 2000. Edinburgh: ISD 
Scotland Publications, 2001). Despite this, UK stillbirth rates have decreased by only 
5% in the period from 2000 to 2008 meaning there is an urgent unmet clinical need for 
research into the underlying causes of mid-late fetal mortality.  
One of the risk factors for late miscarriage and stillbirth is intra-uterine growth 
restriction (IUGR) (Gardosi et al., 2013). The American College of Obstetricians and 
Gynaecologists define IUGR as a condition where the fetus is below the tenth 
percentile of its genetic growth potential with respect to gestational age 
(Gynecologists., 2001). IUGR may complicate 7-10% of all pregnancies (Demicheva 
and Crispi, 2014) and is of importance not only because it may lead to mortality, but 
also morbidities. For instance, in utero cardiac dysfunction can persist postnatally and 
may lead neurodevelopmental problems in childhood and a higher cardiovascular risk 
later in life (Demicheva and Crispi, 2014). Other long term consequences of IUGR 
include an increased risk of developing metabolic syndrome, obesity, insulin 
resistance and well as type II diabetes in adulthood (reviewed by (Salam et al., 2014). 
Whilst the aetiology of IUGR, late miscarriage and stillbirth is attributable to multiple 
factors including fetal chromosomal abnormalities (10%) and haemorrhage (15%), in 
59% of cases fetal deaths remain unexplained (Flenady et al., 2011)  although 23% of 
these cases display IUGR. Where investigated, poorly-defined causes such as 
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uteroplacental insufficiency are often cited, but the actual molecular lesion(s) 
underlying these, in particular those with a maternal origin remain unknown.  
Despite differences to humans, mice provide a powerful model for studying human 
pregnancy as many of the key features of pregnancy are maintained. In humans and 
mice, the yolk sac plays a role in feto-maternal exchange in early pregnancy with the 
placenta taking over in later pregnancy (reviewed by (Cox et al., 2009). In contrast to 
humans, the yolk sac is integrated into the chorioallantoic placenta in mice becoming 
an intraplacental yolk sac (IPYS) which remains functional throughout pregnancy. In 
both species the placenta is haemochorial, meaning that fetal tissue is directly in 
contact with maternal blood, and discoid in shape where chorionic villi are arranged 
in a circular plate. Furthermore, maternal blood from the uterine arteries enter the 
placenta from large diameter spiral arteries located in the maternal decidua which are 
invaded only superficially in mouse in comparison to the human where in addition to 
the decidua they are also remodelled in the myometrium. In both human and mouse 
the umbilical vessels connect the fetal capillaries of the placental exchange region with 
the fetal body circulation (Georgiades et al., 2002a). From an experimental point of 
view mice offer a number of other advantages including an ability to manipulate its 
genome, short reproductive cycle and accelerated lifespan. However, the short 
reproductive cycle means that the mouse embryo is born almost immediately after all 
the organs develop in contrast to the human embryo which continues to stay in the 
uterus for a few more months at the end of organogenesis so that organs continue to 
grow and eventually develop into their proper sizes for birth (Xue et al., 2013). 
Observations in humans and studies in model organisms including mice, have 
highlighted the critical role that the placenta plays in the development and growth of 
the fetus. Disruption of placental development and/or function can lead to placental 
insufficiency, fetal growth restriction and fetal mortality (Rossant and Cross, 2001) . 
Successful placental development, which begins as early as embryonic day (e) 3.5 in 
the mouse, is complex and requires accurate embryo implantation, endometrial 
decidualisation (transdifferentiation of endometrial fibroblasts into decidual cells) and 
remodelling of maternal arteries. As a result, placentation is dependent upon a tightly 
regulated dialogue between the fetus and the mother (materno-fetal dialogue). The 
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placenta, in turn, also drives many of the required changes in maternal physiology (i.e. 
maternal adaptation). This complex materno-fetal dialogue is important for healthy 
pregnancy and requires exquisite regulation of gene expression. Gene expression can 
be controlled at many levels including transcription (Coulon et al., 2013), mRNA 
processing and export (Hocine et al., 2010), mRNA translation and/or mRNA stability 
(Burgess and Gray, 2010; Dever and Green, 2012; Fatscher et al., 2015; Moore and 
Proudfoot, 2009; Orphanides and Reinberg, 2002; Roux and Topisirovic, 2012)). 
However, although recent studies in other systems have drawn attention to the 
importance of translational control (Schwanhäusser et al., 2011), little is known 
regarding the contribution of regulated mRNA translation and/or stability to materno-
fetal dialogue (Rossant and Cross, 2001). Interestingly in this regard, we have found 
that deletion of a member of the poly(A)-binding protein family (PABP), which are 
regulators of mRNA translation and stability, results in maternal genotype-dependent 
mid-late gestational mortality and IUGR.  
 
1.2 Eukaryotic gene expression 
 
For cells to carry out their function and respond to environmental changes 
appropriately, genes must be decoded into proteins in the correct spatiotemporal 
manner. A balance between the protein’s production and degradation determines the 
quantity of a specific protein in a cell, at any given time. In eukaryotes the key 
processes for protein production, are transcription and RNA processing followed by 
translation. Many of these steps involve RNA-binding proteins, of which the poly(A)-





1.2.1 mRNA transcription and processing 
 
The conversion of the genetic information, encoded by deoxyribonucleic acid (DNA), 
into proteins starts in the nucleus with creation of pre-messenger ribonucleic acids 
(pre-mRNAs), which when processed, form the template for protein synthesis. RNA 
polymerase II (RNAPII) transcribes all protein-coding mRNAs and most non-coding 
RNAs (e.g. miRNAs) in a three step process; initiation, elongation and termination. 
During initiation, RNAPII, associated with transcription factors, binds to the promoter 
region of genes which is normally near their 5’ end (reviewed by (Sims et al., 2004). 
The activity of promoters is controlled by the binding of regulatory factors but can also 
be regulated by sequences located at distant sites such as enhancers (Erokhin et al., 
2015). The DNA is melted to expose the DNA template strand allowing it to be read 
in 3’ to 5’ direction, creating an RNA with complementary nucleotides in which 
thymine is replaced by uracil (reviewed by (Sims et al., 2004). Many mRNA 
processing steps occur post-transcriptionally, with the first being addition of a 
methylated guanine to the 5’ end of the emerging RNA strand. This confers stability, 
by protecting it from 5’ to 3’ exonucleases, enzymes which processively remove the 
5’ terminal nucleotides causing degradation (Hocine et al., 2010). Poly(A)-dependent 
termination couples transcription to 3’ end polyadenylation, through cleavage of the 
nascent pre-mRNA and addition of a poly(A)tail of approximately 100-200 adenine 
bases. Cleavage requires a number of factors including cleavage and polyadenylation 
specificity factor (CPSF) which also plays a role in polyadenylation by poly(A)-
polymerase (PAP). Polyadenylation is initially distributive but becomes progressive 
when the nascent poly(A) tail is bound by nuclear PABP (PABPN1, PABP2, PABII). 
PABPN1 enhances the affinity of PAP for poly(A) and also interacts with CPSF. The 
molecular ruler model for PABPN1 function proposes that loss of CPSF-PABPN1 
interactions as the poly(A) tail is extended, disrupts CPSF-PAP-PABPN1 complexes 
resulting in loss of progressive adenylation and therefore PAP, thereby determining 
poly(A) tail length (Eckmann et al., 2011). It is worth noting that about 50% of human 
mRNAs are thought to have alternative polyadenylation sites (APA), with PABPN1 
playing a role in polyadenylation selection (Hollerer 2014, pp. 16). Most eukaryotic 
mRNAs also contain non-coding regions, referred to as introns, which can be 
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interspersed between the exons in the pre-mRNA, and are removed by splicing to form 
“mature” mRNAs (Ghildiyal and Zamore, 2009; Hocine et al., 2010). Removal of 
introns and polyadenylation are both critical for mRNA export to the cytoplasm, with 
PABPN1 appearing to be an active driver of this process since both its targeting by 
viral proteins (Chen et al., 1998; Qiu and Krug, 1994) or siRNA knock-down block 
export (Apponi et al., 2010; Calado et al., 2000). Cytoplasmic PABPs (PABPCs, called 
PABPs hereafter) also shuttle to through the nucleus, although they are predominantly 
cytoplasmic in normally growing cells (Gorgoni and Gray, 2004; Mangus et al., 
2003)..However, nuclear functions for PABPs remains to be described but knock-
down experiments suggest that, in contrast to PABPN1, they are not required for 
mRNA export (Burgess et al., 2011). Indeed export of PABPs appears mRNA-
dependent, suggesting they exit bound to poly(A) tails, however, bulk exchange of 
PABPN1 by PABPs is thought to occur as mRNAs emerge into the cytoplasm 
(reviewed by (Muller-McNicoll and Neugebauer, 2013). Here, PABPs mediate the 
critical role of the poly(A) tail in mRNA translation and stability, mainly by promoting 
the closed-loop mRNA conformation, which enhances ribosome subunit recruitment 
and inhibits access of 3’ to 5’ exonucleases. 
 
1.2.2 Overview of mRNA Translation 
 
Mature mRNAs contain a 5’cap, a 3’poly(A) tail and an open reading frame flanked 
by 5’ and 3’ untranslated regions and can be specifically localised, stored, degraded 
and/or translated to produce proteins (Jackson et al., 2010) following their export into 
the cytoplasm. Translation is mediated by large ribonucleoprotein machines called 
ribosomes, that consist of a 40S small subunit and 60S large subunit in eukaryotes, and 
which together with tRNAs and numerous translation factors decode the nucleotide 
triplets within the open reading frame (also called coding sequence) to the correct 
sequence of amino acids, thereby synthesizing polypeptides. Similarly to transcription, 
translation is divided into three phases: initiation, elongation and termination. 
Initiation, where the translation machinery is assembled on mRNAs, is widely 
 16 
considered to be the main rate limiting regulatory step in translation, and will be 
discussed in more detail below. Following initiation, elongation ensues and results in 
the decoding of the nascent peptide. Termination occurs, when a stop codon (UAA, 
UAG or UGA) is encountered and the nascent peptide is released (Dever and Green, 
2012). In contrast to initiation, elongation and termination are broadly similar in 
prokaryotes and eukaryotes (reviewed by (Kozak, 1999). 
 
 
1.2.3 Translation initiation 
 
Initiation, requires a complex array of eukaryotic initiation factors (eIFs) and can be 
sub-divided into two initial mRNA-independent and seven mRNA-dependent stages: 
1. Assembly of a ternary complex between the initiator tRNA, and eIF2 bound by GTP 
2. Recruitment of the ternary complex to the small ribosomal subunit and associated 
factors (i.e. eIF1, eIF1A, eIF3, eIF5) to form a 43S pre-initiation complex (PIC). 3. 
Binding of eukaryotic initiation factor 4F (eIF4F), composed of eIF4E, eIF4G and 
eIF4A, to the 5’ cap (reviewed by (Jackson et al., 2010). eIF4E is the cap binding 
factor but its affinity for the cap is enhanced in an RNA-dependent manner by eIF4G. 
4. Removal of secondary structure from the 5’UTR to allow PIC binding, a process in 
which the ATP-dependent RNA helicase action of eIF4A is promoted by an additional 
factor, eIF4B. 5. Recruitment of the PIC at or near the cap, a process facilitated in part 
by the interaction between mRNA-bound eIF4G and eIF3 on the small ribosomal 
subunit. 6. The PIC then moves or “scans” along the 5’UTR until it reaches a suitable 
start codon, normally but not always an AUG. 7. Start site recognition involving base 
pairing between the Met-tRNAi and the AUG in the peptidyl-tRNA (P) site of the 
small ribosomal subunit and 8. eIF5-dependent hydrolysis of eIF2-GTP to eIF2-GDP 
and release of eIF2-GDP and several other eIFs. eIF2-GDP must be recycled to eIF2-
GTP by eIF2B for subsequent rounds of initiation. 9. Lastly, large (60S) subunit 
joining occurs, catalyzed by eIF5B, in a GTP-dependent manner, to produce an 80S 
initiation complex containing Met-tRNAi base-paired to AUG in the P site, which is 





Figure 1.1. The initiation pathway in eukaryotes. (From (Merrick, 2003)) 
 
Surprisingly, since these events occur on the 5’UTR, the 3’poly(A) tail is also pivotal 
for efficient translation, through the action of PABPs which are a key component in 
the complex that forms  the closed-loop conformation (reviewed by (Gallie, 1991).  
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1.2.4 mRNA decay 
 
The extent to which an mRNA is utilised to make protein is not only affected by its 
rate of translation but also by its stability, which varies by orders of magnitude between 
mRNAs (reviewed by (Guhaniyogi and Brewer, 2001). The main and rate limiting step 
in mRNA decay is removal of the poly(A) tail (reviewed by (Brook and Gray, 2012). 
Poly(A) tails are initially trimmed by the PAN2-PAN3 complex until reaching a length 
of approximately 110 nucleotides at which point they undergo more rapid degradation 
by the ccr4-Not complex. Upon removal of the poly(A) tail, mRNAs are rapidly 
degraded either by dcp1/dcp2 driven decapping and 5’ to 3’ degradation by Xrn1 
exonuclease or in a 3’-5’ direction by the exosome (reviewed by (Fatscher et al., 2015) 
). Not all mRNAs are degraded in this manner, for instance, those containing premature 
stop-codons are degraded in a deadenylation independent manner by nonsense-
mediated decay pathway (reviewed by (Brook and Gray, 2012).  
 
1.2.5 Dysregulated mRNA translation or stability are 
associated with disease. 
 
mRNA translation and stability are both highly regulated processes which are 
important in almost every aspect of biology . For instance, global translation may be 
down-regulated in response to cell stress, or up-regulated in response to growth factors 
and hormones (Ivanov and Anderson, 2013), enabling cells to respond to environment 
cues. Such global changes are often mediated through signalling cascades that result 
in the phosphorylation of eIF2 or 4E-BP (e.g. mTOR). eIF2 phosphorylation by 
kinases including protein kinase RNA-like endoplasmic reticulum kinase (PERK) and 
protein kinase R (PKR) blocks eIF2-GDP to eIF2-GTP exchange, by eIF2B, limiting 
the amount of active eIF2 available for initiation. 4E-BP is phosphorylated by mTOR, 
and dependent on its phospho-status interacts with eIF4E to sequesters it, preventing 
eIF4F formation (reviewed by (Musa et al., 2016). To achieve the necessary 
reprogramming of gene expression, global control is often accompanied by mRNA-
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specific translational and/or stability control of individual or small subset of mRNAs 
e.g. encoding proteins required to adapt to a specific cell stress (reviewed by (Spriggs 
et al., 2010). However, mRNA-specific regulation often occurs in the absence of global 
changes in protein synthesis, contributing to a wide variety of biological processes and 
normally involves regulatory elements located within the untranslated regions which 
frequently provide binding sites for trans-acting proteins/protein complexes (reviewed 
by (Besse and Ephrussi, 2008). One of the best characterised examples of mRNA 
specific regulation is in iron homeostasis (reviewed by (Wilkie et al., 2005) where, 
dependent on intracellular iron concentrations, iron regulatory protein binds to 5’UTRs 
of target mRNAs (e.g. iron storage protein, ferritin) to repress their translation and the 
3’UTR of other target mRNAs to enhance their stability (e.g. transferrin receptor 
which imports iron). 
Similarly intricate networks have been delineated using the power of Drosophila 
genetics to reveal how morphogen gradients are created by a combination of mRNA 
specific translation and decay (e.g. of Oskar, Bicoid, Nanos, Hunchback) during 
development to establish body patterning (reviewed by (Gurdon and Bourillot, 2001; 
Lipshitz, 2009). Localised translation underlies multiple aspects of neuronal biology, 
including dendrite branching and plasticity and is crucial for processes such as learning 
and memory (reviewed by (Gray et al., 2015; Holt and Schuman, 2013). Finally, much 
attention has been focused in recent years on microRNAs (miRs) that bind to the 
3’UTR of specific mRNAs to repress their translation and/or induce their decay 
(reviewed by (Janas and Novina, 2012).  
Not surprisingly, aberrant control of mRNA translation and stability are associated 
with a wide range of diseases (reviewed by (Hollams et al., 2002). For example, 
dysregulated translation is linked to altered proliferation, survival, and angiogenesis 
and is thus omnipresent in human cancers (reviewed by (Bhat et al., 2015). Whilst 
cancer can be associated with specific translation factors, ribosomes, or upstream 
signalling pathways, one of the best described examples is eIF4E whose oncogenic 
potential was first described in cell lines (Lazaris-Karatzas et al., 1990) (Rinker-
Schaeffer et al., 1993) and later in mice (Ruggero et al., 2004). eIF4E overexpression 
is commonly associated with malignant progression of a number of human cancers 
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such as breast, colon, bladder, lung, prostate, head and neck cancers as well as 
leukaemias, lymphomas and melanomas (De Benedetti and Graff, 2004) and drives 
cellular transformation, tumorigenesis, and metastatic progression in experimental 
models (reviewed by (Graff et al., 2008). Consequently it is an adverse prognosis 
marker in some of these cancers (Khosravi et al., 2015) but is also an emerging 
anticancer drug target (Lu et al., 2016). Similarly other components are causative in a 
wide variety of genetic conditions such as leukoencephalopathy with Vanishing White 
Matter (VWM) as a result of inherited mutations affecting eIF2B subunits, genetic 
syndromes including the Wallcott-Ralinson syndrome, a rare autosomal recessive 
disorder characterised by permanent neonatal or early infancy insulin-dependent 
diabetes in which eIF2AK3 is mutated (Delepine et al., 2000) and in numerous 
ribosomopathies where the biosynthesis of ribosomes is affected (reviewed by 
(Armistead and Triggs-Raine, 2014).   
Disease can also be caused by dysregulation of specific mRNAs by mutations in 
regulatory elements like in hyperferritinamemia cataract syndrome where the iron 
responsive elements (IREs) that finely regulate ferritin mRNA translation in response 
to iron availability are mutated (Roetto et al., 2002). Other example include 
dysregulation of mRNA stability whereby altered mRNA stability, for example of 
human β-globin mRNA leads to thalassemia, an inherited blood disorder in which an 
abnormal form of haemoglobin is made (reviewed by (Peixeiro et al., 2011). Mutations 
can also be in the regulatory trans-acting factors such as fragile X mental retardation 
protein (FMRP) which both represses translation and regulates mRNA stability. 
Absence of FRMP disrupts this regulation and leads to fragile X syndrome (FXS), a 
cause of intellectual disability and common cause of autism (reviewed by (Richter et 





1.2.6 Translation and mRNA stability in reproductive biology 
 
Due to periods of transcriptional quiescence, germ cells and early embryos have 
provided many examples of mRNA-specific regulation as changes in the patterns of 
protein synthesis can only be achieved by the activation, repression or destruction of 
pre-existing mRNAs. The best characterised mechanism of regulating mRNAs in germ 
cells is by dynamic changes in poly(A) tail length where increase in the poly(A) tail 
generally leads to translational activity, whilst shortening correlates with translational 
inactivation (reviewed by (Brook et al., 2009; McGrew et al., 1989; Vassalli et al., 
1989). For example, oocyte mRNAs contain 3′UTR elements that target them for rapid 
poly(A) tail shortening following export into the cytoplasm so that they remain 
translationally silent until they are required. Once required their poly(A) tail length is 
increased in a process known as cytoplasmic polyadenylation (reviewed by (Brook et 
al., 2009). However, not all germ cell mRNAs must undergo changes in poly(A) tail 
length for their activation, as exemplified by the DNA-replication histone mRNAs, the 
only eukaryotic mRNAs to lack a poly(A) tail (Allard et al., 2005). Germ cells also 
encode germ-cell specific translation factors, such as the spermatogonial proliferation 
factor Eif2s3y in males (Yamauchi et al., 2016). 
Whilst the factors (e.g. RNA-binding protein, kinases) known to regulate mRNA 
specific translation/stability in germ cells are present in humans, suggesting that 
regulatory mechanisms are conserved, this has rarely been experimentally examined. 
However, it is clear that cytoplasmic polyadenylation, for instance, occurs during 
human oocyte maturation and injection of reporter mRNAs containing human 3’UTRs 
recapitulates their adenylation in other species (i.e. Xenopus) (Prasad et al., 2008). 
Because of the paucity of studies, the contribution of dysregulated mRNA translation 
and stability to human reproduction is only just starting to emerge. For example, 
disruption of the mammalian target of rapamycin complex 1 (mTORC1) pathway, 
which phosphorylates 4E-BP to regulate eIF4F complex assembly and promotes rRNA 
and tRNA transcription thereby regulating processes such as protein synthesis and 
cellular growth and proliferation (Bhat et al., 2015; Roux and Topisirovic, 2012), leads 
to fertility problems as well as cancer in the female reproductive tract. Specifically, 
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the disruption of Tsc1, a direct inhibitor of mTORC1, results in oviductal hyperplasia 
and implantation failure (Daikoku et al., 2013) as well a reduction in oocyte quality 
and primordial follicle number and subsequent premature ovarian failure (Tanaka et 
al., 2012). 
One of the best characterised examples involving an RNA-binding protein emerged 
from the identification of deletions of the Deleted in AZoospermia (DAZ) genes on 
the Y-chromosome in 10-15% of men with non-obstructive oligo or azoospermia, 
which describes men with little or no sperm (Reijo et al., 1995). These observations 
strongly supported DAZ as a candidate infertility gene, with studies of the two 
autosomal family members, DAZ-Like (DAZL) and BOULE, in animal models 
establishing the critical role of this family in gametogenesis. For instance, Dazl, is 
essential for meiosis and PGC migration and proliferation in both male and female 
mice (Lin and Page, 2005; Ruggiu et al., 1997) and primordial germ cell migration and 
survival in X. laevis (Houston and King, 2000). In mice it has also been shown to also 
function in the maintenance of pluripotency and epigenetic programming of primordial 
germ cells (Haston et al., 2009). The absence of DAZ in model organisms has 
hampered its direct study but transgenic DAZ expression can rescue the Dazl 
phenotype in mice, providing support for a shared molecular function and DAZ 
deletions being causative of failed spermatogenesis in men. Molecular biology studies 
have further established that all family members are mRNA-specific activators of 
translation: they activate the translation of key germ cell mRNAs by binding to their 
3’UTR and recruiting of PABPs, via direct protein-protein interactions, independent 
of the poly(A) tail (Collier et al., 2005).  
 
1.2.7 mRNA translation and stability in pregnancy 
 
In contrast to germ cells and early embryogenesis little is known regarding the 
contribution of regulated mRNA translation and/or stability to pregnancy in any 
species (Rossant and Cross, 2001). However, a handful of examples exist. For instance 
in mice, the knockout of Zfp36L1, a gene which encodes zinc finger protein 36-like 1 
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(Zfp36L1) accelerated mRNA degradation, and resulted in in utero death by e11, most 
likely due to aberrant or failed chorioallantoic fusion (Stumpo et al., 2004). 
Furthermore, Yung et al were the first to provide evidence in 2008 of endoplasmic 
reticulum stress and subsequent protein synthesis attenuation in the placenta may have 
an important role in the pathophysiology of IUGR (Yung et al., 2008). Specifically, 
they showed that there is an increase in phosphorylated eIF2α and a reduction in AKT 
signalling in human IUGR placentas. This is further exacerbated in IUGR placentas 
from pregnancies affected by preeclampsia. In vitro experiments in two trophoblast-
like cell lines, JEG-3 and JAR cells, showed that the reduced AKT signalling resulted 
in reduced 4E-BP phosphorylation, it’s binding to eIF4E and inhibited cap dependent 
translation. The reduction in AKT signalling also resulted in reduced GSK-3 
phosphorylation promoting its activity. Active GSK-3 binds the epsilon subunit of 
eIF2B preventing it from its role in regenerating eIF2.GTP from eIF2.GDP, which is 
crucial for translation initiation.  
The work herein shows that loss of function of a member of the poly(A)-binding 
protein family, PABP4, results in mid-late gestational mortality and IUGR.  
 
1.3 Metazoan poly(A)-binding proteins (PABPs) 
 
PABPs are conserved throughout eukaryotes, with the number of PABPs being linked 
to organism complexity. For instance, Drosophila has only one PABP gene (pABP), 
whilst vertebrates encode three PABPs; PABP1 [PABPC1], PABP4 [PABPC4, 
iPABP] and embryonic PABP [ePABP/ePAB, PABP1L), and mammals two additional 
members, testis-specific PABP [tPABP] and PABP5 [PABPC5]. These share a 
common domain organization made up of four N-terminal non-identical RNA-
recognition motifs (RRMs) and, with the exception of PABP5, a C-terminal region 
composed of a proline-rich linker region and a globular PABC domain (Fig.5) (Blanco 
et al., 2001; Kühn and Wahle, 2004). This is distinct from PABPN1 and ePABP2 
which have a glutamic acid-rich N-terminus (E-rich), a single RNA recognition motif 
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(RRM) and an arginine-rich (R-rich) domain at the C-terminus. However, like 
PABPN1, PABPs interact with the poly(A) tail via their RNA-recognition motifs 
(RRMs). RRMs 1-2 are mainly responsible for high affinity poly(A)-binding (Eliseeva 
et al., 2013) but the specificity of RRMs 3-4 is less clear, although they can interact 
with AU-rich sequences (Eliseeva et al., 2013). The proline-rich region is the least 
conserved domain but mediates ordered binding to poly(A) through its ability to self-
associate (Kühn and Pieler, 1996; Melo et al., 2003). Finally, the PABC domain 
appears to be the predominant protein-protein interaction domain (Albrecht and 
Lengauer, 2004; Kozlov et al., 2001), although the RRM regions also bind a series of 













Figure 1.2 PABP1 domain-specific RNA and protein interactions.  
The domain organisation of PABP1 is depicted identifying the regions of PABP1 which interact with 
RNA and protein partners. RRMs 1 and 2 mediate the majority of poly(A)-binding, but the RNA-
binding specificity of RRMs 3 and 4 remains unclear, although affinity towards AU-rich sequences has 
been shown. RRM sections also bind several protein partners; B-cell translocation gene (BTG)-2, 
deleted in azoospermia-like (DAZL), eukaryotic initiation factor (eIF)-4B, eIF4G, glycine-tryptophan 
protein (GW)182, PABP-interacting protein (Paip)-1, Paip2, Paxillin and upstream of n-Ras (UNR). 
Many PABP1 protein partners which bind the PABC domain contain a PABP-interacting motif (PAM)-
2 e.g. ataxin-2, eukaryotic release factor (eRF)-3, GW182, La-related protein (Larp)-4, Paip1, Paip2, 
poly(A) nuclease (Pan)3 and transducer of Erb (Tob)-1/2. NB: Although only DAZL is depicted, all 
DAZ family members interact with the C-terminal region. Solid line; currently defined minimal binding 
sites. Dashed line; eIF4B binding is not clearly defined, but requires the C-terminus. Adapted from 
(Burgess and Gray, 2010). 
 
PABP1, is the prototypical family member, and is by far the best studied family 
member and has been ascribed multiple roles in mRNA translation, stability and 
localization, although there is currently no evidence for a direct role in the latter 
(reviewed by (Derry et al., 2006; Gorgoni and Gray, 2004; Mangus et al., 2003). The 
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best studied role of PABP1 is in promoting translation initiation when bound to the 
poly(A) tail, with the presence of the cap and poly(A) tail having synergistic effects 
on translation in many systems (Svitkin and Sonenberg, 2004). The magnitude of the 
effect of the poly(A) tail appears dependent on poly(A) tail length, the nature of the 
mRNA and the system in which it is being studied. PABP depletion and add back 
experiments in vitro showed that PABP was important for the effect of the poly(A) tail 
on translation (Svitkin and Sonenberg, 2004), whilst tethering PABP to non-
adenylated mRNAs in X. laevis oocytes, showed that PABP could substitute for the 
poly(A) tail  and that the function of the poly(A) tail is to provide a scaffold for PABP-
binding (Gray et al., 2000). The efficiency of longer poly(A) tails being explained by 
their ability to accommodate more molecules of PABP and/or compete for limiting 
PABP more effectively. Sucrose gradient analysis using defined inhibitors of initiation 
to block initiation intermediates in mammalian cell free extracts showed that PABP 
could enhance the binding of the small ribosomal subunit (Kahvejian et al., 2005). This 
was consistent with reports that PABPs from several species interacted with one or 
more factors that acted at, or prior to, small subunit joining. In mammals these were 
eIF4G, eIF4B, and PABP-interacting protein 1 (PAIP1), a protein with homology to 
the middle and C-terminal domains of eIF4G (Derry et al., 2006; Gorgoni and Gray, 
2004; Mangus et al., 2003). The interaction of PABP1 with eIF4G has been widely 
studied providing much support for a functionally important interaction (Gorgoni and 
Gray, 2004). Moreover, atomic force microscopy studies using purified yeast PAB-1, 
eIF4G and eIF4E showed that these three proteins were sufficient to result in the 
‘closed loop formation’ of the mRNA, observable as diamond ring like structures 
(Wells et al., 1998) (Figure 1.3). These observations explained the synergy of the cap 
and poly(A) tail in promoting initiation and it was suggested that it would result in 
increased affinity of eIF4E for the cap and PABP for the poly(A) tail (Goss and 
Kleiman, 2013). As cap-binding is considered rate limiting, this provides a molecular 
explanation for the observed increase in small ribosomal subunit joining (Kahvejian et 
al., 2005). However, whilst this model has become dogma, some data controvert the 
importance of the PABP-4G interaction (reviewed by (Mangus et al., 2003), and it 
remains to be demonstrated that PABP actually enhances eIF4G binding to mRNA, 
although it is clear RNA-binding by eIF4G is required for its stabilization of eIF4E-
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cap binding (Yanagiya et al., 2009). The effects of Paip1 are less well studied, although 
its absence reduces the effect of the poly(A) tail on translation, and it has been 
suggested to help stabilize the eIF4E-eIF4G-PABP end-to-end complex (Derry et al., 
2006). Direct effects of the reported interaction between eIF4B and PABP on 
translation remain to be shown (Kahvejian et al., 2001). Moreover, it is clear that the 
effects of PABP are pleiotropic as the sucrose gradient analysis also showed an effect 
on 60S joining (Kahvejian et al., 2005), an observation that as of yet, has no firm 
mechanistic basis in metazoans. PABP1 has also been shown to inhibit deadenylation, 
the first step in mRNA turnover, as PABP depletion in cell-free extracts negates the 
stabilizing effect of the poly(A) tail (Brook and Gray, 2012). Although, less well 
understood than its role in translation, this has been explained by a simple steric model 
in which PABP binding to poly(A) physically occludes the entry of deadenylases, a 
model which is supported by the detection of deadenylation intermediates 
corresponding to the sequential loss of PABP footprints (Brook and Gray, 2012). The 
formation of the closed-loop model “clamping” eIF4E on the cap and PABP on the 
poly(A) tail, forming a further barrier to deadenylation-dependent decay, providing 
one possible explanation for the complex links between mRNA translation and 
stability. However, the situation is more complex as the PABC domain of PABP1 
binds to and stimulates the activity of the PAN2/PAN3 complex and can recruit the 
Ccr4-Not complex via intermediate proteins such as TOB (Brook and Gray, 2012). 
These apparently opposing functions in regulating deadenylation remain to be 
understood. PABPs also have less well understood roles in regulating mRNA specific 
translation and stability (Burgess and Gray, 2010). These include their functions in 
promoting the translation of mRNAs undergoing cytoplasmic polyadenylation and in 
the poly(A) tail independent activation of mRNAs by Dazl, where it is recruited to 
form an alternative closed loop complex comprising of Dazl bound to the 3’UTR, 
PABP, eIF4G and eIF4E-bound to the 5’end (Collier et al., 2005). PABP1 can also 
autoregulate its own translation as part of a repressive complex with IMP-1 and Unr 
when all available poly(A) tail sites are occupied (Burgess and Gray, 2010). Similarly, 
PABP participates in a number of different complexes to regulate the decay of specific 
mRNAs. Well characterized examples include α-globin mRNA where its stabilises the 
binding of an RNA-binding protein complex to the 3’UTR occluding an 
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endonucleolytic cleavage site and c-fos mRNA where its interaction with a complex 
of proteins including Paip1, Unr and AUF1 bound to a site within the open reading 
frame prevent deadenylation of the mRNA prior to its translation. PABPs also have 
complex but not fully delineated roles in the control of mRNAs containing AU-rich 
elements (AREs) which can be stabilised, destabilized or repressed by binding of a 
variety of ARE-binding proteins (ARE-BPs, AUBPs) (Burgess and Gray, 2010). 
AUBPs can alter PABP-poly(A)-binding and its interaction with deadenylases to 
either favour or disfavour deadenylation. Moreover, PABPs can antagonise 
interactions of ARE-BPs with deadenylases and, as mentioned earlier, can bind AREs 
directly (Burgess and Gray, 2010). 
 
PABP1 also participates in miRNA-mediated regulation for example via its interaction 
with the miRNA-containing RISC complex which enhances translational repression 
and deadenylation (Goss and Kleiman, 2013). Lastly, it is involved in mRNA 
surveillance pathways where it discriminates between mRNAs with and without 
premature stop codons, the former then being subject to nonsense mediated decay 
(NMD) (Brook and Gray, 2012). Thus, based mainly on studies of PABP1, PABPs are 
considered to be central regulators of mRNA translation and stability (reviewed by 
(Mangus et al., 2003). Many of the functions of PABP1 appear to be conserved in 
ePABP, with ePABP being best studied in Xenopus and mouse (Friend et al., 2012; 
Guzeloglu-Kayisli et al., 2012; Voeltz et al., 2001; Wilkie et al., 2005). Little 
information is available for tPABP with a single study providing data that both 
supported and contradicted a conserved function in translation (Kimura et al., 2009), 
however, as tPABP arose from a retrotransposition of PABP1 and is almost identical 
in sequence, it seems likely that their functions will be conserved. In contrast, the 
absence of the C-terminal region in PABP5 and its relatively poor conservation in the 
RRMs regions may it unlikely that it shares many of the molecular functions of 






Figure 1.3 Simplified “closed-loop” model showing how PABP stimulates translation initiation by 
bringing together the 5’ and 3’UTRs.  
Interaction of PABP1 with eIF4G, which also binds the cap-binding protein eIF4E, brings the ends of 
the mRNA into functional proximity. Additional interactions of PABP1 with Paip1, and perhaps eIF4B 
(shown with a dotted outline), further stabilise this closed loop conformation, which is proposed to 
enhance PABP, eIF4G and eIF4E-binding, increasing the recruitment of ribosomal subunits and 
promoting translation (Burgess et al., 2011; Burgess and Gray, 2010; Brook et al., 2009). The formation 
of this ‘closed-loop’ conformation also protects mRNAs from deadenylation and decay. From (Brook 
et al, 2009) 
 
1.3.1 Expression patterns of vertebrate PABPs 
 
Expression patterns can be informative with respect to putative functional 
consequences resulting from gene deletion. However, to date very little information 
on the tissue and cellular expression of different PABPs is available. Northern blotting 
has shown that both PABP1 and PABP4 mRNAs are expressed in a wide variety of 
mouse tissues (Yang et al., 1995), consistent with analysis of PABP1 protein and 
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PABP4 mRNA in adult tissues and developmental stages in X. laevis which suggest 
that both are widely expressed (Gorgoni et al., 2011; Wilkie et al., 2005). However, 
the expression pattern of PABP1 and PABP4 proteins between and within tissues 
remains largely unexplored. The most detailed analysis of PABP mRNA expression in 
mammals is in mouse and human testis, where PABP1 is found in spermatocytes and 
round spermatids (Feral et al., 2001). The absence of PABP1 mRNA in the 
spermatogonial stem cells shows that the widely held assumption that PABP1 is 
ubiquitous based on its lethality of PAB-1 deleted S. cerevisiae (Sachs et al., 1987) is 
not proven. Testis is also the site of expression of the mammalian specific tPABP with 
its mRNA being present in late pachytene spermatids and haploid round spermatids in 
mouse, and only round spermatids in humans (Kleene et al., 1994). tPABP protein 
distribution mirrors that of its mRNA in mouse testis (Kimura et al., 2009) with 
immunofluorescence suggesting that it is enriched in the chromatoid bodies of round 
spermatids (Kimura et al., 2009) which are RNA-protein rich granules. Proteomic 
analysis of these granules showed they also contain PABP1 (Meikar et al., 2014).  
ePABP was first identified in X. laevis where it is considered to be specific to pre-
neurula embryonic stages and oocytes (Voeltz et al., 2001), indeed it is considered the 
predominant PABP in late oocytes and early embryos, where PABP1 is scarce. ePABP 
mRNA can, however, also be detected at low levels in X. laevis and mouse testis 
suggesting it may be restricted to the gonads within adults (Seli et al., 2005; Wilkie et 
al., 2005), although in humans ePABP mRNA can be detected at very low levels in a 
wide range of tissues (Guzeloglu-Kayisli et al., 2012; Voeltz et al., 2001; Wilkie et al., 
2005). Lastly, RT-PCR analysis of a limited number of tissues in humans suggests that 
PABP5 mRNA may be most highly expressed in brain and ovary (Blanco et al., 2001), 
although technical issues prevent strong conclusions being drawn. (PABP4 is 




1.3.2 Vertebrate PABP phenotypes 
 
Disruption of PABP (pABP) function in Drosophila is associated with embryonic 
lethality, defective oogenesis, spermatogenesis and body patterning and 
neuromuscular defects dependent on the allele, although many of these phenotypes 
have not been described in detail (Blagden et al., 2009; Blanco et al., 2001; Singh et 
al., 2011; Vazquez-Pianzola et al., 2011), and it is not clear to what extent protein 
synthesis is disrupted. C. elegans has two PABPs, and knock-down of either results in 
mild defects such as flaccid body morphology with PAB-1, but not PAB-2 knockdown 
also resulting in male and female infertility (Maciejowski et al., 2005; Simmer et al., 
2003; Smith et al., 2014). However, the absence of clear homologs of the mammalian 
PABP family in these species limits the extent to which these phenotypes inform upon 
the potential functions of specific mammalian PABPs. In contrast, X laevis encodes 
PABP1, ePABP and PABP4 homologs each of which have been knocked-down using 
morpholino approaches (Gorgoni et al., 2011). Injection of morpholinos against 
PABP1 or ePABP into both blastomeres at the two cell stage, revealed that both were 
essential for embryogenesis resulting in loss of anterior and posterior structures, 
developmental delay, curvature of the body axis, movement defects and death with 
100% penetrance, although ePABP embryos reached a maximum of stage 35, in 
contrast to the earlier lethality (stage 30-31) of PABP1 (Gorgoni et al., 2011). 
Sequestration of PABPs in fully grown X. laevis oocytes, by overexpression of Paip2, 
blocked oocyte maturation thereby underlining the importance of PABP function in 
germ cells at times when many mRNAs are regulated by changes in their poly(A) tail 
length (Friend et al., 2012). Oocyte maturation could be rescued by exogenous ePABP 
suggesting an important role for ePABP in this process, consistent with it being the 
predominant PABP present during oocyte maturation (Friend et al., 2012). This result 
does not preclude PABP1 also contributing to this process. Analysis of oocyte mRNAs 
showed that key meiotic mRNAs such as c-mos and cyclin B1 showed defects in their 
poly(A) tail status which prohibited their translational activation (Friend et al., 2012).  
 
To date, only the biological function of germ cell specific PABPs have been explored 
in mammals and, consistent with analysis in X. laevis, female ePABP knock-out mice 
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were infertile (Guzeloglu-Kayisli et al., 2012). These females have normal oestrus but 
present with a significantly elevated number of secondary follicles with their oocytes 
failing to mature in vivo or in vitro, consistent with blocks in oogenesis and 
folliculogenesis. The underlying mechanism was shown, at least in part, to be due to a 
lack of cytoplasmic polyadenylation (Guzeloglu-Kayisli et al., 2012). In contrast, 
neither loss of ePABP nor tPABP affects murine spermatogenesis (Kashiwabara et al., 
2016; Ozturk et al., 2014).  
 
1.3.3 Poly(A)-binding protein 4 (PABP4) 
 
PABP4, (also referred to as inducible PABP (iPABP) or PABPC4) was identified as 
one of the most upregulated mRNAs upon activation of human T cells (Yang et al., 
1995). T cells are part of the adaptive immune system which are antigen activated, 
resulting in the production of lymphokines that act by paracrine mechanisms to 
regulate immune response. As regulation of mRNA stability is a widely documented 
means of controlling mRNAs associated with immune function, it was speculated to 
have a role in regulating the stability of labile mRNAs in T cells. Consistent with this 
idea, PABP4 is a diffusely cytoplasmic protein in cultured cells (Yang et al., 1995), is 
capable of binding to AU-rich sequences in vitro with a higher affinity than PABP1 
(Ranson et al., 1973) and is capable of interacting with Tob (Okochi et al., 2005), a 
protein which recruits deadenylases (Hosoda et al., 2011). Addition of Tob to cell-free 
extracts, programmed with IL-2 mRNA, showed that it could inhibit the modest (2-
fold) enhancement of IL-2 translation by recombinant PABP4 (Okochi et al., 2005). 
Inhibition of IL-2 translation is vital to induce T cell anergy and Tob acts as an anti-
proliferative protein and maintains T cell anergy/quiescence (Hua and Thompson, 
2001) suggesting that the Tob-PABP4 interaction may be important in the translational 
repression of IL-2 mRNA in anergic T cells (Okochi et al., 2005).  
 
Consistent with the modest effect of mammalian PABP4 on IL-2 translation in cell-
free systems (Okochi et al., 2005), knock-down of PABP4 in HeLa cells, either alone 
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or in combination with PABP1, did not significantly impact 35-S methionine 
incorporation, suggesting it may not significantly contribute to overall cellular 
translation rates (Burgess et al., 2011). However, these observations may reflect the 
poor poly(A)-dependence of rabbit reticulocyte cell-free translation extracts (Okochi 
et al., 2005) and the respective levels of PABP1 and PABP4 in HeLa cells (Burgess et 
al., 2011)  as PABP4 is polysome associated in mammalian cell lines (Burgess and 
Gray, 2012).  Alternatively, a more mRNA specific role in translation would be 
consistent with all these findings and its preference for AU-rich RNA sequences 
(Sladic et al., 2004). However, PABP4 may make a more significant contribution to 
overall protein synthesis rates in some biological contexts, as knock-down in X. laevis 
embryos results in a loss of polysomes (Gorgoni et al., 2011),  indicative of a 
substantial protein synthesis defect. Studies in X. laevis also established that PABP4 
has the ability to stimulate translation as efficiently as PABP1 when tethered (Gorgoni 
et al., 2011) and interact with PABP1 partners with roles in translation initiation 
(eIF4G, Paip1), as well as those implicated in regulating PABP1 function (Paip2), and 
in mRNA surveillance (eRF3) (Cosson et al., 2002; Gorgoni et al., 2011). 
 
Experiments in cell lines suggest that mammalian PABP4 may contribute to changes 
in gene expression during specific viral infections and/or cell stresses, as like PABP1, 
it becomes relocated to either stress granules or the nucleus (Burgess et al., 2011). 
Stress granules are foci within the cytoplasm that act as sites of mRNA storage 
(Kedersha et al., 2013), and nuclear relocalisation makes PABP4 unavailable to 
interact with the mRNA translation or stability machinery. However, PABP4 is not 
required for stress granule formation or mRNA export and exits the nucleus bound to 
mRNAs (Burgess and Gray, 2012; Burgess et al., 2011). Thus, these changes in 
PABP4 localisation are likely driven by mRNA redistribution, as bulk mRNA 
accumulates with PABP4 in the nucleus or stress granules during specific 
infections/stresses (Burgess and Gray, 2012; Burgess et al., 2011), although it is 
possible that partitioning PABP4 to different locations may result in different 
outcomes in terms of mRNA fate. 
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Recent investigations of PABP4 in mammalian lines has also identified a potential role 
in erythroid maturation based on a model in which lymphoma-derived murine cells, 
mouse erythroleukemia (MEL), are treated with dimethylsulfoxide (Kini et al., 2014). 
The final stages of erythroid maturation are dependent on mRNA translation/stability 
control, due to the lack of a nucleus, and interestingly, shRNA-mediated depletion of 
PABP4 blocked MEL cell differentiation, as measured by criteria such as haemoglobin 
content. Microarray analysis showed altered levels of a relatively small subset of 
mRNAs including those with AU-rich elements (AREs), suggesting that PABP4 
normally prevents their mRNA decay (Kini et al., 2014). However, the underlying 
mechanism requires further clarification. 
The only whole organism study of PABP4 is in X. laevis (Gorgoni et al., 2011). 
Morpholino knock-down experiments showed it is essential for normal vertebrate 
development, with lethality by stage 51 (Gorgoni et al., 2011). In contrast to PABP1 
and ePABP morphants, PABP4 morphants displayed a range of anterior defects (i.e. 
abnormal intestinal coiling, malformation of the head and eye, cephalic and ventral 
oedema), rather than both anterior and posterior defects (Gorgoni et al., 2011). 
Importantly, cross-rescue experiments revealed that expression of PABP4 was unable 
to completely rescue the early embryonic lethality associated with PABP1 knock-
down (Gorgoni et al., 2011) showing that despite their functional similarities, their 
molecular functions must be at least partly distinct. 
According to the human protein atlas PABP4 is expressed in a wide array of tissues 
including the ovary, endometrium, placenta, pancreas, and brain. Here we extend our 
knowledge of PABP4 function in whole organisms by examining its role in mouse, 




1.4 Physiology of normal pregnancy 
 
Pregnancy is a fascinating and unique physiological state during which the female 
body undergoes profound anatomical and physiological changes in almost every organ 
system. These adaptations begin soon after conception, evolve throughout pregnancy 
and almost completely revert back to the non-pregnant state either near the end of 
pregnancy or after parturition. The ultimate purpose of these alterations is to 
accommodate the needs of the feto-maternal unit. A fully comprehensive review of all 
the changes that occur is beyond the scope of this thesis but the following brief review 
will cover some of the key adaptations, as understanding changes in normal pregnancy 
is key to understanding pregnancy complications, particularly those with a maternal 
origin.   
 
1.4.1 Metabolic adaptations in pregnancy 
 
Pregnancy has been described as a situation of genetic conflict between the fetus and 
mother, where a fetus first needs to modulate the maternal immune response to its 
alloantigens in order to prevent is rejection and a balance between fetal nutrient 
demands with maternal resource allocation has to be achieved (Burton and Fowden, 
2012; Haig, 1993). Maternal glucose and lipid metabolism changes dramatically 
during pregnancy to ensure that the developing and growing fetus has a continuous 
and sufficient supply of nutrients during intermittent maternal food intake, particularly 
in late pregnancy when fetal energy demands peak due to exponential fetal growth. 
  
1.4.2 Glucose metabolism 
 
Maternal physiology during pregnancy is primarily influenced by placental and 
pituitary hormones. These regulate glucose and lipid metabolism to ensure that the 
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fetus has an ample supply of fuel and nutrients at all times but most importantly in late 
pregnancy, when fetal growth and nutrient demand is at its maximum (Butte, 2000; 
Homko et al., 1999). The maternal response is characterized by a switch from 
carbohydrate to fat utilization that is facilitated by both insulin resistance and increased 
plasma concentrations of lipolytic hormones (Butte, 2000). These adaptations result in 
large fluctuations of glucose and insulin between the fed and the fasted state (such as 
an overnight fast) which is characterised by “accelerated starvation” during which 
glucose is stored for the fetus and alternative fuels, such as plasma ketone, free fatty 
acids and glycerol, are maintained for the mother (Butte, 2000; Homko et al., 1999). 
In early- to mid-gestation the so called “first-phase insulin secretion”, which occurs in 
response to a meal, is enhanced as a result of increased stimulation of  cells in the 
pancreas (insulin producing cells within the islets of Langerhans). Overall there is a 
60% increase in insulin secretion but insulin sensitivity remains unaltered promoting 
maternal fat storage due to the lipogenic properties of insulin (Kersten, 2001). In the 
second half of gestation maternal metabolism is modified by the emergence of insulin 
resistance whereby insulin sensitivity becomes 45-70% lower than in non-pregnant 
women, primarily in skeletal muscle, the principal site of whole-body glucose uptake 
(Freemark, 2006; Newbern and Freemark, 2011). In order to overcome the insulin 
resistance, and to prevent gestational diabetes mellitus developing, there is a 
compensatory increase in pancreatic  cell number in conjunction with a lower 
threshold for glucose-stimulated insulin secretion (Brelje et al., 1994; Parsons et al., 
1992). As a result, in the fed state maternal nutrients are utilised for the production of 
fat (adipogenesis), glycogen (glycogenesis) and energy storage. Conversely, in the 
fasted state the mother utilises free fatty acids for energy and spares glucose, amino 
acids, essential fatty acids, and ketones for placental growth and nutrient transport 
(reviewed by (Newbern and Freemark, 2011). 






Figure 1.4 Metabolic changes during late pregnancy. 
Late pregnancy is marked by maternal catabolism that serves to support the dramatic anabolic growth 
of the fetus. The liver uses glycerol and (less so) amino acids to make glucose for the fetus and consumes 
fats, generating in the process ketones that are usable by the brain, muscle, and fetus. Adipose tissue 
releases fatty acids for consumption by both the liver and muscle. The fetus uses amino acids, fats, and 
roughly half of incoming glucose for anabolic growth, while largely relying on the other half of glucose 
for energetic needs. (From (Liu and Arany, 2014)). 
  
 38 
1.4.3 Lipid metabolism 
 
Maternal adaptive changes also occur in lipid metabolism including accumulation of 
maternal fat depots in early pregnancy and hyperlipidaemia, elevated lipids in the 
blood, in late pregnancy (Alvarez et al., 1996; Lopez-Luna et al., 1991; Montelongo 
et al., 1992). The increased levels of lipids in early pregnancy are not only important 
for fat storage, to be used as an alternative energy source to glucose later in pregnancy, 
but are also important for fetal growth and development. Maternal plasma 
concentrations of triglycerides (TG) and non-esterified fatty acids (NEFA) have been 
shown to correlate with fetal lipid concentrations and fetal growth more so than 
maternal plasma glucose (Kitajima et al., 2001; Nolan et al., 1995; Schaefer-Graf et 
al., 2008). Furthermore, intrauterine growth restriction has been associated with 
impaired placental transfer of lipophilic compounds, including not only fatty acids but 
also lipophilic vitamins like retinol and γ - and α-tocopherol  (Gauster et al., 2007) 
which prevent the oxidative deterioration of lipids (lipid peroxidation) (Kamal-Eldin 
and Appelqvist, 1996; Rozanowska et al., 2005). The accumulation of fat in early 
pregnancy is not only the result of increased insulin in the setting of normal insulin 
sensitivity, but also due to an increase in adipose tissue lipoprotein lipase (LPL) 
activity which results in the uptake of NEFA and glycerol by tissues (Herrera et al., 
1988). The decrease in insulin sensitivity in late pregnancy combined with increased 
levels of placental hormones (e.g. growth hormone and placental lactogen II (Fielder 
and Talamantes, 1987)) with lipolytic effects such as increasing lipolysis, decreasing 
LPL activity and increasing TG utilization causes fat stores to decline (Ramos and 
Herrera, 1995). 
These changes in maternal metabolism are brought about by hormones produced by 
the placenta and maternal pituitary gland including oestrogen, progesterone, cortisol 
(in humans), corticosterone (in mice) and, in particular, the Prolactin (PRL)/growth 
hormone (GH)/placental lactogen (PL) family. PRL and GH are secreted by the 
pituitary and share the same ancestral gene (reviewed by (Rawn and Cross, 2008), and 
have been duplicated to take on different functions in the placenta. In mice GH gene 
is single copy whereas in humans, 4 GH genes are expressed exclusively in the 
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placenta and one distinct gene in the pituitary (Rawn and Cross, 2008). The Prl gene 
on the other hand is single copy in humans whereas mice contain 23 Prl gene copies, 
each having a unique spatial and temporal expression pattern and are therefore used as 
markers for different subtypes of trophoblast cells  which constitute much of the 
placenta (Rawn and Cross, 2008; Simmons et al., 2008). 
 
1.4.4 Adipokines - with a focus on leptin and adiponectin 
 
It wasn’t until 1994 that white adipose tissue was firmly established as an endocrine 
organ that, in addition to its role as a reservoir for storing calories, releases a variety 
of bioactive peptides called adipokines (also termed adipocytokines) (reviewed by 
(Kershaw and Flier, 2004). Furthermore, it expresses several receptors that respond to 
circulating hormones and allow it to communicate with distant organs, including the 
central nervous system (CNS). As a result, adipose tissue has a role in a number of 
biological processes including energy metabolism, neuroendocrine function and 
immune function (Kershaw and Flier, 2004). Two adipokines which are associated 
with insulin resistance are leptin and adiponectin (Fasshauer and Paschke, 2003; 
Weyer et al., 2001). Adiponectin has insulin sensitizing, anti-inflammatory and 
antiatherogenic properties (Lihn et al., 2005). Maternal adiponectin serum levels have 
an inverse relationship with birth weight (Ategbo et al., 2006; Jansson et al., 2008; 
Lowe et al., 2010). Fetal adiponectin, on the other hand, is positively correlated with 
birthweight and increased fat stores in early life (Qiao et al., 2012; Sivan et al., 2003). 
Leptin signals to receptors of the cytokine receptor class I superfamily that are found 
in both the CNS and periphery (Bjorbaek and Kahn, 2004).. Leptin is known to reduce 
appetite and increases energy expenditure signalling via the hypothalamus (Campfield 
et al., 1995; Vaisse et al., 1996) but also has direct metabolic effects on several tissues 
primarily stimulating glucose utilization and lipolysis (Barzilai et al., 1997; Bryson et 
al., 1999; Kamohara et al., 1997). In normal pregnancy, adiponectin levels decline in 
mid- to late-gestation resulting in an increased leptin to adiponectin ratio (Catalano et 
al., 2006; Jansson et al., 2008; Masuzaki et al., 1997). Interestingly, a disruption in this 
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ratio has been associated with pre-eclampsia (Atamer et al., 2005; Aydin et al., 2008; 
Hendler et al., 2005; Herse et al., 2009; Lu et al., 2006; Nakatsukasa et al., 2008; 
Naruse et al., 2005; Ouyang et al., 2009; Ozkan et al., 2005; Sharma et al., 2007) and 
gestational diabetes (Ategbo et al., 2006; Kautzky-Willer et al., 2001). Leptin also 
serves as a mitogen for endothelial cells (Bouloumie et al., 1998), haematopoietic cells 
(Gainsford et al., 1996), lung epithelial cells (Tsuchiya et al., 1999)  and pancreatic -
cells  (Islam et al., 1997), therefore it may also have a mitogenic role in the placenta, 
in addition to stimulating growth of tissues in the developing fetus. Leptin is important 
in early pregnancy as it is required at the time of preimplantation/implantation and 
subsequent placental formation (Malik et al., 2001). Interestingly, in humans leptin has 
been found to be secreted by the placenta (Masuzaki et al., 1997), and its maternal 
plasma concentrations increase during pregnancy (Hartmann et al., 1997). The gene 
for placental leptin has a placenta- specific upstream enhancer, implying that placental 
leptin is differentially regulated from leptin of adipose origin (Gavrilova et al., 1997).   
Furthermore, leptin concentration in umbilical serum has a strong positive correlation 
with neonatal fat mass (Marchini et al., 1998; Okereke et al., 2002)  and higher leptin 
concentrations have been found in fetal plasma and placentas from women with either 
type I diabetes or gestational diabetes mellitus (GDM) (Gross et al., 1998; Lepercq et 
al., 1998). Indeed maternal circulating levels increase in rodents and humans, 
particularly mid-late gestation but significantly drops at around birth (reviewed by 
(Herrid et al., 2014). However, in contrast to humans neither the murine conceptus nor 
the placenta are the source of leptin, instead the placenta produces soluble leptin 
receptors (Ob-R) which most likely increases the peptide half-life and allow leptin to 
act on the placenta via a paracrine signalling system (Gavrilova et al., 1997; Malik et 
al., 2005). There is evidence that high levels of PRL or PLs during pregnancy may 
directly interfere with leptin receptor signalling in the brain, resulting in leptin 
resistance (Nagaishi et al., 2014). When the role of high maternal leptin was examined 
during pregnancy in mice it was found that maternal hyperleptinemia isolated from 
maternal obesity or diabetes resulted in decreased placental leptin concentrations and 
reduced fetal birthweight (Yamashita et al., 2001). In this study, leptin administration 
from day 10 of pregnancy for 7 days reduced adiposity and improved glucose tolerance 
in offspring of the diabetes (db/+) mouse model of spontaneous GDM.  
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However, the same leptin treatment of WT mothers decreased placental leptin 
concentration and reduced fetal birth weight. In a separate study leptin injections in 
C57BL/6 mice on day 17 of pregnancy decreased birth weight in both male and female 
offspring (Makarova et al., 2013). Furthermore, maternal hyperleptinemia has been 
shown to result in reduced weight gain in offspring in adulthood even on a high fat 
diet (HFD) (Pollock et al., 2015).  Placental leptin may regulate fetal growth and 
placental function by regulating glucose metabolism and insulin sensitivity 
(Magarinos et al., 2007; Malik et al., 2005; Sagawa et al., 2002a; Sagawa et al., 2002b). 
Furthermore, leptin regulates multiple placental functions such as nutrient transfer 
(Jansson et al., 2003), trophoblast cell invasion (Schulz and Widmaier, 2004) 
trophoblast giant cell differentiation (Schulz et al., 2009) and protein synthesis (Perez-
Perez et al., 2010).  
 
1.4.5 Cardiac and haemodynamic adaptations 
 
Pregnancy is characterized by an increase in blood volume (Longo, 1983), cardiac 
output, glomerular filtration rate and remodelling of spiral and uterine arteries. 
Together these changes bring about a state of high blood flow with low vascular 
resistance that provides the fetus with constant supply of oxygen and nutrients. The 
increase in blood volume leads to cardiac volume overload, which in turn results in 
cardiac hypertrophy that is defined as an increase in heart muscle mass with changes 
in cardiac geometry (reviewed by (Chung and Leinwand, 2014). Cardiac hypertrophy 
associated with pregnancy is physiological rather than pathological and it is reversible 
as early as 7-14 days post-partum in rodents (Umar et al., 2012) and up to a year in 
humans (Clapp and Capeless, 1997).  It is characterized by an increase in chamber 
dimension (Eghbali et al., 2005), which can be associated with a proportional increase 
in wall thickness (Chung et al., 2012). Furthermore, cardiac output reaches its 
maximum in the second trimester that persists until term and is associated with an 
increase in heart rate and stroke volume (Clapp and Capeless, 1997). This pregnancy-
induced cardiac adaptation is believed to be, at least in part, mediated by sex steroid 
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hormones. Progesterone has been shown to increase protein synthesis in cardiac 
muscle (Goldstein et al., 2004) whereas estradiol attenuates the development of 
pressure-overload hypertrophy (van Eickels et al., 2001). Abnormal cardiac adaptation 
to pregnancy is often present in women with pre-existing or pregnancy-induced 
hypertensive disorders such as pre-eclampsia (Tiralongo et al., 2015; Tomsin et al., 
2012). However, it is also present in women with IUGR pregnancies, manifesting as 
significantly smaller left atrial diameter and a cardiac output that failed to increase 




Figure 1.5 Morphometric alterations of the heart in response to pregnancy. 
Pregnancy leads to physiological rather than pathological cardiac hypertrophy which is reversible post-
pregnancy and is characterised by an increase in chamber dimension which can be associated with a 
proportional increase in wall thickness as well the increase in myocyte length and width.  (Adapted from 
(Chung and Leinwand, 2014)). 
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Aberrant cardiac and haemodynamic changes in pregnancy are often associated with 
a defective invasion of trophoblast cells into uterine tissue, resulting in poor 
placentation and insufficient spiral artery and uterine artery remodelling. In a normal 
pregnancy, the uterine artery, radial arteries (Palmer et al., 1992) and spiral arteries of 
the myometrium and decidua (Pijnenborg et al., 1983) undergo structural remodelling 
to reduce vasoactivity (the constriction and dilation of the artery) and increase  
diameter/capacity (reviewed by (Cross et al., 2002; Osol and Mandala, 2009). In 
humans, the remodelling of uterine spiral arteries is the result of a specific trophoblast 
lineage called the extravillous cytotrophoblast which replaces smooth muscle cells and 
thus alters vascular tone (Cross et al., 1994). In mice it is the action of uterine natural 
killer (uNK) cell derived interferon γ (IFN-) that results in a similar loss of smooth 
muscle cells within the metrial gland region at around mid-gestation (Ashkar and Croy, 
1999, 2001; Ashkar et al., 2000). Downstream of this the arterial endothelial cell layer 
is also lost, resulting in haemochorial blood flow through sinuses, however the 
mechanism by which this occurs is not well understood (Cross et al., 2002). Some of 
the primary evidence for the role of uNK cells in spiral artery remodelling is that is 
mice lacking uNK cells or components of the IFN- signalling pathway consistently 
present with abnormal spiral artery remodelling which manifests as smaller artery 
diameter and persistence of the smooth muscle layer (Croy et al., 2000; Guimond et 
al., 1997). In contrast to spiral artery remodelling, the mechanism by which the uterine 
artery remodels is largely unknown  however, as reviewed by Mandala and Esol 
(Mandala and Osol, 2012) steroids such as estrogen and progesterone are believed to 
initiate the process (Guenther et al., 1988; Magness et al., 1993; van der Heijden et al., 
2005) and as gestation progresses, fetoplacental factors, which are unknown but 
vascular endothelial growth factor (VEGF) and placental growth factors (PlGF) 
produced by myometrial and trophoblast cells, become predominant in later gestation 
as demonstrated in a single-horn pregnancy in mice where arterial remodelling is 
restricted the implanted horn (Fuller et al., 2009). Other mechanism include nitric 
oxide (NO), the renin-angiotensin system (reviewed by (Mandala and Osol, 2012) and 




Figure 1.6 Uterine artery remodelling in rodents. 
A) A scaled drawing showing the approximate extent of uterine artery widening and lengthening, with 
no change in wall thickness in the rat which accompanies pregnancy. B) Photograph showing late 
pregnant uterine horn and extent of vascular remodelling in comparison to an age-matched non-pregnant 
uterus and associated vasculature; the uterine artery (UA) and connected arcuate and radial vessels 
(inset, bottom). Ø = dimeter; ω = wall thickness; L = axial length; LP = late pregnant; NP = age-matched 
non-pregnant; UA = uterine artery. (From (Mandala and Osol, 2012)). 
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1.4.6 Haematologic adaptations 
 
Similarly to other body systems, the haematologic system adapts to pregnancy to 
accommodate the demands of the fetoplacental unit but also acts as to protect the 
mother in the event of haemorrhage during pregnancy and at parturition.  One major 
change that occurs is an increase in blood volume that is the combined result of an 
increase in plasma volume and red blood cell (RBC) number. In women, plasma 
volume begins to increase by 6 weeks and expands at a steady pace until it plateaus at 
30 weeks of gestation (Gordon, 2007). In comparison, RBC number increases at a 
slower rate beginning at about 10 weeks but, stimulated by erythropoietin, continues 
to increase progressively until term. As a result, maternal haematocrit (HTC) falls in 
early pregnancy but may rise in later pregnancy. Women with multiple pregnancies 
have larger increases in blood volume than those with singletons and volume 
expansion correlates with infant birth weight; it is unknown whether this is a cause or 
an effect (Gordon, 2007). The exact mechanism underlying the expansion of blood 
volume is unknown, but the hormonal and nitric oxide (NO) changes in pregnancy are 
likely candidates, as the inhibition of NO synthase in pregnant animals results in 
reduced plasma volume as well as increased blood pressure, implying it is also 
important for pregnancy-induced vasodilation (Salas et al., 1995; Zhang and Kaufman, 
2000). Due to a greater increase in plasma volume relative to the increase in RBC 
number, early pregnancy is also characterised by a small decrease in total haemoglobin 
concentration, referred to as physiologic anaemia of pregnancy. Later in pregnancy, 
when plasma expansion plateaus and RBC continues to increase, total haemoglobin 
concentration rises. Interestingly, high haemoglobin concentration at first antenatal 
clinic presentation is associated with an increased risk of IUGR and an almost 2-fold 
increased risk in stillbirth (Stephansson et al., 2000). This association may be more of 
a reflection of an insufficient plasma volume increase which normally ensures reduced 
blood viscosity that not only favours blood flow in the maternal part of labyrinth of 
the placentas (zone of the placenta where maternal and fetal vasculature come into 
close proximity), thus favouring fetal growth and nourishment, but also acts as a 
preventative adaptation to reduce risk of thrombosis in the uteroplacental circulation. 
Other haematological changes include an increase in platelet aggregation and, in some 
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women, a decline in the platelet count in the third trimester of pregnancy (Boehlen et 
al., 2000), possibly due to hyperdestruction and/or haemodilution (Boehlen et al., 
2000; Fay et al., 1983). Since the risk for trauma and haemorrhage in pregnancy is 
high, platelets become activated resulting in a hypercoaguable state relative to non-
pregnancy. Interestingly, women that present with platelet activation before and during 
early pregnancy have a higher risk of developing pre-eclampsia and IUGR (Dundar et 
al., 2008; Hladunewich et al., 2007; Kanat-Pektas et al., 2014), most likely because 




Figure 1.7 Blood and plasma volume and RBC mass changes during pregnancy.  
Plasma volume progressively increases during pregnancy but tends to plateau from about 30 weeks of 
gestation. Blood volume follows a similar pattern with a slower rise from day 0 which further increases 
from approximately 20 weeks of gestation. RBC mass/number rises slowly in early pregnancy but in 
contrast to blood and plasma volume it continues to increase all the way to term. These changes result 
in a fall of the haematocrit in early pregnancy but a rise towards term. (Adapted from (Scott, 1972). 
 
Furthermore, pregnancy is characterised by a progressive increase in the peripheral 
white blood cell count (WBC), primarily due to a rise in segmented (mature) 
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neutrophils and monocytes (Kuhnert et al., 1998; Naccasha et al., 2001; Siegel and 
Gleicher, 1981; Veenstra van Nieuwenhoven et al., 2002). On the other hand dendritic 
cells and circulating natural killer (NK) cells decrease during pregnancy (Cordeau et 
al., 2012; Kuhnert et al., 1998; Shin et al., 2009; Veenstra van Nieuwenhoven et al., 
2002).  
 
1.4.7 Immune adaptations  
 
Maternal immune cells such as uterine natural killer cells, dendritic cells, macrophages 
and T cells are important for reproduction and mediate some key process such as fetal 
allograft recognition and tolerance as well as trophoblast invasion and spiral artery 
remodelling (reviewed by (Bulmer et al., 2010; Erlebacher, 2013; Moffett and Colucci, 
2014).  In the haemochorial human and mouse placenta, fetal trophoblast cells come 
in direct contact with maternal immune cells. This contact primarily occurs in early 
pregnancy in the maternal decidua but also in the labyrinth of the placenta where the 
syncytiotrophoblasts are bathed in maternal blood. Innate immune cells, including 
uterine NK (uNK) cells and macrophages, are dominant in the decidua during 
pregnancy in both mice and humans (Ashkar et al., 2000; Barber and Pollard, 2003; 
Hanna et al., 2006; Moffett and Loke, 2006). Uterine NK cells are phenotypically and 
functionally different from peripheral NK cells (Hanna et al., 2006; Koopman et al., 
2003) and are regulated by stress signals, adhesion molecules and receptors for major 
histocompatibility complex (MHC) expressed by trophoblast cells, including killer-
cell immunoglobulin-like receptors (KIR) and murine lectin-like Ly49 receptors 
(Lanier, 2008). Both KIR and Ly49 are highly polymorphic and individual NK cells 
express from zero to five KIRs (Kieckbusch et al., 2014). The variability of these 
receptors and MHC ligands in both fetus and mother enable each pregnancy to be 
subtly different (Parham and Moffett, 2013). Kieckbusch et al demonstrated in mice 
that uNK cells specific for MHC class I allotype are less responsive as they bind 
inhibitory variations of the receptors mentioned above, resulting in defective 
remodelling of the decidual spiral arteries and reduced fetal growth (Kieckbusch et al., 
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2014). This is demonstrative of the uNK’s critical role in the development and growth 
of the fetus by balancing the invasion of the fetal trophoblast cells, such that the 
invasion isn’t too intrusive where the mother would be at risk of uterine rupture and 
death, whilst promoting the remodelling of spiral arteries for an increased blood flow 
to the feto-placental unit (reviewed by (Moffett et al., 2015).  
 
Macrophages are the second most abundant leukocyte population at the materno-fetal 
interface (Bulmer et al., 1988) and unlike uNK cells, their population does not alter 
dramatically in pregnancy. However, functional studies suggest that they have a role 
in immunosuppression (Mizuno et al., 1994), phagocytosis of cell debris produced by 
during implantation  (reviewed by (Abrahams et al., 2004; Mor and Abrahams, 2003) 
and the prevention of maternal T lymphocyte activation (Heikkinen et al., 2003). 
T helper cells are the third most abundant leukocyte and are the least studied in 
pregnancy in comparison to uNK cells and macrophages (Bulmer et al., 2010). 
Similarly to macrophages, their numbers do not change with gestation however, their 
importance is highlighted by the fact that their absence in pregnancy is associated with 
increased levels of fetal death and reduced placental growth (Athanassakis et al., 1987; 
Chaouat et al., 1988). A balance between T helpers type 1 (Th1) and type 2 (Th2) is 
key for fetal survival (reviewed by (Athanassakis and Vassiliadis, 2002; Sykes et al., 
2012).  Th1 and Th2  differentiate from T helper 0 (Th0) cells and whilst Th1 produces 
an array of inflammatory cytokines, Th2 produces more cytokines considered to be 
anti-inflammatory and associated with a strong antibody response (Sykes et al., 2012) 
therefore a bias towards Th2 in pregnancy is present (Saito et al., 1999), particularly 
at the maternal-fetal interface where trophoblast also contribute to the shift in Th1:Th2 
ratio (Chaouat et al., 1988). However, the complex nature of the immune adaptation is 
highlighted by the fact that despite a Th2 predominance being favourable in 
pregnancy, Th1 cytokines are important in early pregnancy and during labour (Saito 
et al., 1999).  
Also important in pregnancy are regulatory T (Treg) cells (reviewed by (La Rocca et 
al., 2014) which are involved in the regulation of peripheral self-tolerance and immune 
homeostasis (Sakaguchi, 2004, 2005; Wing and Sakaguchi, 2010) and constitute 5-
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50% of the peripheral CD4+ T cell compartment in mice and humans. In pregnancy, 
there is a peripheral increase of CD25+ T cells (Aluvihare et al., 2004) with seminal 
fluid being one of the main drivers of this adaptation (Robertson et al., 2009). There 
are several lines of evidence indicative of their role in promoting the survival of the 
allogeneic fetus by mediating maternal tolerance specifically in early pregnancy 
(Aluvihare et al., 2004; Jin et al., 2009; Shima et al., 2010; Winger and Reed, 2011; 




Figure 1.8 Normal and compromised maternal immune adaptations to pregnancy.  
In normally progressing pregnancies, maternal adaptation to pregnancy occurs, resulting in the 
maintenance of fetal immune tolerance (left). In turn, proper placentation and fetal development is 
supported. This successful adaptation is reflected by a well-developed immune system and a healthy 
child postnatally. Adverse effects of maternal immune adaptation to pregnancy may result from or be 
aggravated by exogenous or endogenous challenges (right). Endogenous challenges may include a KIR 
and HLA-C mismatch (Chazara et al., 2011) (Hiby et al., 2008), low amounts of maternal progesterone 
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(Hartwig et al., 2013) , advanced maternal age, which can be associated with low amounts of 
progesterone (Arck et al., 2008) or 'inflamm-aging' (Cannizzo et al., 2011)  (the low-grade, chronic, 
systemic inflammatory state that characterizes the aging process), possibly insufficient memory 
Treg cells and yet-to-be-identified factors. Exogenous challenges may include stress perception (Glaser 
and Kiecolt-Glaser, 2005) (Karimi and Arck, 2010) , infections (Van Kerkhove et al., 2011) , medication 
such as acetaminophen  (Thiele et al., 2013) and possibly vitamin D deficiency (Brannon, 2012). These 
challenges may result in a failure to maintain fetal immune tolerance and lead to pregnancy 
complications such as fetal loss, preterm labor, preeclampsia and poor fetal development. These 
complications may adversely affect the child's health and compromise their immunity later in life. (From 
(Arck et al., 2008). 
 




Other organs undergo adaptation to pregnancy as well (summarised in Table 1.1). The 
kidney has a number of essential physiological roles such as the excretion of specific 
metabolic waste products (urea, creatinine and uric acid), regulation of water and 
solute excretion. Additionally, secreting hormones (renin, prostaglandins and 
bradykinin) it also plays a role in the regulation of systemic and renal haemodynamics, 
red blood cell production (Adamson, 1996) and bone metabolism (Fukagawa et al., 
2006). Throughout the course of pregnancy, the kidney increases in size and weight as 
a result of the dilatation of the collecting system including the renal pelvis (funnel for 
urine flowing to the ureter) and the ureter (duct for urine passing from kidney to 
bladder) (Gordon, 2007). Global haemodynamic changes including vasodilation, high 
arterial flow and low resistance, as described previously, are primarily the effects of 
the hormone relaxin, released by the ovarian corpus luteum, which also induces 
increased renal plasma flow (RPF) and glomerular filtration rate (GFR) (reviewed by 
(Jeyabalan and Conrad, 2007). Kidney problems in pregnancy such as hypertension, 
renal insufficiency and nephrotic range proteinuria increase the risk of poor pregnancy 
outcome (Imbasciati and Ponticelli, 1991). For example, women with chronic renal 
disease are predisposed to IUGR and preeclampsia. Interestingly, there is also 
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suggestion that anti-angiogenic proteins released by the placenta, such as soluble Flt-
1 (sFlt-1), may play a role in the development of proteinuria and hypertension in 




The spleen is a the body’s largest lymphatic organ and has a number of important roles 
including the production of antibodies, storing platelets, recycling iron, filtering blood 
of foreign material and old/damaged red blood cells and platelets, and finally inducing 
adaptive immune responses (reviewed by (Mebius and Kraal, 2005). The spleen is 
organised into different functional regions including white pulp, red pulp and the 
marginal zone. White pulp, is involved in responding to blood-borne antigens, is the 
splenic lymphoid region containing T-cell zones, also known as periarteriolar 
lymphoid sheath (PALS), and B-cell zones. The red pulp is where blood filtration takes 
place and is composed of sinusoids and connective tissue known as the splenic cords 
of Billroth. Splenic adaptations to pregnancy include an increase in size, associated 
with the expansion of red pulp, and a significant accumulation of mRNAs associated 
with the erythroid lineage (Bustamante et al., 2008). Additionally, it can also act as a 
secondary site of erythropoiesis during stress (Mattsson et al., 1984)  (Welniak et al., 
2001) including pregnancy (Fowler and Nash, 1968) (de Rijk et al., 2002; Mattsson et 
al., 1984).  In the mouse, spleen size peaks at day e13.5 but returns to a non-pregnant 
size by e18.5. The splenic adaptations are believed to be mediated by the actions of 
PRL and PRL-like proteins produced by the placenta, both of which regulate 








The liver, the largest solid organ in the body, has a wide range of essential functions 
including glycolytic and urea metabolism, blood detoxification and modulating 
cholesterol levels, while supporting the digestion by processing the nutrients absorbed 
from the small intestine and secreting bile to aid in the digestion of lipids. Moreover, 
the liver is the primary site of haematopoiesis in the fetus with the bone marrow 
gradually replacing this role by the time of birth (reviewed by (Golden-Mason and 
O'Farrelly, 2002). In adulthood, this haematopoietic potential is retained and can be 
activated stress situations such as severe bone-marrow dysfunction (Golden-Mason 
and O'Farrelly, 2002). The liver contains an array of cells including cholangiocytes, 
endothelial cell, stellate cells and Kupffer cells but is primarily composed of 
hepatocytes (approx. 80%). The liver of the mouse adapts to the demands of pregnancy 
by increasing in size as a result of hepatocyte hyperplasia and hypertrophy (Dai et al., 
2011; Milona et al., 2010). The increase in size is evident by e13, peaks at e18 and 
returns to a pre-pregnancy weight by day 10 postpartum (Dai et al., 2011). The 
enhanced liver metabolism is essential to accommodate the increase demand for 
energy from the developing fetus and the detoxification of fetal metabolites. Liver 
adaptations are most likely driven by mechanisms similar to those previously 
described, including changes in insulin, insulin growth factor (IGF), GH, PLs and sex 
steroids (Augustine et al., 2008; Celton-Morizur et al., 2009; El Khattabi et al., 2006; 
Yamamoto et al., 2006). The potential pathological consequences of gestational 
metabolic stress on the liver are highlighted by pregnancy-specific liver diseases 
including intrahepatic cholestatis of pregnancy, haemolysis, elevated liver enzymes 






The pancreas is both an endocrine and exocrine organ that releases enzymes, such as 
trypsin, amylase and lipase, to help break down foods to mobilise nutrients, and also 
regulates the levels of circulating glucose by releasing insulin and glucagon. Insulin is 
produced by pancreatic -cells in response to a rise in blood glucose, resulting in the 
uptake of glucose by tissues. Glucagon is secreted by -cells in response to decreases 
blood glucose and leads to glycogenolysis, the breakdown of glycogen to glucose, 
primarily in the liver. As discussed previously , insulin resistance manifests in late 
pregnancy and is compensated by a higher rate of insulin biosynthesis resulting from 
a combination of increased -cell proliferation and, primarily, increased -cell 
sensitivity/hyperfunctionality in response to glucose (reviewed by (Bernard-Kargar 
and Ktorza, 2001; Ernst et al., 2011; Sorenson and Brelje, 1997). In rodents, -cell 
hyperfunctionality is observed between days e11 and e19 of gestation and returns to 
normal by parturition. These adaptations are brought about by PLs, PRL, and the sex 
steroids; oestrogen and progesterone (Brelje et al., 1993). Numerous studies indicate 
that failed -cell adaptation during pregnancy can lead to gestational diabetes mellitus 
(GDM), which increases the risk for fetal mortality or morbidity by increasing a risk 
of large-for-gestational-age (LGA) babies (reviewed by (Devlieger et al., 2008). 
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Organ Physical changes in 
pregnancy 
Examples of functional changes in 
pregnancy 
Kidney Increase in weight and 
size (increased vascular 
volume, glomerular size, 
dilated and elongated 
pelvises and ureters) 
Increased renal blood flow and glomerular 
filtration rate 
Increase in secretion of renin, erythropoietin 
and active vitamin D 
Spleen Increase in weight and 
size (primarily increase 
in red pulp) 
Increase in blood filtration rate 
Possible secondary site of erythropoiesis 




(in mice but not human) 
Enhanced metabolism  
Possible secondary site of erythropoiesis 
Pancreas Increase in weight and 
size (increased -cell 
proliferation) 
β-cell hyperfunctionality/ increase in 
sensitivity 
 
Table 1.1 Summary of some of the physical and functional changes of organs in pregnancy. 
 
1.4.9 The placenta 
 
The placenta is a transient organ that is unique to pregnancy and is vitally important 
for the survival, development and growth of mammalian embryos. It is the first organ 
to form during mammalian development and problems in its formation and/or function 
underlie many pregnancy complications (reviewed by (Rossant and Cross, 2001). It 
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acts as the main interface between mother and fetus and is where their circulations 
come into close proximity, allowing efficient nutrient and gas exchange as well as 
removal of fetal metabolic waste, all of which are essential for fetal growth and 
development. Furthermore, it acts an important source of pregnancy-associated 
hormones and growth factors, and is involved in immune protection of the fetus. 
Aberrant placental development and/or dysfunction, as a result of genetic or 
environmental insult, is believed to be a central factor in a high proportion of mid-late 
pregnancy complications such as abruption, pre-eclampsia and unexplained stillbirth 
(Smith and Fretts, 2007). Low birthweight/intrauterine growth restriction, without any 
obvious environmental or fetal causes, is often attributed to placental insufficiency.  
 
1.4.10  Placenta development 
 
In order to uncover the mechanisms that underlie impaired placental function it is 
essential to understand its structure and some of the key milestones in its development. 
Although the gross architecture of the human and mouse placenta differ slightly, their 
overall structures and molecular mechanisms behind placental development are 
considered to be similar (Rossant and Cross, 2001; Watson and Cross, 2005). When 
mature, both human and mouse placenta are composed of three major functional 
layers; 1. the outer maternal layer, decidua basalis (Db), which consists of uterine 
decidual cells, and maternal blood vasculature that supplies, as well as takes away, 
blood from the embryo; 2. an intermediate layer called the junctional zone (Jz) (also 
called spongiotrophoblast layer) which has a largely endocrine function; 3. an inner 
layer closest to the chorionic plate, the labyrinth zone (Lz), where the maternal and 
fetal circulations are brought into close proximity to allow for haemotrophic exchange. 
The labyrinth, analogous to the villus in humans, is involved in the transport of gases, 
nutrients and waste products between the maternal and fetal circulations throughout 




Figure 1.9 Placental development in the mouse. 
After formation of the blastocyst, where extraembryonic lineage formation begins, chorioallantoic 
attachment occurs at e8.5, followed by branching morphogenesis of the labyrinth to form dense villi, 
within which nutrients are exchanged (e8.5–10.5). The mature placenta (e14.5) consists of three layers: 
the labyrinth, the spongiotrophoblast, and the maternal decidua. (From (Watson and Cross, 2005)). 
 
The placenta develops (Figure 1.9, Figure 1.10) from the trophectoderm layer that is 
set aside from the inner cell mass in the blastocyst at embryonic day (e) 3.5. In parallel 
with implantation, the mural trophectoderm (TE) (i.e. trophectoderm not touching the 
inner cell mass) differentiates into trophoblast giant cells (TGCs) to become the first 
terminally differentiated cell type to form during development. These TGCs are vital 
for successful embryo implantation and promoting maternal adaptations to pregnancy 
(Hu and Cross, 2010). This is followed by the differentiation of the polar 
trophectoderm into extra-embryonic ectoderm which develops into trophoblast cells 
of the chorion layer and subsequently the labyrinth, and the ectoplacental cone, the 
 57 
precursor of junctional zone which, when mature, contains spongiotrophoblast cells, 
glycogen trophoblast cells and trophoblast giant cells which line its border with the 
decidua (Simmons et al., 2007).   
 
 
Figure 1.10 Lineage segregation within the mouse blastocyst and early placenta. 
A) At day e3.5, the blastocyst comprises an outer trophectoderm (TE) destined to populate the placenta 
and an inner cell mass (ICM) destined to form the embryo. TE cells not in direct contact with the ICM 
form the mural TE, whereas those adjacent to the ICM form the polar TE. The polar TE gives rise to 
the extraembryonic ectoderm. B) Following implantation, mural TEs initiate the first wave of 
trophoblast giant cells (TGC) differentiation to form primary TGCs (1° TGCs), which contribute 
directly to the parietal TGC (P-TGC) population. Cells within the polar TE continue to proliferate and 
populate the ExE. Some secondary TGCs (2° TGCs) arise directly from the extraembryonic ectoderm. 
Along with 1° TGCs, they compose the parietal TGC (P-TGC) population that lines the implantation 
site. Cells within the extraembryonic ectoderm then differentiate to form the chorionic plate and the 
ectoplacental cone (EPC). The chorionic plate is responsible for populating the mouse labyrinth with 
multinucleated syncytiotrophoblasts (SynTs) and a subset of 2° TGCs called sinusoidal TGCs (S-
TGCs). Together, these cells are responsible for the transport functions of the placenta. Cells within the 
ectoplacental cone can either differentiate into a population of lineage-committed progenitors known as 
spongiotrophoblasts (SpTs), which then differentiate into 2° TGCs, or they can directly differentiate 
into various 2° TGCs subtypes. From (Maltepe et al., 2010). 
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Glycogen trophoblast cells differentiate within the spongiotrophoblast layer of the 
junctional zone and after e12.5 they begin to interstitially invade the decidua 
(Adamson et al., 2002). The extraembryonic mesoderm, also known as the allantois, 
gives rise to the vascular portion of the placenta. At e8.5 the allantois fuses with the 
chorion (the cellular, outermost extraembryonic membrane) in a process called 
chorioallantoic attachment. The chorion begins to fold in order to create spaces called 
villi into which fetal blood vessels grow from the allantois (Cross et al., 2006). During 
this time, the chorionic trophoblast cells begin to differentiate into the two labyrinth 
cells types – the syncytiotrophoblast cells which surround the fetal endothelium of the 
capillaries and the sinusoidal trophoblast giant cells which line the maternal blood 
sinuses. These trophoblasts, together with the fetal vasculature, mark the third 
milestone of placental development where they generate extensively branched villi of 
the labyrinth, starting after e8.5, that continue to grow and become larger and 
increasingly branched up until birth (Cross et al., 2006). If this process fails and the 
labyrinth is not appropriately vascularised (i.e. suitable patterning, branching and 
dilation) it impairs placental perfusion, which can result in poor oxygen and nutrient 
diffusion (Pardi et al., 2002; Watson and Cross, 2005). Following chorioallantoic 
attachment branching of morphogenesis of the labyrinth occurs so that from e10 the 
placenta is capable of hemotrophic exchange where blood-borne materials can be 
exchanged between maternal and fetal blood. Maximum hemotrophic exchange 
doesn’t occur until  14.5 when the placenta is fully mature (reviewed by (Watson and 





Figure 1.11 Comparison of human and mouse gross placental structure. (Adapted from (Rossant and Cross, 2001). 
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1.4.11 Placenta functions 
 
The placenta is not only the main interface between the mother and the fetus, 
responsible to nutrient transport, but is also an endocrine organ capable of controlling 
maternal physiological adaptations to pregnancy. Moreover, evidence is emerging that 
the placenta actively responds to nutritional and metabolic signals from both mother 
and fetus is able to respond to these different cues by altering its structure and function 
thereby regulating fetal growth (reviewed by (Diaz et al., 2014).   
 
1.4.11.1.1 Nutrient and gas transport 
 
Fetal growth is largely dependent on the supply of nutrients and gases (oxygen and 
carbon dioxide) across the placenta (reviewed by (Lager and Powell, 2012). Gas 
transfer is primarily determined by blood flow whereas transport of nutrients can be 
passive or active. Factors that influence placental transport include uteroplacental and 
umbilical blood flows, size of the labyrinth, maternal and placental metabolism, and 
activity/expression of specific transporter proteins in the placental barrier; the 




Glucose, the primary energy source for the fetus, is transported by facilitated diffusion 
and dependent on a number of factors (reviewed by (Baumann et al., 2002) such as 
glucose supply (determined by maternal blood glucose concentration and blood flow) 
and the maternal-fetal glucose concentration gradient, placental glucose metabolism 
(dependent on supply of other energy generating substrates such as oxygen), and 
placental glucose transporter density in the syncytiotrophoblasts of the labyrinth. 
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Glucose transporter proteins (GLUTs) are responsible for the facilitated carrier-
mediated diffusion, in particular GLUT-1 (Slc2a1) and GLUT-3 (Slc2a1). 
 
1.4.11.1.3 Amino acids 
 
Amino acid transport is mediated by active transporters which are either accumulative 
transporters; increasing intracellular amino acid concentrations by mediating uptake 
against their concentration gradient, or exchangers; exchange amino acids between the 
intracellular and extracellular compartments (Lager and Powell, 2012). Amino acid 
transporters are sub-divided into systems (system A, system L and system) depending 
on which type of amino acids they transport and whether they are sodium-dependent. 
System A is sodium-dependent and transports small non-essential neutral amino acids 
such as glycine, serine and alanine. Importantly, it increases the intracellular 
concentration of these amino acids, which are exchanged by system L for extracellular 
essential amino acids, which cannot be made by the body (Lager and Powell, 2012). 
The three isoforms of system A include SNAT1 (Slc38A1), SNAT2 (Slc38a2) and 
SNAT4 (Slc38a4). System L includes LAT1 (Slc7a5) or LAT2 (Slc7a8) (reviewed by 
(Verrey, 2003). System  transports taurine, not strictly an amino acid, but which the 
fetus is unable to synthesize, against its concentration gradient energized by co-
transport with sodium and chloride (Lager and Powell, 2012). 
 
1.4.12 Endocrine functions 
 
The placenta has important endocrine functions that ensure the maintenance of 
pregnancy and reprogram maternal physiology in order for the fetus to thrive. Placental 
endocrine functions in humans and mice are associated with primarily with the 
junctional zone but also the decidua, and although they differ to some extent, both 
species synthesise overlapping sets of pregnancy-specific hormones that bring about 
very similar effects (reviewed by (Malassine et al., 2003) (Figure 1.12). The primary 
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difference is that in mouse, the placenta takes over stimulating the corpus luteum to 
produce hormones for the maintenance of pregnancy, substituting for PRL produced 
by the maternal pituitary, whereas in humans the placenta itself takes over in the 
production of hormones (Strauss et al., 1996). The placental hormones responsible for 
this regulation are mouse PL I (mPLI) and mouse PL II (mPLII). Both these hormones 
are PRL-like hormones and bind to the prolactin receptor (PRLr), which is found not 
only in the ovary but also in a range of maternal tissues. Therefore, the PLs display a 
wide range of activities in addition to the continuous production of progesterone by 
the corpus luteum. PLs also promote fetal growth directly (Talamantes et al., 1980) 
and indirectly by inducing many maternal adaptations such as the changes in maternal 
glucose metabolism (Handwerger and Freemark, 2000) and mobilization of glucose 
from maternal liver glycogen by promoting hepatic gluconeogenesis (Ogren and 
Talamantes, 1988). mPLI and mPLII are both produced by trophoblast giant cells in 
the junctional zone, with mPLI peaking on day e10, declining after day e11 and 
remaining low. Following the peak of mPLI, mPLII increases rapidly by e14 and 
remains high for the remainder of gestation (Talamantes et al., 1980). Furthermore, the 
mouse placenta also produces two non-classical members of the same family; 
proliferin (mPLF) and proliferin-related protein (mPRP) which are also expressed by 
trophoblast giant cells. Both can modulate angiogenesis and have been implicated in 
the appropriate vascularization of the implantation site in early pregnancy by 
stimulating growth of maternal blood vessels in the decidua toward the implantation 




 Figure 1.12  Endocrine comparison of mouse and human placenta. 
Comparative endocrine functions of the murine and human placenta. (A) In mice, the corpus luteum is 
the primary source of progesterone (P4) and estradiol (E2) production required for the maintenance of 
pregnancy as well as maternal adaptations to pregnancy. Initially, mouse pituitary prolactin (mPRL) 
secreted by the pituitary stimulates the endocrine function of the ovary but in later gestation this is taken 
over approx. on day 11 by mouse placental lactogen I (mPLI) and mouse placental lactogen II (mPLII) 
produced by the trophoblast giant cells (TGCs) in the junctional zone of the placenta.(B) In humans, the 
maintenance of the pregnancy is also initially maintained by the corpus luteum stimulated by hCG. In 
later pregnancy, the syncytiotrophoblast layer of the placenta takes over P4 and E2 production and also 
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produces human chorionic somatomammotrophic hormone (hCS) and human placental growth hormone 
(hPGH). (From (Malassine et al., 2003). 
 
Humans also produce PL (hPL), also known as human chorionic 
somatomammotrophic hormone (hCS), which similarly to mPL lactogen has been 
shown to regulate maternal metabolism and fetal growth (Chellakooty et al, 2004 pp. 
384; Mirlesse et al, 1993 pp. 439; Koutsaki et al, 2011 pp. 31; Handwerger and 
Freemark et al, 2000 pp. 343). The PLs regulate fetal growth in concert with 
maternally- and placental-derived insulin-like growth factors (IGF-I and IGF-II) and 
their cell surface receptors (IGF-IR and IGF-IIR) (Constancia et al., 2002; Forbes et 
al., 2008). This has been demonstrated in placental-specific IGF-II knockout mice 
(P0), which lack the placental-specific IGF-II promoter, resulting in reduced placental 
weight and IUGR (Constancia et al., 2002) and in human studies where low circulating 
IGF-I levels or mutations cause severe IUGR (Gibson et al., 2001). Specifically, these 
growth hormones ensure placental blood flow and nutrients to the fetus by controlling 
placental cell turnover, proliferation, survival and differentiation as demonstrated in 
vitro (Forbes et al., 2008) .   
In humans, the placenta produces human chorionic gonadotropin (hCG) which acts as 
a luteinising hormone (LH) -superagonist to maintain the corpus luteum, for the 
production of progesterone, which is taken over approximately after 8 weeks of 
gestation by the syncytiotrophoblast cells in the labyrinth of the placenta. hCG is also 
involved in the differentiation of cytotrophoblasts into syncytiotrophoblasts (Shi et al., 
1993; Yang et al., 2003) further ensuring progesterone production.  
A second major difference between the mouse and human placenta is that the human 
placenta in the second half of gestation produces high amounts of steroids (Albrecht 
and Pepe, 1990; Pepe and Albrecht, 1995). Both progesterone and oestrogen are 
produced by syncytiotrophoblasts, where progesterone is synthesized from maternal 
lipoprotein cholesterol and oestrogen is synthesized from the conversion of androgens 
by syncytiotrophoblastic cytochrome p450 aromatase (reviewed by (Malassine et al., 
2003). Furthermore, differences in the expression of 11 beta-hydroxysteroid 
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dehydrogenase type 2 (11-HSD-2) are present, as it is expressed throughout gestation 
in human but switched off in mid-gestation the mouse (Brown et al., 1996). 11-HSD-
2 inactivates corticosterone (cortisol in humans) by conversion into inert forms 
(cortisone, 11-dehydrocorticosterone) which is believed to protect the fetus from 
maternal glucocorticoids. In humans, low levels or absence of 11-HSD-2 is 
associated with IUGR (Dave-Sharma et al., 1998; McTernan et al., 2001), but this 
effect is strain dependent in mouse as 11-HSD-2 null mice can exhibit normal 
(Kotelevtsev et al., 1999) or reduced birthweight (Holmes et al., 2006).  
 
1.4.13 Pregnancy complication: IUGR and stillbirth 
 
Intrauterine growth restriction, present in 7-10% of pregnancies (Demicheva and 
Crispi, 2014), is defined as the failure of the fetus to reach its genetic growth potential 
and, next to prematurity, is the second leading cause of perinatal death (Chiswick, 
1985; Gardosi et al., 1998). A review of perinatal mortality records highlights that up 
to 53% of preterm stillbirths and 26% of term stillbirths are growth restricted (Gardosi 
et al., 1998). Currently, no treatment is available for growth restriction in utero, with 
the only option to prevent in utero death being pre-term delivery, which may also 
compromise the fetus if it is very premature. Furthermore, IUGR is associated an 
increased risk of neurodevelopmental problems in childhood as well as with a number 
of adult-onset morbidities such as obesity, hypertension, cardiovascular disease and 
type 2 diabetes, in both human epidemiologic studies and in animal models (reviewed 
by (Salam et al., 2014). IUGR also present signs of cardiac dysfunction in utero that 
persist postnatally and may condition a higher cardiovascular risk later in life 
(Demicheva and Crispi, 2014). IUGR is associated numerous causative factors which 
can either individually or synergistically impact fetal growth. Generally, the causes of 
IUGR are classified as maternal, placental and/or fetal although in at least 40% of 
IUGR cases the underlying cause is unknown (reviewed by (Wollmann, 1998). 
Maternal causes include nutritional deficiencies, poor maternal weight gain as well as 
conditions such hypertensive disorders, chronic renal disease, severe anaemia, uterine 
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malformations and diabetes mellitus (Wollmann, 1998). Aberrant maternal uterine 
artery remodelling and subsequent decreased uteroplacental blood flow accounts for a 
high number of IUGR cases (Lyall et al., 2013). IUGR generally develops either in 
early gestation, often referred to as early-onset IUGR, or late in gestation referred to 
as late-onset IUGR. Early-onset IUGR is often associated inappropriate spiral artery 
remodelling and is therefore often considered to be a vascular disorder as in the case 
of preeclampsia (Muresan et al., 2016). Late-onset IUGR in humans is most often 
cause by fetal hypoxemia/hypoxia secondary of placental insufficiency (Muresan et 
al., 2016). 
 
Interestingly, epidemiological studies demonstrated that women born growth-
restricted have an increased risk of having an IUGR baby (Skjaerven et al., 1997). 
Furthermore, a previous IUGR baby increases the risk of IUGR reoccurrence in a 
subsequent pregnancy (Skjaerven et al., 1988). Feto-placental causes include 
chromosomal and or structural anomalies in the fetus and/or the placenta, intrauterine 
infections and multiple pregnancies (Wollmann, 1998). Placental insufficiency is 
recognized as the leading cause of IUGR and refers to the inability of a placenta to 
provide sufficient oxygen and/or nutrients to the fetus; it results from numerous factors 
such as inappropriate placental development, insufficient maternal uterine artery 
remodelling and/or fetal spiral artery remodelling and reduced nutrient transport. 
When diagnosing IUGR it is important to be able to distinguish between fetuses which 
are constitutionally small and not at an increased risk of an adverse outcome versus 
those which are pathologically small and at risk of mortality or morbidity. In order for 
this distinction to be made, a classification of birthweights using population-based sex-
adjusted centiles is often used and is sub-divided as birth weights which are very small 
for gestational age (<3rd percentile), small for gestational age (<10th percentile), 
appropriate for gestational age (10th to 90th percentile) and large for gestational age 
(>90th percentile). Recently, individualized birthweight ratios (IBRs), which take into 
consideration maternal variables such as parity, ethnicity, weight and height are being 
utilised to generate customised birthweight centiles and improve the accuracy of 
diagnosis and prediction of outcome (Clausson et al., 2001; de Jong et al., 1998; 




Figure 1.13 Changes in Doppler flow velocity waveforms of the uterine artery and umbilical 
artery in mouse during gestation. 
A) At e9.5 Doppler flow velocity waveforms show a prominent notch (arrow) which is absent at e15.5 
following remodelling. If inappropriate remodelling occurs waveforms in late gestation resemble 
those of early gestation.  B) Normal umbilical velocity waveforms during gestation showing the 
increase of end diastolic velocity from e15.5 (arrow). (Adapted from (Mu and Adamson, 2006). 
 
accurately defining IUGR (Alexander et al., 1996; Brenner et al., 1976; Gardosi et al., 
1995; Hadlock et al., 1991; Resnik, 2007; Zhang et al., 2011). IUGR is also classed as 
either symmetric or asymmetric. Asymmetric IUGR is characterised by a reduction in 
fetal abdominal circumference, which results from the reduction in liver volume due 
to glycogen depletion in an attempt to compensate for the limited nutrient supply. 
However, the head circumference remains relatively normal. It is believed to often 
manifest in the second half of gestation and is commonly associated with 
uteroplacental insufficiency whereby ‘elevations in placental blood flow resistance 
increase right cardiac afterload and promote diversion of the cardiac output toward the 
left ventricle owing to the parallel arrangement of the fetal circulation and the presence 
of central shunts. Blood and nutrient supply to the upper part of the body thus increase 
and result in relative head sparing’ (Gordon, 2007). Symmetric IUGR is where body 
and head growth are affected to the same degree resulting in a uniformly small fetus. 
This type of IUGR is most often associated with congenital anomalies of fetal origin 
such as aneuploidy syndromes and infection and is believed to more commonly 
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manifest in early pregnancy. It is important to note that the IUGR type can change over 
the course of pregnancy depending on the underlying cause and duration of the insult.  
IUGR is a major risk factor for stillbirth; a devastating outcome of pregnancy which 
in the UK occurs in about one in 200 pregnancies (Smith and Fretts, 2007). Other risk 
factors in women include placental dysfunction (being the most common cause of 
IUGR), nulliparity, advanced age and obesity (Smith and Fretts, 2007). Many cases of 
stillbirths however, occur in women with none of the above risk factors and often 
remain unexplained, particularly after 28 weeks of gestation, irrespective of whether 
the fetus was classifies as SGA or AGA (Figure 1.14). This is partly due to a lack of 
uniform protocols globally for assessment and classification of stillbirths as well as a 
low rate of autopsies (Smith and Fretts, 2007). There is a limited number of test that 
can be done in humans to assess the risk of stillbirth such as measurement the 
measurement of a some placental proteins including pregnancy-associated plasma 
protein A (PAPP-A) (Dugoff et al., 2004; Smith et al., 2002)  and α-fetoprotein  (AFP) 
in maternal blood (Waller et al., 1993). Additionally, the hemodynamic properties of 
the uterine and placental arteries, essential for providing an adequate blood supply to 
the feto-placental unit, can be assessed using Doppler ultrasound (Lees et al., 2001). 
However, these techniques are rarely used in pregnancies which are considered at low 
risk of complications and therefore fail to prevent stillbirths in such cases. Further 
research is needed particularly into the pathophysiology of stillbirth as well as 
developing new, reliable and easy predictive and preventative tests. 




Figure 1.14 Causes of stillbirth with modified version of Wigglesworth classification for all 
singleton births in Scotland, 1992–2001. 
 
Data from 2635 antepartum stillbirths, from a total of 563 719 births (rate 4·7 per 1000). Over the same 
period, there were 320 intrapartum stillbirths in 561 084 singletons alive at the onset of labour. 75% of 
these stillbirths were anoxic, 17% were classified as caused by congenital abnormality, and the 
remaining 8% had diverse other causes. SGA=small for gestational age (smallest decile of birthweight 
for sex and week of gestation). AGA=appropriate for gestational age (rest of population). From (Smith 
and Fretts, 2007). 
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1.5 Work leading up to PhD project 
 
Prior to the start of my PhD, preliminary characterization of the phenotype of Pabp4-
/- and Pabp4+/- mice was undertaken. Interestingly, this revealed a role for maternally 
expressed PABP4 in fetal viability and growth during mid to late pregnancy; forming 
the basis for my PhD studies. Specifically, Pabp4-/- crosses led to a severe reduction in 
litter size (Figure 1.16.A). Analysis of uteri of pregnant Pabp4-/- females 1-2 days prior 
to birth revealed multiple resorbing embryos (Figure 1.16.B). The resorptions were not 
specifically positioned within the uterus and were heterogeneous in size, suggesting 
that death occurred at different developmental stages. Importantly, ~50% of resorbing 
embryos were similar in size to viable embryos and possessed placentas, suggesting 
mid-late intrauterine mortality (Figure 1.16.B). Within these litters, a significant 
number of surviving pups appeared growth restricted (Figure 1.16.C). Interestingly, 
these phenotypes were also present, but less prominent, in Pabp4+/- intercrosses, 
signifying that complete absence of PABP4 function is not required for phenotype 
development (i.e. haploinsufficiency). A histopathological survey showed an absence 
of gross histological abnormalities in other tissues that normally express PABP4 
(Figure 1.15) which, taken together with the haploinsufficiency, increases the 
likelihood that similar phenotypes occur in the human population.  
 
 





Figure 1.16. PABP4 haploinsufficiency and deficiency results in reduced litter size at birth and 
small fetuses (courtesy of Matt Brook).  
A) Litter sizes from timed matings are significantly reduced in Pabp4+/- x Pabp4+/- (HetxHet) (n=14) 
and Pabp4-/- x Pabp4-/- (KOxKO) (n=7) crosses in comparison to Pabp+/+ (WT) control crosses (n=6) at 
e18.5. Statistical significance was assessed by Students t-test and significance was accepted at p<0.05. 
B) e18.5 uterus containing both mid- () and late-stage () resorptions. No viable embryos were 
present. C) Example of observed small for gestational age (SGA) fetuses of different genotype at e18.5 
suggesting SGA is independent of fetal genotype. 
 
Surprisingly, genotype analysis of Pabp4+/- intercrosses at e18.5 revealed that Pabp4-
/- pups were present at approximately Mendelian ratios (Figure 1.17. A) and that 
additional crosses between Pabp4-/- males and Pabp4+/+ females resulted in a normal 
mean litter size (Figure 1.17. B). In contrast, Pabp4+/+ male x Pabp4-/- female crosses 
resulted in a reduced mean litter size (Figure 1.18), indicating that maternal PABP4 






Figure 1.17. Mendelian ratios are observed at e18.5 and PABP4 KO males show normal sized 
litter at e18.5 (courtesy of Matt Brook). 
A) Mendelian ratios are observed for litters at weaning and in viable e18.5 embryos (n=11). B) Pabp4-
/- (KO) males show normal-sized litters at e18.5. Comparison of mean litter sizes based on litters from 
Pabp4+/+ (WTxWT) crosses (n=6) and KOxWT crosses (n=7) at e18.5 (Labels correspond to ♂x♀). 














Mean Litter Size 
** 
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Comparison of mean litter sizes from Pabp4+/+ WTxWT crosses (n=7) and WTxPabp4-/-(KO) crosses 
(n=11) housed as pairs for 30 weeks at birth (Labels correspond to ♂x♀). Statistical significance was 
assessed by two-tailed Mann Whitney test and significance was accepted at p<0.05. p=0.0028 
 
Overall, these data indicate that maternal PABP4 deficiency may provide a novel tool 
for studying defects in the maternal environment, which can lead to pregnancy 
problems including late miscarriage, IUGR and stillbirth.  
Thus, the aim of my PhD is to characterise the phenotype of PABP4-deficient mice to 
establish the timing, nature and physiological and/or cellular basis of the primary 
defect. This will shed light on the biological roles of PABP4 in mammals and, in so 
doing, will contribute to the knowledge of how regulated mRNA translation and 
stability contribute to the feto-maternal dialogue.  
 
 
1.6 Hypothesis  
 
PABP4 acts as a “master regulator” of the expression of factors required for 
coordinated development and/or function of the materno-fetal interface, by regulating 
mRNA translation and stability. 
This hypothesis is addressed in the next four results chapters. 
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Chapter 2 - Materials and Methods 
 
2.1 Buffers and solutions 
 
6 x DNA loading buffer 
-0.03% bromophenol blue 
-0.03% xylene cyanol FF 
-30% glycerol 
-60 mM EDTA 
-10 mM Tris-HCl (pH 7.6) 
 
TAE agarose gel running buffer   
-90 mM Tris-HCl (pH 8.3)  
-90 mM acetic acid 
-2 mM EDTA  
 
 
NuPAGE Transfer buffer (pH 7.4)  
-25 mM Tris-base 




PBS (Phosphate buffered saline) (pH 7.4) 
-137 mM NaCl 
-6.5 mM Na2HPO4  
-2.7 mM KCl 
-1.5 mM KH2PO4 
 
PBS-T (PBS-Tween-20) (pH 7.4) 
-PBS (pH 7.4) 
-0.1% Tween-20 
 
Phospho-Radio-Immunoprecipitation Assay (RIPA) buffer (pH 7.4) 
-50 mM Tris-base  
-150 mM NaCl 
-1 mM EDTA 
-1% NP40 
-0.2% SDS 
-10 mM sodium pyrophosphate 
-25 mM β-glycerophosphate 
-0.5% sodium deoxycholate 
-100 mM sodium orthovanadate 
-5 mM sodium fluoride 
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-1 mM DTT 
-1 complete protease inhibitor cocktail tablet (Roche) 
-10 nM Calyculin A 
 
Protein purification lysis buffer (on ice) 
-20 mM Tris-HCl (pH 8) 
-150 mM NaCl 
-10 mM Imidazole 
-1 complete protease inhibitor cocktail tablet, EDTA free (Roche) 
-1 x BugBuster solution (Novagen) 
-1 mM DTT 
-25 units/ml benzonase 
-1000 units/ml lysozyme 
 
4 x Sample Loading Buffer 
-20% Glycerol 
-200 mM 2-mercaptoethanol 
-4% SDS 
-0.2% Bromophenol blue 
-100 mM Tris-HCl (pH 6.8) 
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Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) running 
buffer (pH 8.8) 
-25 mM Tris-base 
-250 mM Glycine 
-0.1% SDS  
 
20 x SSC (Sodium Chloride / Sodium Citrate buffer) (pH 7.0) 
-3 M NaCl 
-0.3 M Na3C6H5O7.2H2O 
 
TBS (Tris-buffered saline) (pH 7.4) 
-10 mM Tris-base 







2.2 Mouse work 
 
2.2.1 PABP4 Knock-out mouse strategy  
 
The vector and ES cell(s) used to generate the mice for this project were generated by 
the trans-NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP 
Repository (www.komp.org). NIH grants to Velocigene at Regeneron Inc 
(U01HG004085) and the CSD Consortium (U01HG004080) funded the generation of 
gene-targeted ES cells for 8500 genes in the KOMP Program and archived and 
distributed by the KOMP Repository at UC Davis and CHORI (U42RR024244). (For 
more information or to obtain KOMP products go to www.komp.org or email 
service@komp.org.) 
Knock-out first conditional ready PABP4 (MGI:2385206) mice used were created by 
the Sanger Centre  (Hinxton, Cambridgeshire, UK) but were missing a loxP site and 
were therefore not conditional. These mice were named NTP4 (knock-out) and were 
maintained on a C57BL/6N background.  
 
The PABP4 KO strategy is outlined in detail at the start of Chapter 3. 
 
2.2.2 Mouse husbandry and welfare  
 
Animals were maintained in the Biomedical Research Facility at Little France, 
University of Edinburgh on a 12 hour light/dark regime, with humidity maintained at 
55% and temperature between 20 and 25°C as specified in the Animal Act, 1986 
(Scientific Procedures). Food and water were available ad libitum. All animals were 
fed commercial pelleted mouse feed. All procedures were undertaken according to the 
UK Home Office regulations. Animals were culled by inhalation of rising 
concentration of carbon dioxide (Schedule 1 method). Timed matings were carried out 
under my direction by facility staff.  
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2.2.3 Timed matings  
 
To investigate timing of the phenotype and underlying defects timed matings with 
individual pairs were set up using virgin females between 8-12 weeks and male studs 
between 8 weeks up to 6 months. The following crosses were used, Pabp4+/+ x Pabp4-
/- (KO cross) and Pabp4+/+ x Pabp4+/+ (wild-type control cross), male genotype is 
listed first. Females were examined for post-copulatory vaginal plugs with the morning 
of discovery being designated as 0.5 days post-coitum (0.5dpc). Following the 
discovery of a plug, females were separated from the male. Following Schedule 1, 
pregnant dams were placed in a supine position to allow for collection of blood (see 
Blood collection and blood glucose measurements) and the removal of the intact uterus 
through the abdomen.  
 
2.2.4 Maternal organ and feto-placental unit collection and 
measurements 
 
For the collection of e8.5 and e10.5 and e13.5 materno-fetal units, the entire uterus 
was placed into fix (see Fixation, embedding and sectioning). Once fixed, individual 
implantation sites were dissected out and trimmed from excess inter-implantation 
uterine muscular wall (Figure 2.5). Where appropriate maternal body weight was 
determined after removal of the uterus.  
Uteri from later gestation time-points (e15.5 and e18.5) were removed from the 
abdomen with embryos and placentas dissected out prior to measurement and were 
subsequently fixed. This was done by cutting the muscle layer of the uterus followed 
by tearing of the yolk sac with tweezers to obtain the embryo and placenta. The 
allantois was cut to free the placenta from the embryo. The embryo crown-rump length 
was measured using a digital calliper (World Precision Instruments, Ltd.) before being 
weighed and placed into fix. Placental diameter was also measured using a digital 
calliper, weight was also recorded. Placentas were either fixed whole immediately in 
4% NBF (see Fixation, embedding and sectioning) or hemisected using a double-edged 
razor blade with one half snap frozen and the other half fixed in 4% NBF. For all time-
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points maternal organs (brain, heart, thyroid gland, liver, kidney, adrenal 
gland,pancreas and spleen) were dissected out, spot blotted, weighed and fixed. 
 
 
2.2.5 Fetal and Head and abdominal measurements 
 
Following fixation, head and abdominal measurements were taken using digital 
callipers (World Precision Instruments, Ltd.) (Figure 2.1). Head and abdomen 
circumference were calculated from these measurements using the following Ellipse 
formula: 
 
= 𝜋 ∗ √(2 ∗ ((
1
2
 𝑙𝑜𝑛𝑔 𝑎𝑥𝑖𝑠) ² + (
1
2
 𝑠ℎ𝑜𝑟𝑡 𝑎𝑥𝑖𝑠) ²) 
The head:abdominal ratio was calculated from this to determine whether growth 




Figure 2.1 Fetal head and abdomen measurements. 
Head measurements; A – short axis, C – long axis. Abdominal measurements; B – long axis, D – short 




2.2.6 Blood collection and blood glucose measurements 
 
Following Schedule 1, non-pregnant and pregnant dams were placed in a supine 
position, the abdomen was immediately cut open and blood was collected from the 
abdominal aorta. Prior to being transferred to Lithium Heparin 1.3ml microtubes 
(Sarstedt, Germany) blood glucose levels were determine using maltose free Accu-
chek strips and an Accu-chek  glucose meter (Aviva, Roche). For haematological 
analysis, whole blood in the Lithium Heparin tubes was placed on ice and transported 
to Easter Bush Pathology (Edinburgh) where it was analysed using an automated flow 
cytometer-based haematological analyser. For plasma analysis, blood samples were 
centrifuged at 1000 x g for 5 mins in a refrigerated centrifuge at 4 °C. Plasma (the 
resulting supernatant), was immediately transferred into a clean polypropylene tube 
using a pipette. Samples were stored at -20°C prior to analysis, transferred on wet ice 
and immediately analysed on arrival at the the Wellcome Trust Supported Cambridge 
Mouse Biochemistry Laboratory ( Table 2.1).    
Fetal blood glucose was obtained using the same strips and glucose meter as maternal 










The Computer Assisted Stereology Toolbox (CAST) 2.0 system (Olympus, Ballerup, 
Denmark) was used to for stereological analysis of the placenta and has been described 
elsewhere (Coan et al., 2004) but is briefly outlined below. 
 
2.2.7.1 Absolute Placental Volume  
 
A 32-point grid was superimposed on placenta sections using a 1.25x objective lens 
allowing to view a complete placenta section. Points of the 32-point grid which fell on 
the placenta section were counted and the Cavalieri principle was applied to determine 
a volume estimate (Gundersen and Osterby, 1981): 
 
V(obj) = t x Σa = t x a(p) x ΣP 
 
V(obj) is the estimated placental volume, t is the total thickness of the placenta (total 
number of sections multiplied by section thickness), a(p) is the area associated with 
each point, and Σ P is the sum of points on sections (Coan et al., 2004). 
 
Shrinkage due to the process of fixation and embedding was taken into account by 
measuring the diameter of randomly selected maternal erythrocytes and comparing 
this value to that of a fresh maternal erythrocyte and used to calculate a shrinkage 







2.2.7.2 Volume of Placental zones 
 
 A so called ‘meander’ sampling function of the CAST software was used to view 
random fields with the placenta section using a 10x objective lens and point counting 
was done for points which fell on each placental zone. Volume of each zone was 
then estimated using the following equation:  
Vv(struct,ref)  = P(struct) / P(total)   
where Vv(struct) is the volume fraction of a component (e.g., labyrinth zone) within a 
reference space (e.g., placenta), P(struct) is the number of points falling on the 
component, and P(total) is the total number of points falling on the reference space 
(including the component) (Coan et al., 2004). Finally the volume densities for each 
zone were multiplied by total placental volume to convert to absolute quantities (Coan 
et al., 2004). 
 
 
2.2.8 Ultrasound Doppler imaging 
 
Vevo 770 High-Resolution In Vivo Micro-Imaging System (FUJIFILM, VisualSonics, 
Toronto, Canada; equipped with four different transducers with central frequencies 
ranging from 20- 40 MHz) was used to collect ultrasound data from non-pregnant or 
pregnant females at e17.5 of gestation. Females were anesthetized using isoflurane 
(2%), laid in a supine position and paws taped to limb leads on the platform to monitor 
heart and respiration rates whilst ventilated with 100% oxygen and isoflurane 
anesthesia (Figure 2.2). Body temperature was monitored using a rectal thermometer 
and maintained between 36-38°C using a heating pad and a lamp. The abdomen of the 
mouse was shaved and remaining hairs were removed using a chemical hair remover. 
Remnants of the chemical hair remover were washed away using water and gauze. As 
the procedure was terminal lubricant was not applied to the eyes which is normally 
used to prevent damage of the corneas as a result of dehydration. Pre-warmed 
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ultrasound gel was applied to the shaved abdomen and used as an acoustic coupling 
medium. The platform on which the mouse is laid out in a supine position is tilted to 
displace the abdominal organs in the cranial direction helping to reveal the uterine 
artery in the pelvis. The uterine was located ventral to the bladder, by the uterocervical 
junction (Figure 2.3). Furthermore, ultrasound waveforms were obtained for umbilical 
arteries of at least three fetuses in each litter, maternal carotid artery and common 
carotid artery. Ultrasound measurements were taken in collaboration with an 
experienced ultrasound technician, Adrian Thomson. All waveform were analysed 




Figure 2.2. Ultrasound imaging of females. 
Positioning and ultrasound imaging of an anesthetized, dorsally recumbent pregnant mouse (A) as an 
aerial view and (B) in transverse cross-section. All hair was removed from the ventral abdomen after 
the mouse was anesthetized with approximately 2.0% (1.5% to 2.5%) isoflurane. The mouse then was 
placed on the platform and held in position with surgical tape. A thick layer of warm water-based 
coupling gel was applied over the skin of the area to be imaged. A 30-MHz transducer probe was applied 
 86 
to the skin to collect images. The transabdomenal area (boxed region in A) is used for detection of the 
pregnant uterus. All waveforms are saved for later offline analysis. Maternal heart and respiration rates 
were monitored by using an automated system and body temperature was maintained as 36 to 37 °C by 
the warmed platform, which is supported by an integrated rail system. Figures are not to scale. Adapted 
from (Zhang and Croy, 2009). 
 
 
Figure 2.3. Diagram showing the uterine artery and other arteries close to the iliac bifurnication 
and uteroplacental junction. Adapted from (Qu, 2014). 
 
 
2.2.9 Calculation of resistance index (RI) 
 
Waveforms obtained from ultrasound were saved during scanning and were later 
analysed offline using ImageJ software peak systolic and end diastolic velocities were 
measured (Figure 2.4.) and RI index was calculated using the following equation: 




Figure 2.4. A diagram showing where measurements of peak systolic velocity and end diastolic 






Figure 2.5 Collection of e8.5 Implantation sites. 
 A) Photograph depicting an ovary, a uterine horn containing embryos, and the cervix. B) An illustration 
to show where the inter-implantation cuts were made. C) The mesometrial to anti-mesometrial distance 
and width of each implantation site was measured using a digital calliper.  
 
 
2.2.10 Genotyping  
 
Genotyping was initially done by extracting genomic DNA followed by a PCR but 
was switched to being outsourced to Transnetyx® (Cordova, TN).  Both techniques 
are outlined below. 
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Ear clips from pups were used to extract genomic DNA (gDNA). 25 µl of TE/Tween 
+ 10 µl of Proteinase K was added to each ear clip in a PCR tube to submerge. Samples 
were digested to liberate genomic DNA on a 55/95 programme (55° C for 2 hours, 
95°C for 5 mins, room temp. 10 mins),  vortexed and centrifuged at 14000 rpm. 30 µl 
of the resulting supernatant was diluted in 270 µl of water and used for PCR to 
genotype. For each animal, 3 primer sets were used including a negative control where 
the primers were replaced by dH2O. 
A PCR reaction in a total volume of 25 µl was set up as follows: 
dH2O    7.5 µl 
MyTaq HS Mix (Bioline) (components include MyTaq buffer, dNTPs, MgCl2, 
enhancers and stabilizers) 12.5 µl (containing 0.1 μl of 100 mM of each forward and 
reverse primer) (Table 1) 
DNA      5 µl 
 
PCR reactions were run on a Dyad PCR machine (Bio-Rad) on the following 
programme: 
 
95 ° C           3 min 
95 ° C            5 sec              
60 ° C            5 sec               28 cycles      
72 ° C            20 sec 
72 ° C            2 min 
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Products were then run on a 2.5% TAE/agarose gel with a 100bp ladder (NEB) with 
the Wild-type generating a single band of 632bp, the KO two bands (230bp and 550bp) 




Table 2.2.Primer sets used for genotyping of mice. 
Band size (bp)
Knock-out Name 686F CASR1 230
Sequence 5'TGG GTT TGG TTT TCC TCC TG 3' TCG TGG TAT CGT TAT GCG CC
Wild-type Name 686F 686R 632
Sequence 5'TGG GTT TGG TTT TCC TCC TG 3'CAG ACC ACC TCA CAG CAC TC
Heterozygous Name LacF-60 LacR1-60 550






Figure 2.6 Representative position of primers used for genotyping of NTP4 mice.    
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2.2.11 Gel Electrophoresis 
 
Agarose (2-3% w/v) was dissolved in TAE by heating in a microwave until boiling. 
After cooling down, Gel-Red (Biotium) was added to a final concentration of 1/10 000 
and 6x DNA loading buffer was added to samples before loading. 100bp or 1kb DNA 
bench-top ladder (Promega) was loaded in addition to samples for determining DNA 
band sizes. Gels were run in TAE agarose gel running buffer at 25-100 volts and 




Mouse genotypes from ear clips were determined using Transnetyx services (Cordova, 
Tennessee, USA) which use an automated genotyping system using real time PCR 
with primers and specific labelled probes designed for each gene (Table 2.3) which 
identify the presence or absence of the desired genetic region. Briefly tissue samples 
were lysed using Proteinase K and DNA was isolated using the proprietary microbead-
based method by Transnetyx. The DNA was then tested in duplicate using a specific 
quantitative PCR assay with results normalized to a single-copy housekeeping gene.  
 
Name Pabpc4-1 WT 
Forward primer CCCAAGGGCTGGTGTTACAAG 
Reverse primer CCAGCCCAGGGTTTTATTTTGTTTT 
Labelled Probe TTGCCACCACAGTCTGC 
  
Name  LacZ 
Forward primer CGATCGTAATCACCCGAGTGT 
Reverse primer CCGTGGCCTGACTCATTCC 
Labelled Probe CCAGCGACCAGATGAT 
 
Table 2.3 Primers and specific labelled probed used in genotyping by Transnetyx. 
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2.3 Histological analysis 
 
2.3.1 Fixation, embedding and sectioning  
 
Tissues were fixed in 4% NBF (10x the volume of the tissue). After 24 hours of 
fixation, tissues were washed 3x in 70% ethanol before being stored at room 
temperature in 70% ethanol prior to being processed. Tissues were embedded in 
paraffin wax by the in house histology core facility in the MRC Centre for 
Reproductive Health (CRH) on a Leica TP1050 processor (Leica Microsystems).  
Paraffin embedded tissues were sectioned (5 μm) using a Leica RM2135 microtome. 
Sections were floated on a 50°C water bath and mounted on electrostatic charged glass 
slides and dried overnight at 50°.  
 
 
2.3.2 De-waxing and re-hydration 
 
Prior to immunohistochemistry paraffin tissue sections were dewaxed in xylene (2x 5 
min washes) and then rehydrated in graded alcohols (100%, 90%, 70%, 20 sec each). 
Finally, sections were rinsed in tap water. 
 
 
2.3.3 Immunohistochemistry  
 
Following de-waxing and re-hydration slides were submitted to heat-induced antigen 
retrieval in 0.01 M citrate buffer (pH 6.0) for 40 min in a pressure cooker which 
provides good heat-source regulation. Heat induced-antigen retrieval improves 
staining by breaking down-cross linking of proteins caused by NBF fixation and 
revealing protein epitopes necessary for complementary antibody binding. Tissue 
slides were slowly cooled in tap water and transferred to 3% (v/v) H2O2 in dH2O for 
30 min to block endogenous peroxide activity. This was followed by 2x 5min washes 
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in Tris Buffered Saline (TBS). If a mouse antibody was being used on mouse tissue a 
Mouse on Mouse (M.O.M) ImmPRESSTM mouse blocking reagent was applied and 
incubated with tissue for an hour. To block non-specific binding the tissue was then 
blocked in ready to use (2.5%) normal serum from the animal species used to raise the 
secondary antibody (ImmPRESS™, Vector laboratories) (see Table 2.4 for 
detail)(BSA) for 30 min. Excess serum was blotted from sections and incubated with 
1 ̊ antibody diluted in appropriate diluent solution overnight at 4 ̊C .  
The following day slides were washed in TBS (2 x 5min) and incubated with 
ImmPACT™ polymer IgG reagent (Vector laboratories) raised against the species 
primary antibody was raised in  (see Table 2.4 for detail). Slides were washed in TBS 
(2 x 5 min) before DAB substrate was added (1 drop/ml, ImmPACT™ DAB Substrate 
Kit - Vector Laboratories). Incubation periods with DAB solution vary depending on 
the antibody and the tissue, therefore each slide was prepared individually and colour 
change monitored under a light microscope for between 30 seconds to 1 minute. DAB 
reaction was stopped by washing slides in tap water. Slides were counterstained with 
haematoxylin and dehydrated, prior to mounting. Negatives controls included an 
isotype of the primary antibody at the same concentration. Images were captured by a 
Canon DS6031 camera (Canon Europe) using Provis AX70 microscope (Olympus 
Optical) and the Axiovision Rel. 4.8. Software.  
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Protein Source  
Species 
raised 
























Bank Rat 1/270 Yes 













Table 2.4. Details of antibodies and conditions used for Immunohistochemistry. 
 
2.4 Nucleic acid techniques 
 
2.4.1 RNA extraction from snap frozen tissues  
 
Snap frozen placental samples were lysed and total RNA extracted and purified using 
TRI reagent (Sigma-Aldrich) by Bill Richardson (senior lab technician). 
In brief, during sample preparation the snap frozen tissue samples were homogenised 
using a hand held mortar/pestle (Anachem) in TRI Reagent (1ml per 50-100 mg of 
tissue). Samples were allowed to stand for 5 min at room temperature to allow the 
dissociation of nucleoprotein complexes to occur. 0.2 ml of chloroform per ml of TRI 
Reagent was added, shaken for 15 seconds and left to stand at room temperature for 2-
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15min. Samples were centrifuged at 12, 000 x g for 15 min at 2-8 °C resulting in 
separation of the mixture into a red organic phase (containing protein), an interphase 
(containing DNA), and an aqueous phase containing RNA. 0.5ml of 2-propanol per ml 
of TRI Reagent used was added to the aqueous phase and allowed to stand at room 
temperature for 5-10 min. This was followed by centrifugation at 12, 000 x g for 10 
min at 2-8 °C resulting in an RNA pellet at the bottom of the tube which was air dried 
for 5-10 min and subsequently dissolved in 0.1 ml of RNAse-free water. Was 
concentration determined and how stored.  
 
2.4.2 RNA extraction from NBF fixed tissues 
 
RNA was extracted from formalin-fixed tissues using RecoverALL™ Total Nucleic 
Acid Isolation Kit (Life technologies) according to manufacturer’s instructions. In 
brief, the lab bench, pipettes and cutting equipment was cleaned using Ambion RNase 
Zap decontamination solution (Invitrogen) before an approximately 35 mg slice of 
fixed placenta was ground using a pestle and mortar on dry ice. 1ml of 100% ethanol 
was added to the ground up placenta and centrifuged for 2 min at room temperature at 
20817 x g to pellet the tissue. The ethanol was gently removed without disturbing the 
pellet and this was repeated once more after which as much ethanol was removed 
without disturbing the pellet. The pellet was then air dried for 45min at room 
temperature. Digestion buffer and protease was added to each sample and gently 
swirled for the tissue to immerse and incubated for 15min at 50°C, then 15min at 80°C. 
An isolation additive/ethanol mixture was added to the sample and mixed by pipetting 
up and down. The mixture was passed through a filter cartridge and centrifuged at 
10,000 x g for 30 sec and flow through discarded. The sample was washed, centrifuged 
at 10,000 x g for 30 sec and flow through discarded. An additional 30 sec centrifuge 
was undertaken to obtain residual fluid from the filter. 60µl of DNase mix was added 
to the sample and incubated for 30min at room temperature. The sample was washed, 
centrifuged at 10,000 x g for 30 sec and flow through discarded and an additional 
centrifugation performed for 1min to obtain residual fluid from the filter. The filter 
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cartridge was then transferred to a fresh collection tube and eluted with 60µl of room 
temperature elution solution and allowed to sit at room temperature for 1 min. The 
assembly was then centrifuged for 1min at maximum speed to obtain the eluate 
containing RNA and stored at -20°C. The extracted RNA was quantified and 
standardized to a concentration of 100 ng/μL using water.  
 
2.4.3 RNA quantification 
 
Extracted RNA was quantified using a Nanodrop® ND-1000 spectrophotometer 
(Nanodrop Technologies, USA). Absorbance ratio values of 260nm/280nm were used 
as an indicator of the RNA purity with a ratio of approximately 2.0 accepted as 
sufficiently pure RNA. Absorbance ratio values of 260nm/230nm were used as a 
secondary measure of nucleic acid purity with samples having a lower than the 
expected ratio of approximately 2.0 being rejected, due to the likelihood of 
contaminants absorbing at 230nm.  
 
2.4.4 cDNA synthesis  
 
RNA samples were converted into cDNA (reverse transcription) using SuperScript® 
III First-Strand Synthesis System (Invitrogen) following the manufacturers’ 
guidelines. Briefly, 1µl of random primers, 1 µl of 10mM dNTP mix, and 400ng of 
mRNA were made up to a total volume of 10 µl in an Eppendorf tube and incubated 
at 65°C for 5 min. The tube was then placed on ice and the following added: 4µl 
MgCl2, 2µl RT buffer, 2µl 0.1 DTT, 1µl RNase inhibitor and 1µl of SuperScript III 
RT. Contents were gently mixed by pipetting up and down and incubated at 25°C for 
10 min followed by an incubation at 50°C for 50 min. The reaction was terminated at 
85°C for 5 min. Finally, 1 µl of RNase H was added prior to incubation at 37°C for 20 
min. 
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2.5 Real-time quantitative PCR (qRT-PCR) 
 
qRT-PCR works on the same principle as PCR, however the PCR product is measured 
during each cycle. TaqMan® (Life technologies) method of qRT-PCR was utilised. 
In TaqMan® fluorescent light is produced through the addition of a 5’ fluorescently 
labelled probe containing a quencher dye at the 3’-end, specific forward and reverse 
primers to allow for quantification of the target gene relative to a housekeeping gene. 
In this assay the probe anneals to the target DNA sequence in between the forward and 
reverse primers. During amplification the 5’-3’ exonuclease Taq DNA polymerase 
cleaves the probe, releasing the reporter dye from the quencher resulting in 
transmission of fluorescent light when excited by the laser. The amount of fluorescent 
is directly proportional to the amount of DNA produced by the PCR. 
The mastermix was pipetted into a 384-well MicroAmp Fast Optical reaction plate 
(Applied Biosystems), followed by addition of the cDNA and control samples in 
duplicate. The Taqman reaction was performed using the Applied Biosystems 7900HT 
Fast real-time PCR system (Life Technologies, Paisley, UK) as follows; 95°hot start 
for 3 minutes, followed by a 5 second denaturation at 95°C. 40 cycles at 60°C for 15 
seconds for the primers to anneal. The final step in the dissociation stage involved the 
melting of the double stranded PCR (dsPCR) product at 95°C for 15s, annealing at 
60°C for 15 seconds, followed by a final melting of the dsPCR products at 95°c for 15 
seconds. Analysis of qRT-PCR data was carried out using the comparative ΔΔCt 
method. The fluorescence detected from TaqMan® is represented as an amplification 
plot. The cycle threshold (Ct) is directly proportional to the amount of target nucleic 
acid and indicated the number of amplification cycles that cross the threshold. The 
threshold was set to distinguish relevant fluorescence/amplification signal. Each 
cDNA sample was run in triplicate. The expression levels of the target genes were 
normalised to the expression level of Sdha (ΔCt) which was found to be the most stable 
housekeeping gene in the samples in comparison to Gapdh and Acth using SLqPCR 
package in R This value was expressed as a change relative to the reference sample 
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(ΔΔCt = ΔCt sample - ΔCt reference sample). The fold change was then calculated 
using the equation 2-ΔΔCt.  
 
Target gene Catalogue number of Taqman primer 
Snat-1 (Slc38a1) Mm00506391_m1 
Snat-2 (Slc38a2) Mm00628416_m1 
Snat-4 (Slc38a4) Mm00459056_m1 
Glut-1 (Slc2a1) Mm00441480_m1 





Table 2.5 Table of TaqMan® primers used. 
 
2.6 General protein work  
 
2.6.1 Protein extraction from tissues 
 
Throughout protein extraction, samples and buffers were kept on ice to minimise 
protease activity.  
Mouse organs were snap frozen upon collection on dry ice and kept at -80°C before 
being homogenised in phospho-RIPA buffer. The volume of phospho-RIPA buffer 
used was the minimum required to submerge the tissue (approx. 1ml for bigger tissues 
such as liver, 500µl for smaller tissues such as spleen and kidney).   
Qiagen TissueLyser homogeniser (Qiagen) was then used to homogenise the tissue 
(25Hz, 1-2 minutes) followed by 5 minute incubation on ice. Homogenised solutions 
were centrifuged at 14,000 rpm for 10 minutes at 4°C to pellet debris and the 
supernatant collected and stored at -20°C for future applications.  
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2.6.2 Bradford assay  
 
Protein concentrations were quantified using Bradford Protein Assay Reagent (Bio-
Rad). 1 μl of protein sample was added to 99 μl of water and 900 μl of Bradford 
Reagent in a spectrophotometer microcuvette. Using a Genequant Pro 
spectrophotometer (GE Healthcare) the 595 nm absorbance was read and the 
concentration of the sample calculated using a standard curve generated with bovine 
serum albumin (0-20 μg).  
 
2.6.3 Polyacrylamide gel electrophoresis (PAGE)  
 
SDS-polyacrylamide gel electrophoresis was performed using 4-12% NuPAGE 
MOPS (Invitrogen) gels. Samples calculated to have the same protein concentration 
were mixed with the appropriate volume of 4 x sample loading buffer and heated at 
75°C for 10 minutes before loading alongside pre-stained or unstained protein 
Benchmark ladders (Invitrogen). Pre-cast gels purchased from Invitrogen were run 
using NuPAGE MOPS SDS Running Buffer (50 mM MOPS, 50 mM Tris, 0.1% SDS, 
1 mM EDTA; pH 7.7) (Invitrogen) at 100-150V. Gels were run until the loading dye 
reached the bottom of the gel. 
 
2.7 Western Blotting 
 
2.7.1 Transfer and staining of membrane 
 
After SDS-polyacrylamide gel electrophoresis, the gel was immersed in NuPAGE 
transfer buffer for 2 minutes and then transferred onto Immobilon membrane (Thermo 
Fisher) (previously hydrated in 100% methanol for 5 mins and immersed in NuPAGE 
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transfer buffer). The gel and Immobilon-P membrane were then sandwiched between 
4 sheets (2 either side) of Whatman filter paper soaked in NuPAGE Transfer Buffer. 
Proteins were transferred using a fixed current of 100mA per gel for 1 hour using a 
V20-SDB semi-dry blotter (SCIE-PLAS). Transferred protein on the Immobilon 
membrane was visualised by staining using Gelcode Blue (Thermo Fisher) for 10-
15min accordingly to the manufacturer’s instructions. Excess stain was washed off by 
immersing the membrane in 50% methanol before being dried and the positions of the 
molecular weight markers marked using a permanent marker. Following this, the 
membrane was rehydrated in 100% methanol. 
In the following section, all manipulations were performed with the minimal volume 
required to submerge the gel or the membrane except washes which were performed 
in an abundant volume of TBS-T at room temperature on a rocking platform.  
 
2.7.2 Blocking, antibody incubation and detection 
 
Membranes were blocked in either 5% (w/v) skimmed milk in TBS-T or 5% (w/v) 
BSA in TBS-T for 1 hour at room temperature on a rocker, dependent on antibody. 
Primary antibodies were diluted in 5 % (w/v) skimmed milk in TBS-T or 5% (w/v) 
BSA in TBS-T and incubated for 1 hour at room temperature or overnight at 4C on a 
rocking platform. Following primary antibody incubation, the membrane was washed 
3 times for 5 minutes in TBS-T before incubation with an appropriate secondary 
antibody conjugated to HRP diluted in either 5% skimmed milk in TBS-T or 5% (w/v) 
BSA in TBS-T. The membrane was then washed 3 times in TBS-T for 10 minutes and 
incubated in enhanced chemiluminescence solution (ECL) (GE Healthcare) for 1min 
or SuperSignal west femto maximum sensitivity substrate (ultra-sensitive ECL) 
(Thermo Scientific) for 5 min. Finally membranes were blotted dry and exposed to 
ECL Hyperfilm (GE Healthcare) and developed using Exograph compact x4 X-ray 





2.8.1 Brightfield Microscopy 
 
Brightfield images were taken using an Axiocam camera (Zeiss, Welwyn Garden City, 
UK) on an Olympus Ax70 Provis microscope with UPlanFl objectives. Image capture 
was performed using Axiovision software (Zeiss). 
 
2.9 Statistical Analysis  
 
Data are expressed as mean ± standard error of the mean (SEM). Statistical analysis 
was performed using GraphPad (GraphPad Software, San Diego, California, USA). 
The specific statistical test used are described in the legend of each figure. Statistical 




Chapter 3 – Investigation into the breeding 
characteristics of Pabp4-/- dams 
 
3.1 Introduction  
 
The in vivo role of PABP4 in mammals has not been previously explored. To this end, 
Pabp4-targeted, knock-out first, conditional ready mice were created on request by the 
Wellcome Trust Sanger Institute (WTSI) (Hinxton, Cambridgeshire, UK). To create 
these mice, targeted homologous recombination was performed in C57BL/6N 
embryonic stem (ES) cells of parental line JM8.N4 through electroporation of a 
Pabp4-targeting construct to facilitate insertional mutagenesis at the Pabp4 locus 
(Figure 3.1). The resulting ES cells were injected into C57BL/6NTac mouse 
blastocysts to produce multiple chimeric mice which were checked for germline 
transmission. Chimeric mice, where the ES-derived cells containing the Pabp4-
targeting construct contributed to the germline, where mated to create offspring that 
were used to breed to mice which heterozygously contained the Pabp4-targeted 
mutation.  In “knock-out first” mice, gene function is ablated by the inserted cassette 
(as depicted in Figure 3.1), which contains a lacZ expression marker gene and 
neomycin coding sequences (used for selection), both with polyadenylation signals 
that result in cleavage of the nascent pre-mRNA and consequently transcriptional 
termination which should create a whole body functional null. Breeding these mice to 
mice expressing the FLP recombinase allows removal of most of targeting cassette but 
leaves loxP sites flanking a ‘critical’ exon, creating ‘conditional-ready’ mice. For 
PABP4 exon 3, which is present in all Pabp4 splice variants and removal of which 
causes a frame shift leading to complete gene inactivation, is the critical exon. These 
mice can be bred against Cre recombinase expressing mice to delete exon 3 in a time- 
and/or cell-specific manners.  The Pabp4-targeted mice used in this PhD project 
contained the “knock-out first allele” and were found to be missing a loxP site and 
therefore did not have the potential to become conditional-ready. The full systematic 
genetic nomenclature of this targeted non-conditional strain is B6N;B6NTac;B6N-
Pabpc4tm1e(KOMP)Wtsi (for simplicity referred to as Pabp4-/- from now on) and unless 
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otherwise stated this strain was utilized in all experiments. To determine whether the 
genotype of the mice was Pabp4+/+, Pabp4-/- or Pabp4+/-, polymerase chain reaction 
(PCR) was used using allele-specific oligonucleotides (Figure 3.2. A, B and C) such 
that different products were observed in wild-type, knock-out and heterozygous mice. 
Importantly, the absence of a PABP4 protein in Pabp4-/- mice was verified by western 




Figure 3.1 The PABP4 knock-out strategy. 
In “KO first” alleles gene function is ablated by a polyadenylation signal-mediated transcriptional stop 
at the end of the lacZ expression marker gene that is driven off the target gene promoter. The Neo 
cassette used for selection also contains a polyadenylation signal. Removal of the targeting cassette by 
breeding to a mouse expressing FLP recombinase should leave loxP sites flanking a “critical” exon 
generating a conditional-ready mice.  Breeding such mice to strains expressing Cre recombinase should 
result in deletion of the critical exon. SA, splice acceptor site; pA, poly A. Adapted from (Doetschman 





Figure 3.2. Confirmation of PABP4 knock-out.    
A schematic diagram (not to scale) of the genotyping strategy of A) PABP4 wild-type mice and B) 
PABP4 knock-out mice. Vertical lines represent the relative positions of oligonucleotide primers used 
to amplify the specific alleles and visualised on an agarose gel. The expected sizes of the PCR products 
are indicated. C) PCR products representing the different genotypes visualised on a 1% agarose gel. In 
PABP4 KO mice, the PCR extension time is not sufficient to generate the long WT PCR product length 
(as a result of the cassette insertion), therefore no product is obtained. D) Western blot confirming that 





Prior to the start of my PhD, preliminary data from a small cohort of mice indicated 
that PABP4 is not absolutely essential for viability but, interestingly, maternal PABP4-
deficiency led to a reduction in litter sizes at birth with observations of late in utero 
death (see section 1.5 Work leading up to PhD project), opening the possibility that 
Pabp4-/- females may provide a unique model of late miscarriage/stillbirth that is 
maternal in nature. However, the experimental data had relatively low power, the mice 
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utilised had a low backcross status and were not matched for age or parity. Thus, it 
was critical to confirm the veracity of these early observations. Unless stated 
otherwise, all females utilised in experiments here were aged 8-12 weeks, were 
backcrossed against C57BL/6N approximately 8-10 times and were virgin females and 
proven males. Firstly, to verify the parental genetic contribution to the phenotype and 
test the hypothesis that there is an absence of a male genetic contribution to the reduced 
litter size observed at birth, the entire spectrum of PABP4-crosses were set-up and 
litter size at birth monitored. These crosses served simultaneously as breeders therefore 
the litter sizes recorded were of females aged between 8-20 weeks and included 
various parity status.  Importantly, no statistical difference in litter size was observed 
when Pabp4+/+ females were mated to either Pabp4+/+, Pabp4-/-, or Pabp4+/- males 
(Figure 3.3.).  However, all crosses involving Pabp4-/- females showed a statistically 
significant decrease in litter size compared to Pabp4+/+ (Figure 3.3.). These data 
confirm that the phenotype is independent of paternal genotype. They also strongly 
suggest that reduced litter size is not driven by fetal genotype, since it is only altered 
in crosses between Pabp4-/- females with Pabp4+/+ males but not the reciprocal cross 
(Pabp4+/+ females with Pabp4-/- males), despite both resulting in heterozygous pups. 
Thus, the data support preliminary results that the reduction in litter size is dependent 
on maternal genotype. Furthermore, crosses of Pabp4+/- females crossed with either 
Pabp4+/+, Pabp4-/-, or Pabp4+/- males results in a normal litter size (Figure 3.3.) and 
therefore suggests that a single copy of the Pabp4 gene does not result in 










































































































Figure 3.3. Maternal PABP4 deficiency results in reduced litter size at birth. 
Litter size at birth of the entire spectrum of PABP4 crosses. Sample sizes are as follows: ♂ WT x ♀ 
WT (light green dot) n = 104; ♂ HET x ♀ WT ( green dot) n = 15; ♂ KO x ♀ WT (dark green dot) n = 
34; ♂ WT x ♀ HET (light blue dot) n = 8; ♂ HET x ♀ HET (blue dot) n = 190; ♂ KO x ♀ HET (dark 
blue dot) n = 103; ♂ WT x ♀ KO (light red dot) n = 40; ♂ HET x ♀ KO (red dot) n = 16; ♂ KO x ♀ 
KO (dark red dot) n = 75. Data are shown as shown as box and whisker plots with the median (long 
line) and mean (cross) indicated. Significance was analysed by Kruskal -Wallis test and Dunn’s multiple 
comparison test. ns =  ≥  0.05; *** p =   0.001; **** p =  0.0001.  
 
To further test the hypothesis that fetal genotype does not contribute to the phenotype, 
Mendelian ratios from Pabp4+/- inter-crosses were determined at embryonic day (e) 
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18.5/19.5 and at weaning. Consistent with the conclusion drawn from data in Figure 
3.3, genotypic analysis of Pabp4+/- inter-crosses at e18.5/19.5 revealed that Pabp4-/- 
and Pabp4+/- fetuses were present at approximately Mendelian ratios of 25% and 50% 
respectively (Figure 3.4. A). However, at weaning, whilst Pabp4+/- fetuses remained 
to be present at the expected Mendelian ratio of 50%, the ratio of Pabp4-/- offspring 
was found to be only 19% and a chi square test this to be significantly deviant from 
the expected ratios (Figure 3.4. B). Given that Pabp4+/- inter-crosses did not produce 
reduced litter sizes at birth (Figure 3.3.) these data imply that neither fetal PABP4 
deficiency nor haploinsufficiency contribute to the reduction of litter size observed at 
birth in Pabp4-/- females. However, whilst inter-cross litter size is normal at birth, a 
proportion of pups die prior to weaning (Figure 3.4 C), which combined with the non-
Mendelian ratios at weaning imply that post-birth Pabp4-/- offspring have an increased 







Figure 3.4. Genotypic analysis shows Mendelian ratios at e18.5-e19.5 but not at weaning. 
Pabp4+/- females were crossed with Pabp4+/- males and progeny was either (A) collected and genotyped 
at e18.5-19.5 or (B) genotyped at weaning. Frequencies of fetal genotype at e18.5-e19.5 Pabp4+/+ (n 
=34), Pabp4+/- (n =60) and Pabp4-/- (n =37); χ2 = 0.5; at weaning Pabp4+/+ (n =149), Pabp4+/- (n =324) 
and Pabp4-/- (n =108) χ2 = 13.5. Data were analysed using the chi square test (test value = 5.99). (C) 
Post-partum loss of Pabp4-/- pups appears to bi-phasic with the first loss occurring between 2-4 days 




To interrogate the breeding characteristics of Pabp4-/- females in more detail and, 
importantly, to assess them in the context of a reproductive life span, individual pairs 
of Pabp4-/- females with Pabp4 +/+ males (from now on referred to as ‘PABP4 maternal 
KO pairs’ for simplicity) and Pabp4 +/+ females with Pabp4-/- males (from now on 
referred to as ‘PABP4 paternal KO pairs’ for simplicity) were set up for 30 weeks at 
the age of 8 weeks. Both parental crosses  produced heterozygous offspring providing 
a suitable control for investigating the maternal nature of the phenotype believed to be 
independent of both paternal and fetal genotype.  
 
 
Figure 3.5. Average litter size from multiple pregnancies in PABP4 female mice is reduced.  
Combined mean litter sizes at birth (+/- SD) from 30 weeks. ♂WT X ♀WT (green dots) n = 7; ♂WT X 
♀KO (red dots) n = 11; ♂KO X ♀WT (blue dots) n = 10. Data are shown as shown as box and whisker 
plots with the median (long line) and mean (cross) indicated. Significance was analysed by Kruskal -
Wallis test and Dunn’s multiple comparison test.. ns =  ≥  0.05; * p =   0.05; ** p =   0.01; **** p = 
 0.0001.  
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In parallel, pairs of age matched Pabp4+/+ females and Pabp4+/+ males (from now 
referred to as ‘PABP4 WT pairs’ for simplicity), of the same strain, were set up as 
wild-type controls. Firstly, data gathered from this experiment showed that Pabp4-/- 
females produced significantly smaller litters based on mean number of fetuses born 
per litter from each pair (Figure 3.5.) compared to both other pairings. However, no 
significant difference was observed between the mean litter size of PABP4 WT pairs 
and PABP4 paternal KO pairs suggesting that the reduced litter sizes from the Pabp4-
/- females was not due to heterozygous fetuses being haploinsufficient, providing 
further support for the maternality of the phenotype.  
Generally, inbred females of most strains do not produce more than five litters (Green, 
1991) and exhibit greatly reduced fecundity by the age of 8-10 months (Silver, 1995). 
It was hypothesized that Pabp4-/- females may have an exacerbated decline in 
fecundity in comparison to Pabp4+/+ females and to this end litter sizes were 
interrogated in consecutive pregnancies over the 30-week period. PABP4 maternal KO 
pairs had reduced litter sizes in multiple but not all of their pregnancies in comparison 
to PABP4 WT and PABP4 paternal KO pairs (Figure 3.6). However, this was due to 
a high variability in WT and PABP4 paternal KO pair litter sizes (i.e. 3rd and 5th litters 
in Figure 3.6.) as the litter sizes of PABP4 maternal KO pairs were consistently low 
throughout the 30 week period. The variability of WT and PABP4 paternal KO pair 
litter sizes is most likely associated with the loss of fecundity of some of the Pabp4+/+ 
females, which also explains the low number of litters by litter 6 irrespective of pair 
genotype. When litter size was graphed separately according to parental genotype, it 
was revealed that the small litter sizes of PABP4 maternal KO pairs (1st litter size mean 
= 5.2) further declined by  3 fold by the end of the 30 week period (6th litter size 
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mean= 1.7) (Figure 3.7). In contrast to this, despite the high variability of litter sizes, 
particularly of the PABP4 WT pairs from the 2nd litter onwards, PABP4 WT females 
did not show a significant decrease in litter size over time (1st mean litter size of WT 
pair = 7 8; 1st mean litter size of reciprocal pair = 5.9 ±; 6th mean litter size of WT pair 
= 6.7; 6th mean litter size of reciprocal pair = 5 [n of 1]) (Figure 3.7). These data imply 
that the fecundity of Pabp4-/- females is compromised from their first litter and further 




Figure 3.6. Maternal PABP4 deficiency results in reduced litter sizes in multiple pregnancies. 
Mean litter size (+/- SD) in 6 consecutive litters where the same male was mated with the same female were surveyed over 30 weeks. ♂WT X ♀WT (green bars) 1st litter  n = 
7 pairs; 2nd litter n = 7 pairs; 3rd litter n = 7 pairs; 4th litter n = 5 pairs; 5th litter n = 5 pairs; 6th litter n = 3 pairs. ♂WT X ♀KO (red bars) 1st litter n = 11 pairs; 2nd litter n = 10 
pairs; 3rd litter n = 9 pairs; 4th litter n = 6 pairs; 5th litter n = 5 pairs; 6th litter n = 2 pairs. ♂KO X ♀WT (blue bars) 1st litter n = 10 pairs; 2nd litter n = 10 pairs; 3rd litter n = 6 
pairs; 4th litter n = 4 pairs; 5th litter n = 3 pairs; 6th litter n = 1 pair. Data are shown as shown as box and whisker plots with the median (long line) and mean (cross) indicated. 
Significance was analysed by Kruskal -Wallis test and Dunn’s multiple comparison test. ns =  ≥  0.05; * p =   0.05; ** p =   0.01
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Figure 3.7. Litter size declines in consecutive pregnancies in PABP4 maternal KO pairs but not in WT or 
PABP4 paternal KO pairs. 
Mean litter sizes (+/- SD) born in 6 consecutive litters surveyed over 30 weeks. A) ♂WT X ♀KO (red bars) 1st 
litter n = 11 pairs; 2nd litter n = 10 pairs; 3rd litter n = 9 pairs; 4th litter n = 6 pairs; 5th litter n = 5 pairs; 6th litter n 
= 2 pairs. B) ♂WT X ♀WT (green bars) 1st litter  n = 7 pairs; 2nd litter n = 7 pairs; 3rd litter n = 3 pairs; 4th litter n 
= 5 pairs; 5th litter n = 5 pairs; 6th litter n = 3 pairs. C) ♂KO X ♀WT (blue bars) 1st litter n = 10 pairs; 2nd litter n 
= 10 pairs; 3rd litter n = 6 pairs; 4th litter n = 4 pairs; 5th litter n = 3 pairs; 6th litter n = 1 pair. Data are shown as 
shown as column bars with SD. Significance was analysed by two-tailed Mann Whitney test. ns = ≥  0.05; * p =  




 Figure 3.8. Time to first litter is increased in Pabp4-/- females but inter-litter interval is unaltered. 
A) Mean time to first litter surveyed over 30 weeks. B) Mean inter-litter interval surveyed over 30 weeks. ♂WT 
X ♀WT (green dots) n = 7; ♂WT X ♀KO (red dots) n = 12; ♂KO X ♀WT (blue dots) n = 10. Data are shown as 
box and whisker plots with the median (long line) and mean (cross) indicated. Significance was analysed by 
Kruskal -Wallis test and Dunn’s multiple comparison test.. ns =  ≥  0.05; * p =   0.05. 
 
Consistent with the preliminary data implying that some litters are completely resorbed, (see 
section 1.5 Work leading up to PhD project), time to first litter is increased in PABP4 maternal 
KO pairs (Figure 3.8. A), although the observed increase in mean inter-litter interval does not 
reach statistical significance (Figure 3.8. B). To investigate whether the offspring of Pabp4-/- 
females are more likely to die post birth, the percentage offspring survival to weaning for each 
female was calculated but showed no statistically significant difference (Figure 3.9.), although  





Figure 3.9. Survival to weaning is not reduced in heterozygous offspring from Pabp4-/- dams. 
% mean survival of fetuses to weaning for each individual dam over 30 weeks. ♂WT X ♀WT (green dots) n = 
34; ♂WT X ♀KO (red dots) n = 43; ♂KO X ♀WT (blue dots) n = 34. Data are shown as shown as box and 
whisker plots with the median (long line) and mean (cross) indicated. Significance was analysed by Kruskal -
Wallis test and Dunn’s multiple comparison test. ns = p ≥ 0.05;  
 
Overall from the 30 week experiment, it can be concluded that Pabp4-/- females have reduced 
fecundity which results in a reduction of litter size at birth. Interestingly, the litter size continues 
to decrease, proportionally more than WT, with age suggesting that loss of PABP4 results in 
both reduced initial fecundity and deteriorating fecundity over time. Importantly, this reduction 
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 Figure 3.10. Litter size is significantly lower for Pabp4-/- dams with the exception of a period between December 2013 and June 2014. 
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Litter size at birth of Pabp4 +/+ females (WT; green dots) crossed with males of any genotype and Pabp4 -/-females 
(KO; red dots) crossed with males of any genotype. Litter size numbers are based on data collected from the 
colony breeding between July 2012 and September 2015 and binned into 5-6 months periods. July 2102-Nov 2012  
WT n = 14, KO n = 17; December 2012-June 2013 WT n = 44, KO n = 47; July 2013- November 2013 WT n = 
13, KO n = 14; December 2013- June 2014 WT n = 30, KO n = 28; July 2014- November 2014 WT n = 35, KO 
n = 20; December 2014- June 2015 WT n = 34, KO n = 19; July 2015- September 2015 WT n = 13, KO n = 12. 
Data are shown as shown as box and whisker plots with the median (long line) and mean (cross) indicated. 
Significance was analysed by two-tailed Mann Whitney test. . ns =  > 0.05; * p =   0.05; ** p =   0.01; **** p 
=  0.0001.  
 
Collated breeding data from the PABP4 colony was used to further extrapolate breeding 
information about Pabp4-/- females. Litter sizes at birth from Pabp4-/- and Pabp4+/+ females 
irrespective of paternal genotype (working with the assumption that paternal genotype does not 
impact the phenotype, Figure 3.3.) were used to create a temporal picture of the colony’s 
breeding over 3 years. For each year, the data collected was binned into periods of July to 
November and December to June. This analyses provided further support for the reduced 
fecundity of Pabp4-/- females, although between December 2013 and June 2014 there was no 
significant difference in litter size between Pabp4-/- and Pabp4+/+ females. It seems unlikely 
that a seasonal effect would be responsible for the divergence in the phenotype, given that this 





Figure 3.11. Litter size of Pabp4-/- dams is related to which ordinal litter it is. 
Litter sizes of Pabp4 +/+ females (green dots) A) and Pabp4-/- females (red dots) B) crossed with males of any genotype in consecutive pregnancies based on data collected from 
the colony breeding between July 2012 and September 2015. Pabp4 +/+females; 1st litter n = 76, 2nd litter n = 44, 3rd litter n = 23, 4th litter n = 14, 5th litter n = 10, 6th litter n = 6. 
Pabp4-/- females; 1st litter n = 70, 2nd litter n = 63, 3rd litter n = 44 , 4th litter n = 22, 5th litter n = 9, 6th litter n = 3. Data are shown as shown as box and whisker plots with the 



























































































































Table 3.1. The litter size mean is higher in 1st to 3rd litters between December 2013 and June 2014 in comparison to other time period
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A number of alternative possible explanations exist, however, given that Pabp4-/- females 
showed a more severe decrease in their fecundity than WTs as they age and/or acquire 
multiparity (Figure 3.11. B.), it was hypothesised that during this period the breeding Pabp4-/- 
females were young with a low number of prior number of pregnancies. To investigate this, 
the relationship between ordinality and litter size was examined for Pabp4-/- and Pabp4+/+ 
females (irrespective of stud male genotype). Intriguingly, the first litter in Pabp4-/- females 
tended to be smaller in size compared to second and third litters with the fourth to sixths litters 
being the smallest (Figure 3.11. B.). In contrast, Pabp4+/+ females had steady litter sizes of 
approx. 6-7 pups throughout their reproductive life span (Figure 3.11. B). Taking this into 
consideration, it was hypothesized that between December 2013 and June 2014 the reduction 
in litter size of Pabp4-/- females was temporarily lost due to females having primarily their 
second and third litters which resulted in an increase of the litter size mean, however this was 
not the case (Table 3.1). Interestingly, the first 3 litters born to Pabp4-/- females in this period 
had on average a higher mean litter size ranging from 5.7 to 6.7 in comparison to an average 
of around 4 in the other time periods which would explain the increased litter size mean during 
this time-period (Table 3.1). Other explanations for this temporary change in phenotype, such 
as the number of breeding pairs within the room are addressed in the discussion. 
 
The reduction and further decline in fecundity suggests that Pabp4-/- females could have 
problems with oogenesis/ovulation, fertilisation, implantation and/or in utero fetal death. 
Interestingly, in this regard PABP function is required for oogenesis both in invertebrates 
(Ciosk et al., 2004; Clouse et al., 2008; Ko et al., 2013; Ko et al., 2010; Kugler and Lasko, 
2009; Lall et al., 2005; Maciejowski et al., 2005; Vazquez-Pianzola et al., 2011) and non-
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mammalian vertebrates (Friend et al., 2012), and the germ cell specific ePABP is required for 
oogenesis in mice (Ozturk et al., 2012; Seli et al., 2005). However, a role for PABP4 in 
oogenesis has not been previously addressed, although PABP4 appears to be present in 
mammalian ovary (Figure 1.15 in section 1.5 Work leading up to PhD project). To this end, 
the expression of PABP4 in the adult mouse ovary was investigated (Fig. 13). Pabp4-/- ovary 
was analysed in parallel as a negative control in addition to an IgG negative control ( C), and 
showed only weak immunostaining of a single large pre-antral oocyte, supporting the 
specificity of the antibody, and consistent with the known “stickiness” of oocytes (Figure 3.12. 
C), which can lead to “background”. In the Pabp4+/+ ovary, PABP4 was found to be expressed 
in all granulosa cells within follicles at all stages of maturation, these cells support the oocyte 
and are necessary for its development. It was also expressed in the progesterone secreting 
corpus luteum which is derived from luteinisation of the follicle following ovulation (Figure 
3.12. A). Weak expression was observed in the thecal cells that surround the follicle and in the 
stroma. PABP4 was clearly expressed in oocytes in pre-antral follicles, and appeared to be 
more weakly expressed in antral follicles, however caution is required with respect to this weak 
antral oocytes expression, due to the background observed in oocytes from Pabp4-/- mice 
(Figure 3.12 C). PABP1 expression was also investigated for a comparison to PABP4 and to 
detect any potentially compensatory changes in expression in the Pabp4-/- ovary. Like PABP4, 
PABP1 showed robust expression in the granulosa cells, but in contrast appeared to be absent 
in the oocytes (Figure 3.12. B), and it’s expression pattern did not appear to change in the 
absence of PABP4 (Figure 3.12. D). It is unknown what function PABP4 may have in the 
ovary. Furthermore, PABP4 and PABP1 were also found to be expressed in the pituitary which 
releases, in addition to other hormones, gonadotropins that stimulate follicle growth and 
ovulation (Figure 3.13.). The pituitary is composed of three regions; posterior pituitary (also 
known as Pars nervosa), anterior pituitary (also known as pars distalis) and pars intermedia. 
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The anterior pituitary contains three different cell types; chromophobes, acidophils, which 
secrete growth hormone, and basophils which release gonadotropins, corticotrophin and 
thyroid stimulating hormone. Importantly, PABP4 shows robust expression in the anterior 
pituitary but is also detectable in the posterior pituitary and pars intermedia (Figure 3.13. A). 
PABP1 is expressed in all three regions. In the anterior pituitary which produces gonadotropins, 
PABP1 expression appears more uniform of that of PABP4 (Figure 3.13. C, D), although 
PABP1 expression appears less uniform in Pabp4-/- pituitary (Figure 3.13. E, F). Further 
information on the PABP4 and PABP1 expressing cell types, would require double 







Figure 3.12. Expression analysis of PABP4 and PABP1 in the adult mouse ovary. 
Sections of Pabp4+/+ and Pabp4-/- adult mouse ovary were stained by immunohistochemistry for PABP4 




Figure 3.13. Expression analysis of PABP4 and PABP1 in the adult mouse pituitary. 
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Sections of Pabp4+/+ and Pabp4-/- adult mouse pituitary from day e18.5 were stained by 
immunohistochemistry for PABP4 (A, C, E), PABP1 (B, D, F) or rabbit IgG control (insert in E). 
Images A, B x2 magnification images are shown; C, D, E, F x40 magnification images are shown. 
 
The analysis of PABP4 expression is consistent with the defect possibly stemming 
from a defect in oogenesis, ovulation or implantation (e.g. poor fertilisation or oocyte 
quality). However, these data do not exclude Pabp4-/- females having a direct 
implantation (e.g. uterine) defect or failure in post-implantation pregnancy. Thus to 
inform upon possible causes, litter sizes were determined at a spectrum of embryonic 
stages including embryonic (e) days 8.5, 13.5, 15.5 and 18.5 for Pabp4-/- and Pabp4+/+ 
females mated with Pabp4+/+ males. At e8.5 no significant decrease in litter size was 
observed (Figure 3.14), strongly implying that oogenesis, ovulation, fertilisation and 
implantation are not majorly affected in these mice.  Mean litter size was also 
comparable between Pabp4-/- and Pabp4+/+ females at e13.5 providing further 
confirmation that events leading up to and including implantation did not account for 
the reduction in litter size, and further establishing that no  significant loss of pups   
occurred prior to mid-gestation. In contrast to this, at e15.5 and e18.5 litter sizes 
showed a small but statistically significantly reduction in  Pabp4-/- compared to 
Pabp4+/+ females mated with either Pabp4+/+ or Pabp4-/- males and Pabp4-/- mated with 
Pabp4+/+ males. Consistent with this limited reduction in litter number at these stages, 
occasional late fetal resorptions were noted at e15.5 and e18.5. However, the most 
profound difference in litter size occurred after e18.5 where at birth the mean litter size 
of Pabp4-/-  females was 4.024 (±0.3014) whereas the mean litter size of a Pabp4+/+ 
female mated to Pabp4+/+ males was 7.113 (±0.3671) or 6.345 (±0.3265) when mated 
to a Pabp4-/- male (Figure 3.14).This data directly support Pabp4-/- females having a 
post-implantation defect in pregnancy that leads to fetal death and becomes apparent 
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Figure 3.14. Litter size is lower in Pabp4-/- dams from e15.5 of gestation with biggest drop between 
e18.5 and birth. 
Litter sizes investigated throughout gestation and at birth. e8.5 - ♂WT X ♀WT (green dots) n = 9, ♂WT 
X ♀KO (red dots) n = 9 ; e13.5 - ♂WT X ♀WT (green dots) n = 14, ♂WT X ♀KO (red dots) n = 8; 
e15.5 ♂WT X ♀WT (green dots) n = 13, ♂WT X ♀KO (red dots) n = 14, ♂KO X ♀WT (blue dots) n 
= 13; e18.5 - ♂WT X ♀WT (green dots) n = 17, ♂WT X ♀KO (red dots) n = 19, ♂KO X ♀WT (blue 
dots) n = 12; at birth = ♂WT X ♀WT (green dots) n = 53, ♂WT X ♀KO (red dots) n = 41, ♂KO X 
♀WT (blue dots) n = 55. Data are shown as shown as box and whisker plots with the median (long line) 
and mean (cross) indicated. For e8.5 and e13.5 time-points significance was analysed by two-tailed 
Mann Whitney test and for e15.5, e18.5 and birth by Kruskal -Wallis test and Dunn’s multiple 






The role of mammalian PABP4 outside of cell lines had not been studied and to address 
this important gap in our knowledge an investigation of Pabp4-/- mice was undertaken. 
The Pabp4-targeted mice used contained the “knock-out first allele” where gene 
function is ablated by a polyadenylation signal-mediated transcriptional stop at the end 
of the lacZ expression marker gene that is driven off the target gene promoter. LacZ 
encodes β-galactosidase and is considered to be a convenient reporter gene as it has a 
simple enzymatic assay, is easily detected in situ and is cell autonomous and 
importantly can act as a sensitive marker of gene activity (Cohen-Tannoudji et al., 
2000). Based on numerous experiments it is generally accepted that lacZ behaves as a 
neutral reporter gene (Forss-Petter et al., 1990; Goring et al., 1987; Klarsfeld et al., 
1991) and reviewed in (Cui et al., 1994). However, interestingly when lacZ sequences 
are associated with regulatory sequences of ubiquitously expressed genes it can lead 
to a transcription-silencing effect (Cohen-Tannoudji et al., 2000). To verify that the 
effects we are seeing are due to the loss of PABP4 rather than the expression of lacZ 
experiments will need to be replicated in PABP4 KO mice with reporter-less deletion 
of the allele. These experiments are currently undergoing could not be initially done 
as the Pabp4-targeted mice obtained initially were missing a loxP site and therefore 
did not have the potential of having a reporter-less deletion allele. 
The work outlined in this chapter confirm and extend upon preliminary data, 
establishing that PABP4 is not essential for viability or fertility in mice, but that 
maternal loss of PABP4 results in reduced fecundity primarily as a result of fetal 
lethality which occurs between e18.5 and birth. Whilst this compromise in fecundity 
is apparent from the first litter it further declines with increasing age and parity in an 
exacerbated manner in comparison to Pabp4+/+ females and Pabp4-/- females take 
longer to produce a first litter. Whilst the genetic crosses strongly support the maternal 
nature of the phenotype, ideally embryo transfer experiments would be done, wherein 
Pabp4+/+ mice transferred into a Pabp4-/- female would result in the recapitulation of 
the mid-late fetal death phenotype. However, embryo transfers are highly variable in 
terms of live births per embryos transferred, meaning that the numbers required to gain 
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power within this experiment are prohibitive. It would be interesting to track back the 
breeding history of Pabp4-/- females that had Pabp4-/- mothers to see whether their 
phenotype differs from Pabp4-/- females born to Pabp4+/- mothers. 
Phenotypic insight into PABP4-defiency was only previously available in X. laevis 
where PABP4 was found to be essential for development, as knock-down resulted in 
defects in anterior structures and lethality by stage 51 (d17 of development; final stage 
66 occurs by 58 days) (Gorgoni et al., 2011). Based on the findings in X. laevis, the 
viability of Pabp4-/- mice was perhaps surprising since the additional mammalian-
specific family members, tPABP and PABP5, are unlikely to compensate due to their 
restricted expression and lack of domain conservation, respectively. Moreover, the 
substantial reproductive differences between X. laevis and mammals mean that the 
phenotype observed here could not have been predicted from the prior work. This 
differs from ePABP where the oogenesis defects associated with loss of ePABP 
function in X. laevis (Friend et al., 2012) were recapitulated in mice (Ozturk et al., 
2012; Seli et al., 2005). However, differences in ePABP phenotypes between non-
mammalian and mammalian vertebrates also exist, as ePABP is not required for early 
development in mice (Friend et al., 2012; Ozturk et al., 2012; Seli et al., 2005), 
presumably due to differences in the timing of onset of zygotic transcription, when 
synthesis of so-called “somatic” PABPs resumes (Friend et al., 2012).   
Collated breeding data from the breeding colony revealed that Pabp4-/- females 
temporarily diverged from the described phenotype and produced equivalent litter 
sizes to Pabp4+/+ females. This was not correlated with age, multi-parity or likely 
seasonal in nature. There was a high number of Pabp4+/- males crossed with Pabp4-/- 
females in this time-period, however, this is unlikely to be the cause for the divergence 
as there is no supporting evidence that paternal Pabp4 genotype is a determinant of 
litter size. In support of this conclusion, other periods with particularly high number 
of Pabp4+/+ males crossed with Pabp4-/- females (December 2012-June 2013) did not 
result in an increased litter size. It has been reported that exposure to male, but not 
female technicians, induces a robust stress response (Sorge et al., 2014) and the mice 
were looked after by a male technician, however, staffing gender was constant. A 
factor which could potentially be the cause of the divergence is a change in the number 
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of breeding pairs reported by the animal facility staff, which was particularly high in 
this time period, meaning more male mice were present. Chemicals in male urine 
called ‘priming pheromones’ regulate the reproductive maturation and timing of 
ovulation in mice by inducing a series of hormonal responses by targeting production 
of gonadotropins or gonadotropin releasing hormone and thereby affecting ovulation 
rate (GnRH) (Bronson, 1971; Bronson and Maruniak, 1975).  It has been shown that 
exposing females to male-soiled bedding results in a significant increase in both the 
implantation scars and litter size in mice without a reduction in bodyweight of the 
offspring (Zhiqin, 1992). Furthermore, exposure to a male or male urine significantly 
increased the number of mature follicles in voles (Jemiolo et al., 1980). If an increase 
in the number of males and the effect of pheromones was the cause of the transient 
increased litter size, it would suggest that PABP4 has a role in controlling ovulation 
rate. Interestingly in this respect, PABP4 was found to be expressed in the adult ovary 
(Figure 3.12.) and pituitary (Figure 3.13.). Thus, the hypothesis may be that the 
absence of PABP4 in the adult female results in a reduced ovulation rate which can be 
reversed by the presence of a stimulus, such as a priming hormone, which positively 
influences ovulation. This hypothesis is currently not supported by the presence of 
normal litter sizes at e8.5 and e13.5 (Figure 3.14), although a subtle effect on litter 
size may be evident at these stages (Figure 12). Whilst the data argue that rates of 
implantation are not significantly altered, they do not exclude the possibility that 
decidualisation and/or implantation are abnormal in PABP4-deficient females, with 
the phenotypic effects not becoming apparent till later in gestation. 
Attachment/implantation of the blastocyst and decidualisation are all crucial and 
limiting steps in placentation and the growth of the fetus and thus successful pregnancy 
(reviewed in (Cha et al., 2012). Deferred implantation, like in mice lacking Pla2g4a 
(a gene for Cpla2α which generates arachidonic acid for prostaglandin synthesis) for 
example, results in embryo crowding, conjoined placentas, retarded fetoplacental 
development and reduced litter size (Song et al., 2002). Abnormal endometrial stromal 
cells on the other hand can, for example, result in premature decidual senescence, 
causing preterm birth with neonatal death or abnormal placentation with shallow 
trophoblast invasion resulting in preeclampsia (Cha et al., 2012). This highlights the 
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importance of establishing if, and where, PABP4 is expressed in the endometrium and 
the decidua.  
Although the initial preliminary data also suggested that Pabp4-/- females present with 
fetuses small for their gestational age (SGA), which is a known risk factor for mid-late 
fetal lethality or stillbirth in women, birth weight and offspring size were measured in 
the breeding experiments here, due to the disturbance of the breeding pairs potentially 
leading additional to pup death. (Breeding strategies for maintaining colonies of 
laboratory mice, 2007, The Jackson laboratory, Bar Harbor). However given the strong 
association between fetal size and stillbirth, analysis of potential IUGR is the major 
focus of the next chapter. 
Importantly, the maternal-dependent mid-late fetal loss observed in these mice is 
reminiscent of stillbirth in women, an under researched area of unmet clinical need. 
To date, little analysis on the genetics of stillbirth has been carried out although some 
genome wide association studies (GWAS) are available in lifestock (Pausch et al., 
2011), implicating a handful of loci. However, women whom suffer from stillbirth or 
late miscarriage may go onto to have healthy pregnancies but are at higher risk of 
subsequent stillbirth (Lamont et al., 2015), supporting a potential genetic component.  
 
Since Pabp4-/+ female mice are not haploinsufficient, loss of PABP4 function is 
unlikely to substantially contribute to stillbirth in human populations as a single gene 
disorder. However, Pabp4-/- mice are viable, fertile and lack gross morphological or 
behavioural abnormalities meaning that Pabp4 mutations may act as a risk factor for 
stillbirth alongside other genetic or environmental factors. Moreover, identification of 
the pathways and mRNAs dysregulated in these mice can shed light on further 
pathways and gene candidates that may account for a significant proportion of 
stillbirths which are not attributed to factors such as fetal abnormalities.  
There are relatively few animal models which report reduced litter size due to late 
gestational death as a result of maternal factors/genotype with the most reported 
underlying maternal cause being the inadequate remodelling of the maternal and/or 
placental vasculature resulting in low uterine and/or placental blood flow to the 
fetoplacental unit. Inappropriate vasculature remodelling has been reported to be 
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induced by for example by maternal high fat diet (Frias et al., 2011; Wallace et al., 
2002) but also using genetic models which hamper the function of uterine natural killer 
cell (uNK) function (Kieckbusch et al., 2015), which are crucial to this process (Ashkar 
and Croy, 1999, 2001; Ashkar et al., 2000; Hanna et al., 2006). Furthermore, low doses 
of LPS to IL10-/- mice have been reported to result in increased intrauterine death 
believed to be associated with increased uNK cell number and cytotoxicity (Murphy 
et al., 2005). Reports of reduced litter size and late fetal death which do not involve 
the remodelling of maternal vasculature include maternal metabolic dysfunction 
secondary elevated maternal corticol levels which were shown to result in an increased 
rate of stillbirth in ovine pregnancy (Keller-Wood et al., 2014). Pabp4-/- dams may 
represent a unique opportunity to increase our knowledge on the underlying molecular 








Chapter 4 - Analysis of fetal intrauterine 




Intrauterine growth restriction is when a baby fails to reach its genetic growth potential 
due to intrinsic and/or extrinsic reasons and is the second most common cause of 
perinatal death (Chiswick, 1985; Gardosi et al., 1998). After excluding congenital 
abnormalities, more than 50% of stillbirths were found to have preceding IUGR  
(Gardosi et al., 2005). Furthermore IUGR is associated with morbidities in later life 
(Salam et al., 2014). Currently, it is impossible to predict IUGR prior to pregnancy and 
in early pregnancy and diagnosis poses difficulty with the detection rate in low-risk 
pregnancies as low as 15% (Backe and Nakling, 1993), and the majority of IUGR cases 
are therefore identified from birthweight of live or stillborn babies. When IUGR is 
detected, the only treatment is monitoring fetal well-being and the induction of 
delivery if well-being becomes compromised. IUGR can be classified as symmetrical 
or asymmetrical with symmetrical being more often early-onset and associated with 
by fetal intrinsic anomalies whereas extrinsic factors tend to be associated with late 
onset and maternal and/or placental causes (Nardozza et al., 2012). Importantly, the 
type of IUGR can change throughout pregnancy depending on the underlying cause 
and the duration of the insult. Placenta insufficiency is implicated in up to 65% of 
cases of stillbirth in high-income countries (Heazell et al., 2015). The fetal:placental 
(F:P) weight ratio and birthweight:placental (BW:PW) ratio provides an insight into 
placental efficiency as it informs on the grams of fetus produced per gram of placenta 
(Wilson and Ford, 2001). In preliminary investigations of Pabp4-/- females some 
fetuses were found to be putatively growth restricted. Intriguingly, initial data 
suggested that this may be independent of genotype as some Pabp4+/- fetuses were 
found to be appropriately sized whereas others appeared to be growth restricted in late 
gestation (Figure 4.1). The objective of this chapter was to investigate the veracity of 
this data, and to extend it by establishing the underlying genetics (i.e. fetal and/or 
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parental), the type and extent of the IUGR and whether it changes throughout gestation 




Figure 4.1. Preliminary data showing that some fetuses are small in comparison to litter mates. 
Example of observed putatively growth restricted fetuses of different genotype at e18.5 suggesting 
that being small is independent of fetal genotype.  
 
4.2 Results  
 
To address whether reduced size was a genuine phenotype of PABP4 deficiency and 
whether, similar to the reduction in litter size, it was maternal in nature, timed-matings 
of Pabp4+/+ males with Pabp4-/- females and Pabp4-/- males with Pabp4+/+ females 
were set up. The latter mating is referred to as the ‘paternal KO cross’. Both matings 
produce Pabp4+/- foetuses but, importantly, the conceptus only grows and develops in 
a Pabp4 deficient dam in one of the crosses, allowing for a comparison between 
maternal environments. Additionally, timed-matings of Pabp4+/+ males with Pabp4+/+ 
females were set up to determine the baseline fetal outcome in wild-type matings. If 
maternal PABP4 deficiency results in small fetuses in comparison to fetuses from a 
wild-type cross and more importantly from a paternal KO cross, they can be defined 
as IUGR because fetuses from these two crosses have the same genetic growth 
potential. Timed-mated females were checked for vaginal plugs (VP) (counted as e0.5) 
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and following removal of the uterus at day e18.5 of pregnancy, fetuses were weighed 
and crown-rump length measured, as commonly done in the clinic to establish human 
size for gestational age. Importantly, e18.5 Pabp4+/- fetuses from Pabp4-/- dams were 
found to have both significantly reduced weight (8.5%) relative to Pabp4+/+and 
Pabp4+/- fetuses from Pabp4+/+ dams, revealing that maternal PABP4 deficiency does 
indeed lead to IUGR (Figure 4.2.) with some fetuses more growth restricted than others 
(Figure 4.3). The crown to rump length was found to be insignificantly reduced (3%) 
(Figure 4.2.), however this measurement is less accurate the weights of fetuses. 
Interestingly, the weights of Pabp4+/- fetuses from Pabp4+/+ dams showed a small but 
significant increase in weight compared to Pabp4+/+ foetuses (Figure 4.2. A and C), 
although this was not replicated for crown-rump length measurements (Figure 4.2. B-
C). The basis for this is unclear, but it could imply that Pabp4+/- fetuses have altered, 
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Figure 4.2. Weight and size of fetuses from Pabp4-/- dams is significantly reduced at e18.5.               
 Pabp4+/- fetuses from Pabp4-/- dams have reduced bodyweight (A) and (B)  crown-rump length in 
comparison to both Pabp4+/+ and Pabp4+/- fetuses from Pabp4+/+ dams. C) Comparison of fetal 
bodyweight and crown-rump length % normalised to the ♂ WT x ♀ WT cross. Each symbol corresponds 
to an average per genotype within a single litter. ♂ WT x ♀ WT (green dot) n = 17; ♂ WT x ♀ KO (red 
dot)    n = 18; ♂ KO x ♀ WT (blue dot) n = 12. Data are shown as box and whisker plots with median 
(long line) and mean (cross) indicated. Significance was analysed by Kruskal-Wallis test and Dunn’s 





Figure 4.3. Fetuses from Pabp4-/- dams show a range of IUGR. 
 
As maternal, dependent IUGR was present (Figure 2), placental weight and diameter 
were examined and found to be comparable amongst the three crosses (Figure 4.4.) 
suggesting that the IUGR was not accompanied by abnormal placental size. However 
an decreased F:P weight ratio was found in fetuses from Pabp4-/- dams (13.4% 
decrease in comparison to WT, and 5.6% compared to the paternal KO cross) (Figure 
4.4.), revealing a disproportionality between fetal and placental size in the absence of 
maternal PABP4, consistent with reports that F:P ratio is commonly altered in 
intrauterine growth restriction (reviewed by (Hayward et al., 2016). 
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Figure 4.4. Placental diameter and weight are unaltered at e18.5 which results in an increased 
fetal to placental ratio in fetuses from Pabp4-/- dams. 
Pabp4+/- placentas from Pabp4-/- dams have comparable weight (A) and diameter (B) to Pabp4+/+ and 
Pabp4+/- placentas from Pabp4+/+ dams. As a result F:P weight ratios in Pabp4-/- dams are reduced (C). 
Comparison of F:P % means normalised to the ♂ WT x ♀ WT cross (D).  Each symbol corresponds to 
an average per genotype within a single litter. ♂ WT x ♀ WT (green dot) n = 17; ♂ WT x ♀ KO (red 
dot)    n = 18; ♂ KO x ♀ WT (blue dot) n = 12. Data are shown as box and whisker plots with median 
(long line) and mean (cross) indicated. Significance was analysed by Kruskal-Wallis test and Dunn’s 
multiple comparison test.  ns = > 0.05; * p = ≤ 0.05; ** p = ≤ 0.01; *** p = ≤ 0.001; **** p = ≤ 0.0001. 
 
To assess the IUGR phenotype further, head and abdominal circumference 
measurements were obtained for Pabp4+/+ fetuses from Pabp4+/+ dams and Pabp4+/- 
fetuses from Pabp4-/- dams to determine whether the IUGR observed was asymmetrical 
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(evidence of brain sparing) or symmetrical. Asymmetric fetuses have disproportionate 
growth restriction whereby the head growth is preferentially maintained resulting in a 
relatively normal sized head/brain and a reduced abdomen. In humans, this type of 
IUGR is normally observed in the second half of gestation and is most often associated 
with placental insufficiency and/or a lack of uterine remodelling (reviwed in 
(Nardozza et al., 2012)). Symmetrical IUGR is characterised by a proportional 
decrease of both the head and the abdomen. It generally develops in early pregnancy 
and is most often but not excusively associated with fetal congenital abnormalities and 
other causes of mainly fetal origin (Nardozza et al., 2012). Pabp4+/- fetuses from Pabp4-
/- dams exhibited both reduced head and abdominal circumferences, in comparison to 
Pabp4+/+ fetuses from Pabp4+/+ dams, which resulted in normal head: abdomen ratios 
and therefore the IUGR was defined as symmetrical (Figure 4.5.), ruling out brain 
sparing in Pabp4+/- fetuses from Pabp4-/- dams. Similar measures were not understaken 
for reciporocal crosses as Pabp4+/- fetuses from Pabp4+/+- females do not shown growth 
restriction compared to Pabp4+/+ fetuses from WT crosses. It is tempting to speculate 
from this observation about the etiology of the phenotype in that it suggests it may 
originate early in pregnancy and that oxygen and nutrient delivery to the fetus may in 
large be normal. Furthermore, it suggests that the pregnancy of Pabp4-/- dams is a 
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Figure 4.5. Measurements of head and abdominal circumference at e18.5 reveal symmetrical 
growth restriction in fetuses from PABP4 deficient dams.  
A) Measurements of head circumference. B) Measurements of abdominal circumference. C) Head to 
abdomen circumference ratio. Each symbol corresponds to an average per genotype within a single 
litter. ♂ WT x ♀ WT (green dot) n = 21; ♂ WT x ♀ KO (red dot)   n = 17. Data are shown as box and 
whisker plots with median (long line) and mean (cross) indicated. Significance was analysed by 




Having established that maternally dependant IUGR is present at e18.5 we then posed 
the question: at what stage during pregnancy does IUGR develop and does the extent 
and/or prevalence of restriction alter? To address this, the same crosses were set up as 
for the investigation of e18.5 and fetuses and placentas were weighed and measured at 
e15.5 and e13.5. At e15.5 Pabp4+/- fetuses from Pabp4-/- dams showed reduced 
weights (Figure 4.6. A, C; 11%) and crown-rump length (Figure 4.6. B, C; 3%) in 
comparison to both Pabp4+/+ or Pabp4+/- fetuses from Pabp4+/+ dams. The extent of 
the reduction in length was similar to that seen at e18.5, whilst weight was more 
reduced at e15.5 than E18.5 (compare Figure 4.2. C and Figure 4.6. C), revealing that 
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Figure 4.6. Weight and size of fetuses from PABP4 deficient dams is significantly reduced at 
e15.5.          
Pabp4+/- fetuses from Pabp4-/- dams have reduced bodyweight (A) and (B)  crown-rump length in 
comparison to both Pabp4+/+ and Pabp4+/- fetuses from Pabp4+/+ dams. C) Comparison of fetal 
bodyweight and crown-rump length % normalised to the ♂ WT x ♀ WT cross. Each symbol corresponds 
to an average per genotype within a single litter. ♂ WT x ♀ WT (green dot) n = 17; ♂ WT x ♀ KO (red 
dot)    n = 18; ♂ KO x ♀ WT (blue dot) n = 12. Data are shown as box and whisker plots with median 
143 
 
(long line) and mean (cross) indicated. Significance was analysed by Kruskal-Wallis test and Dunn’s 
multiple comparison test. ns = > 0.05; * p = ≤ 0.05; ** p = ≤ 0.01; *** p = ≤ 0.001; **** p = ≤ 0.0001. 
 
Similarly to e18.5, placental weight and diameter were comparable amongst the three 
crosses and importantly the differences in F:P ratios observed at e18.5 were 
recapitulated at e15.5 showing an decrease of 12.0% in Pabp4+/- fetuses from Pabp4-
/- dams compared to WT (Figure 4.7.). 
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Figure 4.7. Placental diameter and weight are unaltered at e15.5 which results in an increased 
fetal to placental ratio in fetuses from Pabp4-/- dams.  
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Pabp4+/- placentas from Pabp4-/- dams have comparable weight (A) and diameter (B) to Pabp4+/+ and 
Pabp4+/- placentas from Pabp4+/+ dams. As a result F:P weight ratios in Pabp4-/- dams are reduced (C). 
Comparison of F:P % means normalised to the ♂ WT x ♀ WT cross (D).  Each symbol corresponds to 
an average per genotype within a single litter. ♂ WT x ♀ WT (green dot) n = 17; ♂ WT x ♀ KO (red 
dot)    n = 18; ♂ KO x ♀ WT (blue dot) n = 12. Data are shown as box and whisker plots with median 
(long line) and mean (cross) indicated. Significance was analysed by Kruskal-Wallis test and Dunn’s 
multiple comparison test. ns = > 0.05; * p = ≤ 0.05; ** p = ≤ 0.01; *** p = ≤ 0.001; **** p = ≤ 0.0001. 
 
To determine whether the IUGR at e15.5 was also symmetrical, head and abdominal 
circumference measurements were taken (Figure 4.8.). Compared to the Pabp4+/+ 
fetuses from Pabp4+/+ dams, Pabp4+/- fetuses from Pabp4-/- dams showed equivalent 
reductions in head (Figure 4.8. A) and body circumference (Figure 4.8. B) indicative 
of an unaltered head:abdomen ratio (Figure 4.8. C) representing symmetrical IUGR.  
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Figure 4.8. Measurements of head and abdominal circumference at e15.5 reveal symmetrical 
growth restriction of fetuses from Pabp4-/- dams.  
A) Measurements of head circumference. B) Measurements of abdominal circumference. C) Head to 
abdomen circumference ratio. Each symbol corresponds to an average per genotype within a single 
litter. ♂ WT x ♀ WT (green dot) n = 16; ♂ WT x ♀ KO (red dot)   n = 30. Data are shown as box and 
whisker plots with median (long line) and mean (cross) indicated. Significance was analysed by 




As IUGR was well established by e15.5, an earlier time-point, e13.5, was investigated 
to identify the onset of the phenotype. This analysis was carried out on a mixture of 
previously fixed and freshly collected samples, which were analysed separately 
(Figure 4.9.  Figure 4.10.) to take into account differences that are due to fixation (see 
discussion). Due to lower litter numbers, fetal measurements post-fixation were 
plotted as individual data points as well as litter means Although plots of individual 
fetuses is potentially informative the data should be considered as litters given that the 
experimental unit is the mother and also to avoid overpowering the studies.  Pabp4+/- 
fetuses from Pabp4-/- dams being significantly smaller in weight and size in 
comparison to the Pabp4+/+ fetuses from Pabp4+/+ dams when plotted individually 
(Figure 4.9. A-B). However, significance was not present when the data was plotted 
as litter means (Figure 4.9. E-F). In contrast, data collected from fetuses immediately 
following dissection showed no significant difference in weight or size irrespective of 
whether plotted as individual fetuses (Figure 4.10. A-B) or litter means (Figure 4.10. 
E-F, only n=3 for Pabp4-/- dams). Placenta weight and diameter were unaltered 
irrespective of whether they were fixed or freshly collected (Figure 4.9. C, G; Figure 
4.10. C, G). As a result the F:P weight ratio was altered in the case of fixed material 
when considered as individual data points (Figure 4.9. D) but were unaltered when 
considered as litter means (Figure 4.9. H). For freshly collected data the F:P weight 
ratio was unaltered irrespective of whether plotted as individual data points or litter 
means (Figure 4.10. D, H). Overall, due to the low n numbers and the contradictive 
results with these two cohorts, it is difficult to draw conclusions on whether Pabp4+/- 






Figure 4.9. Measurements post-fixation at e13.5 suggest that fetuses from Pabp4-/- dams are 
growth restricted presented as individual data points but not as litter means. 
Fetal and placental measurements and F:P ratio at e13.5 post-fixation presented as individual data points 
(A-D) and litter means (E-F). Pabp4+/- fetuses from Pabp4-/- dams have reduced weights (A) and 
reduced crown-rump lengths (C) in comparison to Pabp4+/+ and Pabp4+/- fetuses from Pabp4+/+ dams 
when graphed as individual data points but not when compared as litter means (E-F). Placental weight 
is unaltered as individual data points (C) and litter means (G). As a result, F:P is altered for individual 
data points of Pabp4+/- fetuses from Pabp4-/- dams  but not as litter means (H). ♂ WT x ♀ WT (green 
dot) n = 44 (individual fetal data points; A-D); 6 (litter means; E-H); ♂ WT x ♀ KO (red dot)    n = 27 
(individual data points; A-D); 5 (litter means; E-F). Data are shown as box and whisker plots with 
median (long line) and mean (cross) indicated. Significance was analysed by Student’s t-test. ns = > 






Figure 4.10. Fresh measurements at e13.5 suggest that fetuses from Pabp4-/- dams are not growth 
restricted. 
Fetal and placental measurements and F:P ratio at e13.5 of freshly collected material presented as 
individual data points (A-D) and litter means (E-F). Pabp4+/- fetuses from Pabp4-/- dams have 
comparable bodyweight (A, E), crown-rump length (B, F), placental weight (C, G) and F:P weight ratio 
(D, H) as individual data points and litter means in comparison to Pabp4+/+ and Pabp4+/- fetuses from 
Pabp4+/+ dams. ♂ WT x ♀ WT (green dot) n = 53 (individual fetal data points; A-D); 6 (litter means; 
E-H); ♂ WT x ♀ KO (red dot)    n = 20 (individual data points; A-D); 3 (litter means; E-F). Data are 
shown as box and whisker plots with median (long line) and mean (cross) indicated. Significance was 
analysed by Student’s t-test. ns = > 0.05. 
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4.3 Discussion  
 
The primary aim of this chapter was to establish whether, as preliminary data 
suggested, fetuses of Pabp4-/- dams are small for gestational age but, more importantly, 
to determine the extent to which they are intrauterine growth-restricted (IUGR), using 
fetal weight and crown-rump length measurements, and the nature of IUGR 
(symmetrical or asymmetrical) by obtaining anthropomorphic measurements. Further, 
I wished to define when in gestation the growth restriction is established and whether 
its severity alters over time. A final aim was to gain an insight into whether placental 
insufficiency is present by investigating the effect of parental genotype on placental 
size (diameter) and weight and thereby determining the fetal to placental weight ratio 
(FPR).  
Pabp4+/- fetuses from Pabp4-/- dams have a significantly reduced bodyweight and 
crown-rump length at e15.5 and e18.5 in comparison to Pabp4+/- (and Pabp4+/+) 
fetuses from WT females (Figure 4.2 and Figure 4.6). Furthermore, at both these time-
points in gestation, Pabp4+/- fetuses from Pabp4-/- dams exhibit significantly reduced 
abdominal and head circumferences, indicative of symmetrical IUGR (Figure 4.5 and 
Figure 4.9). The placentas of these fetuses have equivalent diameters and weights to 
Pabp4+/+ and Pabp4+/- fetuses from WT females resulting in a reduced F:P ratio at 
e18.5 (Figure 4.3) and e15.5 (Figure 4.7). Taken together, these results suggest Pabp4-
/- dams provide a model of IUGR where the underlying cause is maternal.  However, 
whilst highly suggestive, an embryo transfer experiment, as discussed in Chapter 3, 
would provide an additional level of proof with respect to the maternal nature. As 
measures of IUGR are not directly dependent on the number of pups within litters, 
such experiments are potentially feasible, and are ongoing (see Chapter 7).  
Pabp4-/- female mice have the potential to be a model of a yet uncharacterised novel 
maternal causes of IUGR, independent of fetal and paternal genotype. In humans there 
remains a high number of IUGR cases with unknown aetiology, particularly in non-
anomalous fetuses and in the absence of recognised maternal causes such as severe 
maternal medical conditions e.g. hypertension that may result in pre-eclampsia, 
152 
 
chronic infections (e.g. inflammatory bowel disease), maternal hypoxia (e.g. asthma, 
cystic fibrosis), and other diseases including diabetes, glomerulonephritis, collagen 
disease, and severe anaemia (reviewed by (Wollmann, 1998) (Nardozza et al., 2012). 
The nutritional status of the mother prior to pregnancy, pregnancy weight gain and low 
maternal age can also contribute to the incidence of IUGR (Wollmann, 1998). 
Indicators of relevant aspects of maternal health e.g. blood glucose, haematocrit and 
weight gain are examined in Pabp4-/- mice in later chapters.   
In animal models, genetic manipulations have shown that the fetus and/or placenta are 
the main cause of IUGR, and only in a few cases has a maternal contribution been 
reported. Nonetheless these provide precedence that maternal genetics can influence 
pregnancy outcome. For example, a maternal contribution has been evoked for models 
in which loss of endothelial nitric oxide synthase (eNos), an enzyme which acts as a 
potent vasodilator via relaxation of smooth muscle cells (Moncada et al., 1991), results 
in aberrant uterine and spiral artery remodelling and IUGR (Kulandavelu et al., 2012; 
Kusinski et al., 2012). However, IUGR is present only when eNos-/- dams are carrying 
eNos-/- fetuses (Kulandavelu et al., 2012). Interestingly, the eNos+/- fetuses in eNos-/- 
dams are able to achieve normal fetal weight despite uterine arterial lumen diameter 
and blood flow as well as spiral artery length being compromised suggestive of a 
fetal/placental ability to compensate for the underlying maternal underlying defects 
which can lead to IUGR. However, without an embryo transfer experiment, in this case 
it cannot formally be concluded that the eNos-/- fetus itself is not the underlying causal 
factor of reduced fetal bodyweight. Nonetheless, given the importance of uterine and 
spiral artery remodelling in pregnancy, it is attractive to speculate that eNos+/- fetuses 
are capable of compensating for a maternally derived aberrant vascular remodelling to 
achieve a normal bodyweight. Data regarding vascular remodelling in Pabp4-/- females 
is presented in the next chapter. 
As previously mentioned, maternal Pla2g4a knockout leads to a deferral of the 
initiation of implantation, specifically a short delay in the initial attachment reaction, 
which causes late development defects including retarded feto-placental development, 
embryo crowding, conjoined placentas and reduced litter size (Song et al., 2002). This 
delay is distinct from diapause in wild-type mice which can be induced by lactation or 
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experimentally as resumption of uterine responsiveness to the blastocyst results in a 
normal pregnancy outcome (Dey, 1996). A transfer of wild-type blastocysts to 
Pla2g4a-/- uteri results in delayed implantation frequency therefore uterine 
insufficiency for implantation is hypothesized to be the primary cause of the 
phenotype. A similar phenotype of delayed implantation and embryonic development, 
altered embryo spacing, conjoined placentas and embryonic death is also observed in 
mice lacking the gene for a lysophatidic acid (LPA) receptor LPA3 (Ye et al., 2005). 
The deletion of this gene results in the down-regulation of cyclooxygenase 2 (COX2) 
and subsequent low levels of prostaglandins, important for implantation. 
As we do not observe embryo crowding, conjoined placentas or significant numbers 
of resorptions by mid gestation (day12; (Song et al., 2002)), it could be hypothesized 
that a delay in implantation is not the underlying cause of the Pabp4-/- phenotype. 
However, the morphology of e8.5 implantation sites is examined in Chapter 5, and 
direct measures of implantations rates at e5.5 and counting the number of somites of 
embryos from Pabp4-/- females would more directly determine whether maternal 
Pabp4-/- genotype leads to any delay in implantation and/or development relative to 
the day of gestation. A further example in which the maternal genotype is implicated 
in problematic pregnancy is the knockout of metalloproteinase-9 (Mmp9). In this 
model, the loss of MMP primarily from the fetus but also partly from the mother leads 
to pre-eclampsia like symptoms accompanied by IUGR (Plaks et al., 2013), no pre-
eclamptic symptoms have been noted in Pabp4-/- mice: Following embryo transfers of 
Mmp9+/+ embryos into Mmp9-/- mothers, shallow invasion of the mature trophoblasts 
from the ectoplacental cone (ECP) into the maternal decidua was reported, as indicated 
by the presence of small ECPs, blood pools, and debris plugs blocking the invasion of 
the EPC into the mesometrial pole of the decidua (Plaks et al., 2013). Interestingly, 
Mmp9+/+ embryos were still more likely to survive and develop more normally in a 
Mmp9-/- dams in comparison to the reciprocal (paternal KO) setup of Mmp9-/- embryos 
into a Mmp9+/+ dams (Plaks et al., 2013), highlighting the importance of fetal Mmp9-
/- genotype in adverse pregnancy outcome. Knockout of NFIL3 results in incomplete 
remodelling of spiral arteries, placental defects, fetal growth restriction but normal 
litter size (Boulenouar et al., 2016)  3.3 Discussion). Importantly, these effects are 
maternal in origin as Nfil+/+ females crossed with KO produce normal sized fetuses 
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and placentas (Boulenouar et al., 2016). NFIL3, is a maternal transcription factor 
required by innate lymphoid cells (ILC) such as the uterine natural killer (uNK) cells. 
uNK cells increase in the uterus in early pregnancy and are important in pregnancy 
adaptations such as uterine spiral artery remodelling and the phenotype of this mouse 
closely mirrors that of natural killer (NK) cell-deficient mice (Ashkar et al., 2000; 
Kieckbusch et al., 2014).  
At both e15.5 and e18.5 the fetuses of Pabp4-/- dams are characterised by symmetrical 
growth restriction (Figure 4.5 and Figure 4.9), however it is unclear when this growth 
restriction manifests as data from e13.5 is currently inconclusive (Figure 4.9 and 
Figure 4.10). Thus, future work will include completing a full powered data set using 
freshly dissected e13.5 materno-fetal units. Such measurements are normally made on 
freshly dissected material, as the fixation process shrinks tissue. Moreover, use of fresh 
material would allow direct comparisons with the datasets at e15.5 and e18.5. There 
are two subtypes of symmetrical IUGR; 1. congenital anomalies of fetal origin such as 
aneuploidy syndromes, 2. normal ‘constitutionally small’ fetuses with a developmental 
delay which are generally not associated with complications (Nardozza et al., 2012).  
Given that the symmetrical growth restriction phenotype described herein is maternal 
genotype-dependent, it suggests that it does not fall into the typical causal categories 
normally attributed to symmetrical IUGR, however it may be suggestive of an origin 
early in pregnancy. Asymmetrical IUGR on the other hand, often manifests in the 
second half of gestation and is most commonly associated with aberrant utero-
placental insufficiency as a result of improper uterine and decidual artery remodelling 
that leads to reduced blood flow and elevated blood flow resistance (Nardozza et al., 
2012). This could be interpreted to suggest that uterine and decidual artery remodelling 
is normal in Pabp4-/- dams. The use of Doppler ultrasound to establish the resistance 
index of the uterine artery and immunohistochemical analysis for the presence/absence 
of smooth muscle actin in decidual spiral arteries is used to investigate this 
experimentally (Chapter 5). 
At both e15.5 and e18.5 Pabp4+/- fetuses from Pabp4-/- dams have reduced fetal (F) 
weights but their placentas (P) have comparable weights to that of WT fetuses, leading 
to an decreased F:P ratio with a more pronounced difference present at e18.5 (Figure 
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4.4 and Figure 4.7). Recently reviewed by Hayward et al, (Hayward et al., 2016) F:P 
ratio and the birthweight:placental (BW:PW) weight ratio, commonly used in humans, 
inform on the efficiency of the placenta as it describes the number of grams of fetus 
produced per gram of placenta (Wilson and Ford, 2001). Placental failure is implicated 
in up to 65% of cases of stillbirth in high-income countries (Heazell et al., 2015). 
Interestingly it is also a predictor of adverse health outcomes later in life as a low 
BW:PW ratio in humans increases the risk of hypertension in childhood (Hemachandra 
et al., 2006) with an increased risk of cardiovascular disease and stroke in adulthood 
(Risnes et al., 2009). Similarly to humans, in mice the F:P ratio increases as gestation 
progresses, but in a more dramatic manner increasing from F:P=4 at e16 to roughly 
F:P=11-14 at e19, reflective of the exponential fetal growth with no change in placental 
size but an increase in nutrient transfer rate in late gestation (Coan et al., 2008; 
Dilworth et al., 2011). In human problematic pregnancies BW:PW ratios are decreased 
in small for gestational age babies in comparison to appropriately sized for gestational 
age babies, with the difference being most prominent in early gestation (Imada et al., 
2012; Macdonald et al., 2014; Molteni et al., 1978).  In the previously mentioned 
mouse model of IUGR, eNos-/-, F:P is reduced et e17.5 (Kulandavelu et al., 2012; 
Kusinski et al., 2012). Furthermore, mice lacking insulin-like growth factor 2 (Igf2) 
are growth restricted from day e12 onward and present with a reduced F:P near term, 
suggestive of nutrient transport not adapting appropriately in response to placenta size 
changes (Constancia et al., 2005). However, in placental-specific Igf2 knockout (Igf2-
P0) mice the fetuses have a higher F:P ratio throughout gestation, whereby placentas 
are small but have increased efficiency. However, their increased efficiency to 
compensate for size is insufficient towards the end of gestation as fetuses become 
growth restricted before term. These observations are indicative of both of placental 
adaptation and of its failure (Constancia et al., 2002).  At e15.5 placental efficiency is 
suboptimal and by e18.5 the abnormal function becomes more pronounced. As 
placental insufficiency and IUGR are a significant risk factor for stillbirth (Heazell et 
al., 2015; Smith and Fretts, 2007) an attractive hypothesis is that the growth restriction 
present in Pabp4-/- dams is the cause/or contributes to the dramatic reduction in litter 
size between e18.5 and birth. As the nature of the placental insufficiency is unclear 
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from an F:P ratio, Chapter 5 focuses on placental morphology and function in pregnant 




Chapter 5 - Placental structure and function 




Although IUGR and stillbirth are in many cases unexplained some of the known 
associated factors are maternal disease, fetal genetic abnormalities and/or placental 
insufficiency. The placenta is largely extraembryonic in origin being derived from the 
trophectoderm layer, which is set aside from the inner cell mass in the blastocyst at 
e3.5, and gives rise to the labyrinth and junctional zones. The maternal constituent of 
the placenta is the decidua basalis which arises from growth, proliferation and 
differentiation of endometrial stromal cells and an influx of immune cells during 
implantation. A complex bi-directional communication between the mother and fetus 
is key to placental development and may be aberrant in Pabp4-/- mice. Due to the 
maternal genotype-dependent nature of the phenotype, it is envisaged that a failure to 
receive or correctly respond to fetal “signals” or a disruption of maternal ‘signals’ to 
the fetus could result in aberrant placentation and subsequent placental insufficiency. 
One of the first important such events is the release of several cytokines from 
decidualised cells in response to maternal estrogen. These include leukemia inhibiting 
factor (LIF) which stimulates trophoblast outgrowth (Cai et al., 2000) and thus appears 
particularly important in triggering events required for implantation (Stewart et al., 
1992). The trophoblasts of the blastocyst also secrete molecules, for example 
interleukin-1β (IL-1β), whose receptor is expressed on uterine epithelium and 
endometrial cells (Simon et al., 1994) and alters the expression of specific integrins, 
structurally transforming the plasma membrane of the epithelial endometrium (Simon 
et al., 1998).  
During implantation uterine stromal cells proliferate and differentiate into enlarged 
secretory decidual cells which form an implantation chamber around the conceptus 
(Bilinski et al., 1998). Decidualisation initially occurs at the anti-mesometrial pole of 
the implantation site and on embryonic day 5 (e5) a wave of decidualisation occurs 
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around the embryo forming the primary decidual zone, followed by a second wave of 
decidualisation and the formation of the secondary decidual zone at e6 (Huet-Hudson 
et al., 1989). At e7 decidualization also takes places at the mesometrial pole which 
coincides with expansion of the embryo, primary trophoblast invasion and apoptosis 
of the anti-mesometrial decidua (Welsh and Enders, 1985). The placenta forms at the 
mesometrial pole where it is in direct contact with the mesometrial decidua.  
Currently no information is available as to whether PABPs are expressed within 
implantation sites and the placenta hampering the understanding of whether mis-
regulated implantation/placental development may be causative in the maternal 
genotype-dependent phenotype or whether they may be a consequence of a primary 
defect beyond the uterus. Thus this chapter investigates PABP4 expression in the non-
pregnant uterus, during implantation, and in the mature placenta. Furthermore, this 
chapter investigates implantation site shape and weight, ectoplacental cone 
morphology as well as volumetric changes of the total placenta and of individual 
placental zones in Pabp4-/- dams. Aspects of placental function are also examined by 
investigating uterine and spiral artery remodelling and glucose levels in the fetal versus 




To address the current lack of information on whether PABPs are expressed within the 
uterus prior to pregnancy or the implantation sites following conception, expression of 
PABP4, and the closely related PABP1, was examined in Pabp4+/+ non-pregnant 
uterus, e5.5 and e8.5 implantation sites by immunohistochemistry (IHC). The non-
pregnant uterus is an important hormone-responsive reproductive organ whose 
primary role is to receive the fertilised oocyte and allow it to implant and develop 
successfully to term. PABP4 and PABP1 were found to be strongly expressed in the 
luminal epithelium and glandular epithelium with PABP1 being also strongly 
expressed in what is most likely stromal fibroblasts, based on morphology and location 
(Figure 5.1 A, B). Neither the pattern nor levels of PABP1 expression appreciably 
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changed in the absence of PABP4 (Figure 5.1 D), although conclusions with regards 
to levels require additional techniques, such as western blots, as IHC is not 
quantitative. However, because Pabp4-/- and Pabp4+/+ samples were stained on the 
same slide, differences in staining intensity is potentially informative.  Next the 
expression of PABP4 and PABP1 was investigated in e5.5 and e8.5 implantation sites. 
Interestingly, at e5.5 PABP4 was found to be largely absent in the primary decidua 
zone surrounding the embryo but present in non-decidualised zone in the anti-
mesometrial endometrium surrounding the primary decidual zone and the mesometrial 
endometrium (Figure 5.2. A). Furthermore, it was expressed in the epithelium of 
endometrial glands (Figure 5.2. A). PABP1 showed a similar pattern of expression but 
was generally more widely expressed throughout the implantation site, including 
weaker expression in the decidualising cells surrounding the embryo (Figure 5.2. B.). 
At e8.5 PABP4 was found to be expressed in the ectoplacental cone, maternal decidua 
which contains large numbers of leukocytes (indicated by an asterisk), primarily 
uterine natural killer cells (uNK) and the embryo (Figure 5.3. A). Interestingly, 
similarly to e5.5, PABP4 appeared to be largely absent from the zones undergoing 
decidualisation which are outlined by a dotted line and appear as paler and larger cells 
(Figure 5.3. A). PABP1 showed a very similar pattern of expression to PABP4 at e8.5 
but in contrast to e5.5 also appeared to be largely absent from zones undergoing 
decidualisation (Figure 5.3. B). These data show that a burst of expression of PABP4 
occurs in the stromal cells surrounding the primary decidualised zone following 
conception. However its expression appears transient as it is absent in within the 
primary decidualised zone, suggesting it may be important for the stromal to decidual 





Figure 5.1. PABP4 and PABP1 expression in the non-pregnant uterus. 
Immunohistochemical analysis of (A) PABP4 expression and (B) PABP1 expression in the Pabp4+/+ 
non-pregnant uterus and analysis of (C) PABP4 expression and (B) PABP1 expression in the Pabp4-/- 
non-pregnant uterus. Rabbit IgG control (insert in C). 50 µm scale bars and x20 magnifications are 
shown.  
 
The presence of PABP4 in the decidua at these stages (Figure 5.2, Figure 5.3), raises 
the possibility that it’s loss could affect early events resulting in IUGR and fetal death 
later in pregnancy, despite normal number of implantations being observed at e8.5 
(Figure 3.14, Chapter 3) in Pabp4-/- females. For instance, data in hand cannot rule out 
a delay in blastocyst attachment nor shallow invasion of trophoblasts following 
implantation. Thus to investigate whether implantations in Pabp4-/- females deviated 
from normal morphology, multiple parameters of Pabp4+/- implantation sites from 
Pabp4-/- and Pabp4+/+ females were compared. Interestingly this revealed that all 
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measured parameters i.e. implantation weight, width and mesometrial to anti-
mesometrial (M/AM) distance differed in Pabp4-/- females (Figure 5.4. A, C, E) 
indicating that these implantations have an altered shape (Figure 5.4G). However, 
when the measurements were considered as litter means, only the M/AM distance 
remained significantly increased in implantations sites from Pabp4-/- females (Figure 
5.4. B, D, F). Whilst the apparent absence of precedents for this in the literature make 
it difficult to draw conclusions from this data alone, the distinct shape supports the 
idea that implantation may be altered e.g. due to problems such as delayed 
implantation, aberrant decidualisation, disparate trophoblast invasion and/or disparate 









Figure 5.2. PABP1 and PABP4 expression pattern in WT e5.5 implantation sites. 
Section of Pabp4+/+ implantation sites at embryonic day (e) 5.5 stained by immunohistochemistry for A) PABP4 and B) PABP1. Rabbit IgG control (insert in B). Both are 




Figure 5.3. PABP1 and PABP4 expression pattern in WT e8.5 implantation sites. 
Sections of Pabp4+/+ implantation sites at embryonic day (e) 8.5 stained by immunohistochemistry for A) PABP4 and B) PABP1. Rabbit IgG control (insert in B). Dotted line 
outlines decidualised stromal fibroblasts in the primary and secondary decidual zone which surround the embryo. x2 magnifications are shown. 
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Figure 5.4. Despite normal implantation numbers Pabp4 +/- implantation sites from Pabp4-/- females have 
an altered shape and reduced weight at e8.5.  
e8.5 implantation site morphometric parameters measured following 4% NBF fixation and shown as (A, C, E) 
data-points for individual implantation sites or (B, D, F) litter means. Morphometric parameters measured include 
(A, B) implantation width, (B) mesometrial to anti-mesometrial distance and (C) implantation weight. (D) 
Schematic representation of implantation sites in Pabp4+/+ and Pabp4-/-females. Individual implantation site data-
points ♂ WT x ♀ WT (green dot) n = 75; ♂ WT x ♀ KO (red dot) n = 60. Averages per genotype within a single 
litter ♂ WT x ♀ WT (green dot) n = 6; ♂ WT x ♀ KO (red dot) n = 7. Data are shown as box and whisker plots 
with median (long line) and mean (cross) indicated. Significance was analysed by Student’s  t-test. ns = > 0.05; * 
p = ≤ 0.05; ** p = ≤ 0.01; *** p = ≤ 0.001; **** p = ≤ 0.0001. 
 
To obtain an indication of whether trophoblast cell invasion may be impaired in the 
mesometrial chamber of Pabp4-/- versus Pabp4+/+ females at e8.5, immunohistochemical 
analysis using an anti-cytokeratin 7/8 antibody was undertaken. At implantation sites 
cytokeratin 7/8 can be used to distinguish between maternal cells and fetal trophoblast cells 
and at e8.5 it reveals the ectoplacental cone (Figure 5.5.). Minus primary antibody controls 
support the specificity of this detection (data not shown). The ectoplacental cone is a derivative 
of the early post-implantation trophoblasts (polar trophoblasts) that continue to multiply and 
proliferate on the mesometrial side of the uterus, and which probably gives rise to the junctional 
zone of the placenta (Rossant and Cross, 2001). Cells in the ectoplacental cone act as a frontline 
population of cells invading the mesometrial chamber to initiate placentation (Tesser et al., 
2010). No striking visual differences were apparent between the Pabp4+/- and Pabp4+/+ 
ectoplacental cones (Figure 5.5) from Pabp4-/- and Pabp4+/+ females respectively, although 
quantitative measures were not undertaken. 
In summary, PABP4 expression at the time of implantation means it is feasible that the lack of 
maternally expressed PABP4 may result in aberrant implantation. Consistent with this idea, 
investigation of implantation site morphometry revealed an altered shape in Pabp4-/- females 
although formation of the ectoplacental cone was not notably impacted. Further quantitative 
measures would be necessary to determine if invasion and the thickness of the mesometrial and 
anti-mesometrial poles in the implantation chamber and/or size/stage of the embryo is altered 







Figure 5.5. Cytokeratin7/8 expression in e8.5 implantation sites. 
Sections e8.5 implantation sites immunostained for cytokeratin 7/8, which is expressed in trophoblast cells, to 
visualise the ectoplacental cone in implantation sites (A, C, E) from three different crossed of ♂Pabp4+/+ x 
♀Pabp4+/+ and a  (B, D, F) ♂Pabp4-/- x ♀Pabp4-/- . Mesometrial pole and anti-mesometrial pole are oriented in 
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the same direction in all images with ectoplacental cone (EPC) and parietal trophoblast giant cells (P-TGCs) 
indicated (dashed lines) in (A). Rabbit IgG negative controls (not shown) were negative for any cytokeratin 7/8 
expression. 
 
PABP4 expression in maternal cells during implantation means that any intrinsic placental 
defect could have pre-placentation origins (e.g. those observed in implantations at E8.5). 
However, if also expressed within the maternal component of the developing/mature placenta, 
an intrinsic placental defect may also result from its absence at later stages of pregnancy, or a 
combination thereof. As described in detail in Chapter 1, the placenta is made up of several 
functional compartments/zones that contain different cell types namely the chorionic plate, 
labyrinth, junctional zone and the maternally derived decidua basalis. The decidua basalis is 
the outer most compartment and is the sole maternal compartment of the placenta, serving as 
the attachment site of the placenta to the mother, and arises from a structural and functional 
transformation of the endometrium in early pregnancy. It largely consists of decidual (stromal) 
cells and remodelled maternal vasculature which supplies oxygenated blood and nutrients to 
the fetus and placenta as well as removing metabolic waste from approximately e10.5. Other 
cell types within the decidua basalis include immune cells such as macrophages, T cells, uNK 
cells and fetaly derived spiral artery-associated trophoblast giant cells (SpA-TGCs) (Hu and 
Cross, 2010). Between the decidua basalis and the spongiotrophoblast layer sits a line of 
parietal trophoblast giant cells, which in early pregnancy invade the uterus by remodelling the 
extra-cellular matrix (Cross et al., 1994). These cells produce hormones, including prolactin-
like hormones, placental lactogens and cytokines that regulate aspects of maternal physiology 
and paracrine factors, which regulate the feto-maternal interface (Cross et al., 1994). These 
cells together with spongiotrophoblast and glycogen trophoblast cells make up the junctional 
zone. Spongiotrophoblast cells, along with TGCs are the main endocrine cells of the placenta. 
As their name suggests, glycogen cells accumulate glycogen and around e16.5 these cells travel 
from the junctional zone to the decidua, within close vicinity of spiral arteries that supply the 
feto-placental unit, (Adamson et al., 2002; Georgiades et al., 2002a) and are believed to provide 
an energy boost in the final stage of growth prior to birth (Bouillot et al., 2006). In addition to 
these functions, the junctional zone has also been suggested to limit the growth of maternal 
blood vessels into the placenta by producing anti-angiogenic proteins such as soluble fms-like 
tyrosine kinase-1 (sFlt-1) and proliferin-related proteins (Adamson et al., 2002; He et al., 
1999). The labyrinth zone is where hemotrophic exchange between fetal and maternal blood 
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occurs and is the zone of the placenta in which changes have most often been associated with 
IUGR (Kraus FT, 2004). It is primarily composed of two layers of multi-nucleated 
syncytiotrophoblast cells but also contains maternal blood canal-associated trophoblast giant 
cells (C-TGCs) and sinusoidal trophoblast giant cells (S-TGCs) (Hu and Cross, 2010). Finally, 
the chorionic plate is the result of allantois (structure from which fetal blood vessels develop 
and grow) and chorion (folds to form villi) fusion, called chorioallantoic attachment, at e8.5 
which is the first step in labyrinth development (Rossant and Cross, 2001; Watson and Cross, 
2005).  
IHC was performed in mature (e18.5) Pabp4+/+ placentas using PABP4 and PABP1 antibodies 
(Figure 5.6, Figure 5.7). Low magnification images revealed that PABP4 and PABP1 were 
expressed within all the functional layers (Figure 5.6 A and B). Importantly, isogenic antibody 
controls and the absence of PABP expression in some cell types supported the specificity of 
the antibodies (data not shown). Higher magnification images of the three main zones of the 
placenta suggested that PABP4 was most highly expressed within the junctional zone although 
cells lacking detectable PABP4 are also present within this layer (Figure 5.7 A, E). It is also 
present in the decidua basalis, and the labyrinth zone (Figure 5.7. C, G). Within the junctional 
zone, PABP4 expression can be observed in parietal trophoblast giant cells and the 
spongiotrophoblast layer but not in glycogen trophoblast cells (Figure 5.7 E). PABP1 showed 
a similar pattern of expression but was generally more widely expressed in all the different 
placental zones (Figure 5.7 B, D, F, H), including the glycogen cells trophoblast cells (Figure 
5.7. E). Together this data shows expression of PABP4 in the maternal, as well as fetal- derived 
zones of the placenta, meaning that the primary defect in Pabp4-/- mice could reside within the 






Figure 5.6. PABP4 and PABP1 expression pattern in the mature Pabp4+/+ placenta.  
Sections of Pabp4+/+ e18.5 placenta stained by immunohistochemistry for (A) PABP1 and (B) PABP4. Dotted lines delineate the different substructures of the placenta including 








Figure 5.7. PABP4 and PABP1 expression in individual placental compartments of the mature Pabp4+/+ 
placenta. 
Sections of Pabp4+/+ e18.5 placenta stained by immunohistochemistry for (A, B) PABP4 and PABP1in three main 
compartments of the placenta with decidua basalis (DB), junctional zone (JZ) and labyrinth zone (LZ) indicated. 
(C, D) PABP4  and PABP1 expression in the decidua basalis; (E, F) the junctional zone with trophoblast giant 
cells (TGCs), spongiotrophoblast  (SpT) and glycocen trophoblast (GlyT) cells indicated  and(G, H) the labyrinth 
zone. Rabbit IgG control (insert in G). (A, B) x10 magnification images, (C, D, E, F, G, H) x40 magnification 
images.  
 
IUGR is often associated with placental insufficiency; a broad term used to describe different 
placental abnormalities including changes in total placenta size or that of a specific zone, 
placental hemodynamic changes as a result of abnormal maternal uterine artery remodelling 
and/or maternal decidual spiral artery remodelling and/or changes in nutrient/gas transport. 
Given the expression pattern of PABP4, we hypothesized that the placentas of Pabp4-/- females 
may present with one or more of these abnormalities, either contributing to the IUGR or as an 
attempt to adapt to minimise the phenotype. To explore this hypothesis, both placental 
morphology and function were examined. To examine placental morphology, I undertook 
volumetric analysis of placentas from Pabp4-/- mice in the laboratory of Prof Graham Burton 
at the Centre of Trophoblast Research (CTR) using stereology. Stereology is a well-established 
technique that can be utilised to determine three-dimensional quantities, including volumes, 
from two-dimensional histological sections (Coan et al., 2004). Total placental and specific 
compartmental volumes including that of maternal blood spaces, which transcend the 
junctional zone and decidua basalis, were determined for e18.5 placentas of Pabp4-/- and 
Pabp4+/+ females crossed with Pabp4+/+ males. A late (e18.5) time-point was chosen for 
analysis as any causal or compensatory differences in total/compartmental volumes are most 
likely evident by this time. From each litter, a random placenta was selected, excluding 
placentas of fetuses by the ovary to prevent a weight/size bias (Louton et al., 1988). Half of 
each selected placenta was fixed and exhaustively serial sectioned at 5 µm prior to every 20th 
section being stained using haematoxylin and eosin (H&E). These sections were then utilised 
to perform measurements using a computer assisted stereology toolbox (CAST) system as 
described previously (Coan et al., 2004). This revealed that the total volume of Pabp4+/- 
placentas from Pabp4-/- and Pabp4+/+ females was equivalent (Figure 8A), consistent with the 
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normal placental weight and diameter (data from Chapter 4 Figure 3 is reproduced in Figure 
5.8 B, C). Although the placenta achieves its maximum volume at e16.5, the relative size of its 
functional zones continue to change with the labyrinth expanding until term, and the junctional 
zone reducing in volume possibly due to decreased spongiotrophoblast proliferation and 
migration of glycogen cells into the maternal decidua (Coan et al., 2006). As total placental 
volume alone cannot inform on any differences in the volumes of individual placental zones 
i.e. the junctional zone, labyrinth zone and decidua basalis, additional stereological measures 
were taken. Importantly, the volumes of maternal blood spaces (Figure 5.9 A) and the labyrinth 
zone (Figure 5.9 B) were found to be unaltered in Pabp4+/- placentas from Pabp4-/- females in 
comparison to controls (Figure 5.9 A, B). This rules out aberrant growth of maternal blood 
vessels into the placenta which would result in a larger volume of maternal blood spaces and a 
decrease in the labyrinth zone, a particularly frequent feature in IUGR that results in decreased 
hemotrophic exchange of nutrients (Watson and Cross, 2005), as causal in Pabp4-/- mice. 
Critically, the volume of the junctional zone volume was found to be significantly reduced 
(Figure 5.9 C) with a corresponding increase in the volume of the decidua basalis (Figure 5.9 
D), explaining the lack of overall change in the volume of the placenta (Figure 5.8 A). Taken 
together these results identify an altered placental structure as a feature of pregnancies within 
Pabp4-/- females (Figure 5.9 E), in which the size of the labyrinth is maintained but reciprocal 
changes in the size of the junctional zone, that provides much of the endocrine function, and 
the maternally derived decidua are present. It is unclear if decidua volume was increased as a 
result of a junctional zone volume decrease or vice versa and whether these changes are a cause 
or an effect of the Pabp4-/- phenotype. However, given that the phenotype is dependent on 
maternal genotype, it is reasonable to conclude that the primary defect does not lie in the fetal-
derived junctional zone but either in the decidua basalis or in another aspect of maternal 
physiology e.g. a reciprocal change in junctional zone size may retard its efficacy in directing 
maternal adaptation. It is also equally possible that a change in another aspect of maternal 
physiology (e.g. failure of the spleen to adapt) may be directly causative of the IUGR and the 
















































































































Figure 5.8. Total placental volume is unaltered in placentas from Pabp4 -/- females, consistent with normal 
fresh placental weight and diameter. 
(A) Total placental volume assessed by stereology in Pabp4+/- placentas from Pabp4-/- females and Pabp4+/+ from 
Pabp4+/+ females. (♂ WT x ♀ WT (green dot) n = 11; ♂ WT x ♀ KO (red dot)   n = 9). (B) Weight and (C) 
diameter of freshly collected Pabp4+/- placentas from Pabp4-/- females and Pabp4+/+ placentas from Pabp4+/+ 
females (♂ WT x ♀ WT (green dot) n = 16; ♂ WT x ♀ KO (red dot)   n = 17) – shown in previous chapter. Each 
data-point represents an individual placenta measurement. Data are shown as box and whisker plots with median 
























































































































































































































Figure 5.9. Junctional zone volume is decreased and decidua basalis volume is increased in Pabp4+/- 
placentas from Pabp4 +/+ females at e18.5. 
Placental compartment volumes assessed by stereology in e18.5 placentas. Pabp4+/- placentas from Pabp4-/- dams 
have (A) normal maternal blood space and (B) labyrinth zone volume but (C) reduced junctional zone and (D) an 
increased decidua basalis volume in comparison to Pabp4+/+ from Pabp4+/+ females. These differences result in 
an altered placental sub-compartmental structure (E). (♂ WT x ♀ WT (green dot) n = 11; ♂ WT x ♀ KO (red dot)   
n = 9. Each data-point represents an individual placental measurement. Data are shown as box and whisker plots 
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with median (long line) and mean (cross) indicated. Significance was analysed by Student’s t-test. ns = > 0.05; ** 
p = ≤ 0.01. 
 
In parallel to examining effects of PABP4 deficiency on placental composition, its effects on 
aspects of uterine and placental function (vascular remodelling and fetal blood glucose levels), 
were analysed. In pregnancy the maternal cardiovascular system undergoes major adaptations 
in response to the developing fetus, including increased cardiac output, angiogenesis and the 
adaptation of existing vasculature. The remodelling of the uteroplacental vasculature from a 
high to low resistance and low to high flow plays a critical role in sustaining an adequate blood 
flow at the maternal-placental interface, thus providing the fetus with appropriate nutrients and 
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Figure 5.10. Common carotid artery resistance index is comparable in non-pregnancy between Pabp4 -/- 
and Pabp4 +/+ females but is increased in Pabp4 -/- females at e17.5 of gestation. 
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Doppler flow velocity waveforms obtained for the common carotid artery in non-pregnancy and at e17.5 of 
gestation for Pabp4+/+ (WT; green dot) and Pabp4-/- (KO; red dot) females. (A) Location of common carotid artery 
visualised using ultrasound, common carotid artery and inner carotid artery are indicated. (B) Representative 
common carotid artery velocity waveforms of WT and KO females. Resistance index was calculated from velocity 
waveforms in (C) non-pregnant females (♀ WT (green dot) n = 5; ♀ KO (red dot) n = 5) and (D) in pregnant 
females at day e17.5 of gestation (♀ WT (green dot) n = 5; ♀ KO (red dot) n = 4). Each data-point represents an 
individual common carotid artery. Data are shown as box and whisker plots with median (long line) and mean 
(cross) indicated. Significance was analysed by Student’s  t-test. ns = > 0.05; *p = ≤ 0.05. 
 
Deficiencies of the maternal uterine vasculature which become clinically evident in the last 
half of gestation are associated with pregnancy complications including IUGR (Todros et al., 
1999). Therefore, we sought to examine the functional characteristics of uteroplacental blood 
flow in Pabp4-/- and Pabp4+/+ females by taking Doppler measurements of the uterine artery 
and umbilical artery and calculating their resistance index (RI), which are commonly used in 
the clinic to determine placental insufficiency and the risk/presence of IUGR. The 
measurements of the umbilical artery reflects the vascular resistance on the fetal side whereas 
uterine artery measurements inform about the resistance on the maternal side but both are used 
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Figure 5.11. Inner carotid artery resistance index is comparable in non-pregnancy and at e17.5 between 
Pabp4-/- and Pabp4+/+ females. 
Doppler flow velocity waveforms obtained for the inner carotid artery in non-pregnancy and at e17.5 of gestation 
for Pabp4+/+ (WT; green dot) and Pabp4-/- (KO; red dot) females. (A) Location of inner carotid artery visualised 
using ultrasound with inner carotid artery indicated. (B) Representative non-pregnant inner carotid artery velocity 
waveforms of WT and KO females. Resistance index was calculated from velocity waveforms in (C) non-pregnant 
females (♀ WT (green dot) n = 5; ♀ KO (red dot) n = 5) and (D) in pregnant females at day e17.5 of gestation (♀ 
WT (green dot) n = 5; ♀ KO (red dot) n = 4). Each data-point represents an individual inner carotid artery. Data 
are shown as box and whisker plots with median (long line) and mean (cross) indicated. Significance was analysed 
by Student’s t-test. ns = > 0.05; *p = ≤ 0.05. 
 
RI is a measure of pulsatile blood flow that reflects the resistance to blood flow caused by 
microvascular beds which are distal to the site of measurement and is calculated with the 
formula: RI = ([peak systolic velocity – end diastolic velocity] / peak systolic velocity). The 
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functional properties of the uterine artery can also be evaluated by examining the characteristics 
of the Doppler waveform, specifically whether there is ‘notching’. Notching is a phenomenon 
where a ‘notch’ (indicated by white arrow in Figure 5.10 B, Figure 5.11B) is present in the 
descending waveform in early diastole. The highest risk pregnancies present with severe 
notching and an abnormal resistance index. However, problems with uterine artery remodelling 
can present as mild notching with the absence of an abnormal resistance index, due to normal 
blood flow at the end of diastole, which still increases the risk of an adverse fetal outcome. 
Thus, it is important to evaluate both parameters.  
Interestingly, arterial remodelling in pregnancy is not the same across the whole arterial tree 
and the carotid artery stiffens independently of other arterial beds (Visontai et al., 2002) with 
a decline in its elasticity towards the end of pregnancy (Karkkainen et al., 2014). This stiffening 
is functionally distinct from the remodelling of maternal arteries, with the notching 
characteristic of “normal” arteries being retained in the inner and common carotid artery in 
mice (Visontai et al., 2002), allowing them to serve as internal controls for the extensive 
changes in uterine and umbilical arteries. Therefore, Doppler measurements of the inner and 
common carotid artery (CCA) were also determined to assess their haemodynamic properties. 
Carotid artery RI was measured in non-pregnant and pregnant females, at e17.5, as opposed to 
e18.5, as pilot studies showed that the slightly smaller size of the fetuses at this time-point 
made it marginally easier to take uterine artery Doppler measurements as the uterine artery was 
more accessible and easier to find. The changes in remodelling at e17.5 should be reflective of 
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Figure 5.12. Uterine artery resistance index is comparable at e17.5 between Pabp4-/- and Pabp4+/+ females. 
Doppler flow velocity waveforms obtained for the uterine artery at e17.5 of gestation for Pabp4+/+ (WT; green 
dot) and Pabp4-/- (KO; red dot) females. (A) Location of uterine artery visualised using ultrasound with bladder 
and uterine artery indicated. (B) Representative uterine velocity waveforms of WT and KO females. Resistance 
index was calculated from velocity waveforms in (C) in pregnant females at day e17.5 of gestation (♀ WT (green 
dot) n = 5; ♀ KO (red dot) n = 4). Each data-point represents an individual uterine artery. Data are shown as box 
and whisker plots with median (long line) and mean (cross) indicated. Significance was analysed by Student’s t-






This revealed that the common carotid artery RI was comparable in non-pregnant Pabp4-/- and 
Pabp4+/+ females (Figure 5.10) but at e17.5 of pregnancy, despite having a similar notched 
waveform (Figure 5.10. B), it was significantly increased in Pabp4-/- females (Figure 5.10). In 
contrast, the RI of the inner carotid artery was the same in non-pregnant and e17.5 pregnant 
Pabp4-/- and Pabp4+/+ females (Figure 5.11. B, C, D), with similar waveforms. It remains to 
be determined whether Pabp4-/- females have arterial stiffness in the CCA. 
Importantly, uterine artery RI at e17.5 (Figure 5.12. B, C) was found to be unaltered between 
the genotypes and no notching was observed in the waveforms of uterine arteries in Pabp4+/+ 
or Pabp4-/- dams which suggests that uterine artery remodelling preceded normally. Similarly, 
the umbilical arteries (Figure 5.13 B, C) of Pabp4+/+ and Pabp4-/- mice showed equivalent RI 
and absence of notching indicative of the vascular resistance being normal on the fetal side. 
Taken together these data indicate that deficient vascular remodelling of these vessels is not 
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Figure 5.13 Umbilical artery resistance index is comparable in fetuses of Pabp4-/- and Pabp4+/+ females. 
Doppler flow velocity waveforms obtained for the umbilical artery at e17.5 of gestation for Pabp4+/+ (WT; green 
dot) and Pabp4-/- (KO; red dot) females. (A) Location of uterine artery visualised using ultrasound with umbilical 
artery indicated. (B) Representative uterine velocity waveforms of WT and KO females. Resistance index was 
calculated from velocity waveforms in (C) in pregnant fetuses at day e17.5 of gestation (♀ WT (green dot) n = 
13; ♀ KO (red dot) n = 14). Each data-point represents an individual umbilical artery. Data are shown as box and 
whisker plots with median (long line) and mean (cross) indicated. Significance was analysed by Student’s t-test. 
ns = > 0.05; *p = ≤ 0.05. 
 
Having gathered evidence that the uterine artery appears to be appropriately remodelled, the 
remodelling of spiral arteries (SpA) was investigated. SpA lie within the decidua and are 
remodelled between e8.5 and e12.5 (reviewed by (Zhang et al., 2011) independently of the 
uterine artery. This involves the action of interferon-γ derived from maternal uterine natural 
killer cells (Ashkar et al, 1999; Ashkar et al, 2000; Ashkar et al, 2001). Interestingly, the 
volume of the decidua of Pabp4-/- dams was shown to be significantly increased (Figure 5.9), 
although this may not be associated with abnormal SpA remodelling. SpA remodelling can be 
assessed qualitatively by the absence of smooth muscle actin (SMA) and presence of 
trophoblast cells, using SMA and cytokeratin 7/8 markers in IHC, respectively. SMA is 
normally present in endothelial cells which are replaced in the vascular media by trophoblast 
cells during remodelling (Adamson et al., 2002). Remodelling was assessed at day e13.5, when 
the maternal vasculature should be remodelled and at day e18.5 when the IUGR phenotype is 
well established but preceding the major onset of fetal death (Figure 5.14). SMA was largely 
absent in SpA of Pabp4+/+ females at e13.5, and e18.5, as expected (Figure 5.14 A, B) and 
importantly was also largely absent in Pabp4-/- females (Figure 5.14 D and E). Appropriate 
remodelling of the SpA was confirmed by the presence of trophoblast cells lining the arteries 
(Figure 5.14 C, F) providing evidence that transition of SpA also occurs normally. Appropriate 
remodelling of both the uterine arteries, assessed by Doppler ultrasound, and spiral arteries, 
assessed by IHC, as well as the presence of normal umbilical artery haemodynamics are in line 
with symmetrical IUGR that is observed in Pabp4-/- females as the poor uteroplacental blood 
flow is generally considered to result in asymmetrical IUGR. This has been experimentally 
demonstrated by interventions such as uterine artery ligation and occlusion which both result 






Figure 5.14. Spiral artery remodelling appears to be normal in Pabp4-/- females. 
 Representative images of decidua of 3 different Pabp4-/- females (D-F) and Pabp4+/+ (A-C) females which were visually analysed at the midsagittal plane, a vertical plane 
through the midline of the decidua, following serial sectioning of 5 µm and immunostaining of one section every approximately every 30 µm, as indicated. 
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The previous data suggest that sufficient blood flow is delivered to and across the placenta, but 
does not inform on its capacity to transport nutrients across the materno-fetal interface, which 
are necessary for supporting growth, especially later in pregnancy where the majority of fetal 
growth occurs. Thus the delivery of nutrients was investigated, by measuring fetal blood 
glucose levels. Fetal blood glucose measurements were collected from non-fasted dams, 
therefore read-outs were subject to dam food-intake although the impact of this variable was 
minimised by collections being done at the same time of the day (around 2pm when females 
are resting and not feeding). The measurements revealed that at e15.5, Pabp4+/- fetuses from 
Pabp4-/- females have significantly lower blood glucose levels compared to those from wild-
type or reciprocal crosses, the latter also producing Pabp4+/- fetuses (Figure 5.15 A, B). 
Importantly, non-fasted maternal blood glucose levels were unchanged in Pabp4-/- females at 
e15.5 and e18.5, suggesting that maternal glucose homeostasis is normal (Figure 5.16 A, B), 
and therefore that the reduced fetal glucose levels may not simply reflect less glucose reaching 
the placenta via the maternal circulation. Therefore, this result could be indicative of a placental 
nutrient transport deficiency in Pabp4-/- females, which may be reflected in, or due to, reduced 
glucose transporter mRNA levels. Therefore the mRNA levels of placental glucose 
transporters, Glut-1 (Slc2a1) and Glut-3(Slc2a3), were examined at e15.5 and e18.5. No 
significant difference was seen in their mRNA levels at e15.5 (Figure 5.17), however, both 
were significantly upregulated in placentas from Pabp4-/- females at e18.5 (Figure 5.18). Taken 
together, these results suggest that the reduced fetal glucose is not due to decreased levels of 
Glut-1and Glut-3 mRNAs. The upregulation of these mRNAs at e18.5 may reflect a 
compensatory mechanism in response to continuing low fetal glucose levels that is not 
sufficient to rescue levels of fetal blood glucose. Reciprocal crosses to examine glucose 
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Figure 5.15. Fetal blood glucose is significantly decreased in Pabp4+/-fetuses from Pabp4-/- females in 
comparison to both Pabp4+/- and Pabp4+/+ fetuses from Pabp4+/+ females at e15.5 and e18.5. 
Non-fasted fetal blood glucose measured using a blood glucose meter at (A) e15.5. (♂ WT x ♀ WT (green dot) n 
= 36; ♂ WT x ♀ KO (red dot)    n = 31; ♂ KO x ♀ WT (blue dot) n = 10) and (B) e18.5 of gestation (♂ WT x ♀ 
WT (green dot) n = 33; ♂ WT x ♀ KO (red dot)    n = 24; ♂ KO x ♀ WT (blue dot) n = 69). Each symbol 
corresponds to an individual fetal measurement. Data are shown as box and whisker plots with median (long line) 
and mean (cross) indicated. Significance was analysed by Kruskal-Wallis test and Dunn’s multiple comparison 









































Figure 5.16. Maternal blood glucose is comparable in Pabp4-/- and Pabp4+/+ females at e18.5. 
Non-fasted maternal blood glucose measured using a blood glucose meter at (A) e15.5 (♀ WT (green dot) n = 11 
; ♀ KO (red dot) n = 9) and (B) e18.5 of gestation (♀ WT (green dot) n = 18; ♀ KO (red dot) n = 14). Each symbol 
corresponds to an individual maternal measurement. Data are shown as box and whisker plots with median (long 
line) and mean (cross) indicated. Significance was analysed by Student’s t-test. ns = > 0.05; ** p = ≤ 0.01; *** p 
= ≤ 0.001; **** p = ≤ 0.0001. 
 
Given this result, it was also of interest to examine the mRNA levels of other placental nutrient 
transporters. Thus the levels of three isoforms of system A placental amino acid transporters 
Snat-1 (Slc38a1), Snat 2 (Slc38a2) and Snat-4 (Slc38a4), were examined. These were chosen 
as data suggests they dysregulated in genetic and dietary models of IUGR (Constancia et al., 
2002; Jansson et al., 2006; Kusinski et al., 2012; Malandro et al., 1996; Stanley, 2012). Amino 
acid transporter Snat-2 mRNA levels were unaltered in Pabp4 +/- placentas from Pabp4+/+ and 
Pabp4-/- females in comparison to Pabp4+/+ placentas from Pabp4+/+ females at e15.5 (Figure 
5.19). At e18.5 Snat-2 mRNA levels were statistically higher in Pabp4 +/- placentas from 
Pabp4-/- females in comparison to Pabp4+/+ placentas whilst Snat-1 and Snat-4 remained 
unaltered (Figure 5.20). Equivalent amino acid transporter mRNA levels in Pabp4-/- females in 
comparison to control at e15.5 with a subsequent increase in Snat-2 mRNA levels at e18.5 may 
be indicative of a compensatory mechanism for abnormal amino acid levels or transport. 
However, reciprocal crosses to rule out a fetal genotype effect at e18.5 remain to be completed. 
Although the expression levels of the Glut and Snat genes was normalised to the expression of 
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the most stable housekeeping gene out of two  ideally they should be normalised to at least two 
housekeeping genes as the use of only one may lead to relatively large errors. 

































G lu t-1 G lu t-3
    W T x      K O
    W T x      K O





Figure 5.17 The expression of facilitated glucose transporter marker genes is unaltered in Pabp4+/- 
placentas, regardless of parental genotype, and in Pabp4+/+ controls.  
qRT-PCR for facilitated glucose transporters in e15.5 placentas. Each expression value was been normalised to 
the expression value of Sdha, the most stable housekeeping gene out of two determined using SLqPCR package 
in R. (♂ WT x ♀ WT (green bar) n = 6; ♂ WT x ♀ KO (red bar) n = 6; ♂ KO x ♀ WT (blue bar) n = 5). 
Significance was analysed by Kruskal-Wallis test and Dunn’s multiple comparison test.. ns = > 0.05. 
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Figure 5.18 Facilitated glucose transporters, Glut-1 and Glut-3, are up-regulated in Pabp4+/- placentas 
from Pabp4+/+ females at e18.5. 
qRT-PCR for facilitated glucose transporters in e18.5 placentas. Each expression value was been normalised to 
the expression value of Sdha, the most stable housekeeping gene out of two determined using SLqPCR package 
in R. (♂ WT x ♀ WT (green bar) n = 11; ♂ WT x ♀ KO (red bar) n = 9). Significance was analysed by Student’s 
t-test. * p = ≤ 0.05. 
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Figure 5.19 The expression of amino acid transporter reporter gene, Snat-2, is downregulated in Pabp4+/- 
placentas from Pabp4+/+ females.  
 qRT-PCR for amino acid transporters in e15.5 placentas. Each expression value was been normalised to the 
expression value of Sdha, the most stable housekeeping gene out of two determined using SLqPCR package in R.  
(♂ WT x ♀ WT (green bar) n = 6; ♂ WT x ♀ KO (red bar) n = 6 ; ♂ KO x ♀ WT (blue bar) n = 5). Significance 
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Figure 5.20 Amino acid transporter, Snat-2, is up-regulated in Pabp4+/- placentas from Pabp4+/+ females at 
e18.5. 
qRT-PCR for amino acid transporters in e18.5 placentas. Each expression value was been normalised to the 
expression value of Sdha, the most stable housekeeping gene out of two determined using SLqPCR package in R.  
(♂ WT x ♀ WT (green bar) n = 11; ♂ WT x ♀ KO (red bar) n = 9). Significance was analysed by Student’s t-test. 






In the previous chapter, I demonstrated that Pabp4-/- mice present with a maternal genotype-
dependent reduction in the F:P ratio. One explanation for this may be placental insufficiency 
and therefore the aim of this chapter was to test the hypothesis that placental development at 
the feto-maternal interface and/or placental structure and/or function is altered in Pabp4-/- 
dams. PABP4 and PABP1 expression at the feto-maternal interface had not previously been 
investigated and it was not known which cell types, and their cognate functions, may be 
impacted by the deletion of Pabp4. Interestingly, investigation in e5.5 implantation sites 
revealed that PABP4 expression is present in the endometrial glandular epithelium and non-
decidualised stromal fibroblasts surrounding the primary decidual zones, in which PABP4 is 
largely absent (Figure 5.2 A). PABP1 showed more widespread expression including weak 
staining in the decidual zone (Figure 5.2 B). It may therefore be hypothesised that PABP1 may 
be more important for decidualisation. However, PABP4 is absent in the stromal cells prior to 
conception (Figure 5.1 A.), making it tempting to speculate that its burst of expression in the 
non-decidualised stromal fibroblasts surrounding the primary decidual zone may play some 
role in their morphologic, metabolic, and secretory changes that mark the transition to decidual 
cells and which allow for proper embryo implantation (Abrahamsohn and Zorn, 1993). Future 
expression studies at earlier stages will be needed to determine when the burst of PABP4 is 
initiated. Delineating the timing of onset of PABP4 expression provide some insight into the 
signal that induces stromal cell PABP4 expression and may inform on any potential role in 
decidualisation. However, PABP4 is also expressed in the endometrial uterine glands which 
are also important for implantation and decidualization as they secrete factors that support the 
early stages of pregnancy including amino acids, glucose and lipids and importantly LIF which 
is critical for blastocyst attachment and implantation (Filant and Spencer, 2013; Paiva et al., 
2009). The importance of the glandular epithelium is shown by studies in which deletion of 
centromere protein B (Cenpb) induces abnormal uterine and glandular epithelium, resulting in 
age-dependent reproductive deterioration with females unable to produce more than one litter 
(Fowler et al., 2000).  
At e8.5 PABP4 and PABP1 show very similar patterns of expression (Figure 5.3) and are 
primarily found in the ectoplacental cone and mesometrial decidua basalis, which is infiltrated 
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by a high number of macrophages and lymphocytes, primarily uNK cells.. Additionally, both 
PABP1 and PABP4 are expressed in non-decidualised stromal fibroblasts found outside of the 
secondary decidual zone at the anti-mesometrial pole (Figure 5.3 A, B). The ectoplacental cone 
is the result of continued proliferation of the polar extraembryonic ectoderm, is the first sign 
of placental development and contains precursors of the spongiotrophoblast cells and 
secondary TGCs (Bevilacqua, 2014). The anti-mesometrial and mesometrial endometrium are 
two distinct anatomical regions of the pregnant mouse uterus which exhibit differing biology 
and physiology. Decidualisation initially occurs at e4.5 anti-mesometrially proximal to the 
implanting embryo resulting in a clear distinction between the implantation sites from inter-
implantation regions. Decidualisation then spreads to the mesometrial endometrium and 
continues to expand towards the myometrium, however, a region of non-decidualised cells is 
preserved throughout gestation near the myometrium, where PABP1 and PABP4 are highly 
expressed, in contrast to decidualised cells (Figure 5.3). At e8.5 the majority of the mesometrial 
decidua facing the myometrium has not yet decidualised but is highly infiltrated by CD45+ 
leukocytes (Yamada, 2014). The mesometrial decidua is also the site of trophoblast invasion, 
maternal vascular remodelling and placental development. These raise the possibility that the 
knockout of Pabp4 could directly impact the processes associated with the mesometrial 
endometrium such as trophoblast invasion, maternal vascular remodelling and placental 
development.  
Multiplex detection of PABP4 and/or PABP1 with specific leukocyte markers will be needed 
to establish which of these are expressing one or both PABPs. However, mouse models where 
these leukocytes are compromised or completely absent (Croy et al., 1997) (Guimond et al., 
1999; Guimond et al., 1997), would predict abnormal vascular remodelling, poor mesometrial 
decidual development and small placentas if their function was affected by loss of PABP4. 
Currently we have no evidence of any of these phenotypic characteristics since spiral arteries 
appear to be adequately remodelled in Pabp4-/- dams, as indicated by the absence of smooth 
muscle actin (Figure 5.14), placentas are an equivalent size to that of Pabp4+/+ dams.  
Whilst our data argue that PABP4 does not appear to be absolutely essential for decidualisation, 
or can be compensated for by PABP1 (see below), enabling implantation, this process may be 
less overtly compromised by its absence leading to downstream consequences that ultimately 
manifest in the observed phenotypes. Markers can be used to investigate the decidualisation 
process include desmin (Glasser and Julian, 1986), alkaline phosphatase (ALP) (Finn and 
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Hinchliffe, 1964), decidual prolactin-related protein (dPRP) (Candeloro and Zorn, 2007) and 
bone morphogenetic protein 2 (BMP2) (Lee et al., 2007) in Pabp4-/- mice. If appropriate, 
induced decidualisation can also be studied in pseudopregnant Pabp4-/- mice, for example, 
using blastocyst-sized Sepharose beads (Concanavalin A-coated) which in contrast to an 
intraluminal oil injection or scratch only induces “focal decidualisation” instead of the whole 
uterine horn (Bany, 2014; Yamada, 2014), more closely mirroring decidualisation triggered by 
a blastocyst.  
As mentioned above, PABP1 may be able to compensate for the lack of PABP4 at e5.5 and 
e8.5 as its expression pattern appears to include most, if not all, maternal PABP4 expressing 
cells. To gain more insight into potential compensation, qualitative (IHC) expression of PABP1 
in Pabp4-/- implantation sites would be informative, although a lack of change would not rule 
out compensation given their expression patterns. However, the altered shape of implantation 
sites from Pabp4-/- dams suggests that PABP4 may have distinct roles in early pregnancy which 
PABP1 is unable to fully compensate for. This is consistent with previous studies where 
PABP4 was unable to fully rescue the PABP1-knockdown phenotypes in X. laevis (Gorgoni et 
al., 2011). Alternatively, PABP4 and PABP1 may have identical functional roles but may differ 
in their expression in a given cell type with meaning PABP1 is not available to compensate, 
more detailed co-expression studies would inform on this. Finally, even if present and 
functionally equivalent, PABP1 may be unable to fully compensate if total PABP levels are 
critical.  
It is unknown what underlies the change in the shape of implantation sites from Pabp4-/- dams. 
The ectoplacental cone appears to be visually grossly normal, i.e. no obvious misorientation, 
difference in size or anomalies such as blood pools and ECM debris between the tip of the EPC 
and the mesometrial decidua, as for example reported in Mmp9-null embryos which fail to 
implant properly (Plaks et al., 2013). Further investigation of the peri-implantation period is 
required, e.g. timing of implantation, decidualisation, trophoblast invasion depth and number 
of somites in embryo (to check for developmental delay), particularly considering that the 
M/AM distance is increased when compared both as individual data points but also when 
averaged per litter (Figure 5.4). Defects occurring during the peri-implantation period have 
been reported to have ripple effects with consequences later in gestation such as embryo 
crowding, defective decidualisation, placentation, intrauterine growth and miscarriages as 
reviewed by Cha et al. (Cha et al., 2012). 
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Our data also establish that PABP4 and PABP1 are expressed in the mature placenta (e18.5), 
with PABP4 present in the junctional zone with more limited expression in the decidua basalis 
and labyrinth zone (Figure 5.7). In contrast, PABP1 has a more widespread pattern of 
expression. At e18.5 placentas from Pabp4-/- dams have a decreased junctional zone volume 
and an increased decidua basalis volume with no change in labyrinth in comparison to placentas 
from Pabp4+/+ dams (Figure 5.9). It is unclear whether these differences arise independently 
or whether one is causative of the other as suggested by the size changes appearing reciprocal. 
There are several models of IUGR with a reduced junctional zone which are dependent on fetal 
and/or placental genotype or a low maternal protein diet, however, to our knowledge no models 
have been reported where the decidua basalis is increased. This unusual finding may reflect 
that unlike other IUGR models, our phenotype is dependent on maternal genotype. The decidua 
basalis is the fetal-maternal interface were fetal trophoblast come into contact with maternal 
decidual cells and vasculature and communication between the two sides is particularly 
important in early gestation when the decidua is being invaded and spiral arteries are being 
remodelled, thus it acts as a site of maternal protection and control of trophoblast invasion. 
Further functions of the decidua include maternal immunomodulation, to protect against 
immune attack on the semi-allogeneic conceptus, and paracrine control of uterine vascular 
remodelling (Yamada, 2014). In later gestation the function of the decidua is not well studied 
and it is largely regarded as the point of attachment of the fetus and mother and the site of 
maternal blood entry into the labyrinth as well as a barrier. It is also the region to which the 
glycogen cells migrate to from the junctional zone prior to mobilisation of their glycogen stores 
for energy (Coan et al., 2006). As the decidua basalis, in contrast to the rest of the placenta, is 
maternal in origin and therefore is the only part of the placenta which is Pabp4-/- in our studies, 
changes in its size are intriguing. The basis for this increase, as well as its potential 
consequences on placental function and/or feto-maternal communication should be 
investigated further. For instance, expression analysis of PABPs and morphological analysis 
with appropriate markers at key intermediate stages of placenta development (i.e. e10.5 and 
e13.5) in Pabp4+/+ and Pabp4-/- placentas may shed light on the origins of these differences 
e.g. timing of onset. Similarly, the use of markers at e18.5 could inform on the changes in 
cellular composition that account for the increased size and glycogen assays could shed light 
on whether there is a failure to mobilise glycogen stores for energy which could affect fetal 
growth and comparative decidua basalis size. The function of the junctional zone is better 
understood; it has an important endocrine role, producing hormones such as placental growth 
factor and placental lactogens, which effect embryonic growth both directly and indirectly by 
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stimulating maternal adaptation to pregnancy. In support of reduced junctional zones being 
implicated in impaired fetal growth, the smallest placentas of WT mouse litters have a reduced 
junctional zone but also decidua basalis at e16 which coincides with the fetus being 
significantly smaller in comparison to their litter mates (Coan et al., 2008). By e19 the 
junctional zone and decidua were found to be comparable to larger placentas and the fetuses 
were noted to catch up in their growth (Coan et al., 2008). Intriguingly Coan et al also noted 
that reduced junctional zones at e16 was accompanied by significant upregulation of the system 
A amino acid transporter system, reminiscent of our own observations that Snat-2 is 
upregulated in Pabp4-/- dams at e18.5 (Figure 5.18). Thus it is interesting to speculate whether 
a smaller junctional zone negatively affects amino acids availability to the fetus due to its role 
in regulation maternal adaptation to pregnancy, and that upregulated amino acid transport may 
reflect a compensatory change? Evidence suggests that placental lactogens produced by the 
junctional zone interact with leptin to increase appetite and food intake which is one possible 
mechanism by which it may increase amino acid availability in normal pregnancy (Ladyman 
et al., 2010). Further histological analysis with markers can shed light on whether reductions 
in specific cell type populations or size account for the difference and standard molecular 
techniques can be used to determine whether the expression of key hormones are altered (e.g. 
qRT-PCR, ELISA).  
It is important to remember that the junctional zone is fetal rather than maternal origin and that 
the maternal genotype dependence of the IUGR and mid-late fetal death means that the primary 
defect that drives these phenotypes does not lie in the junctional zone. Rather changes in the 
junctional zone are a downstream consequence of this initial defect but may still be integral to 
the disease mechanism. Whilst this may be true, it is important to remember that the volumetric 
analysis that identified this junctional zone reduction did not include a reciprocal cross. This 
means that Pabp4+/+ and Pabp4+/- junctional zones were compared. Thus it is formally possible 
that fetal Pabp4 heterozygosity leads to the reduced junctional zone, and it is therefore 
genetically separable from the phenotype development. In contrast a normal size junctional 
zone in the reciprocal cross would lend further weight to the hypothesis that the reduced 
junctional zone is downstream of the initial maternally derived deficit but may nonetheless be 
important in phenotype development e.g. via inappropriate maternal adaptation. Thus this 
analysis could prove powerful.  
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Investigations of blood flow waveforms and RI of the uterine artery using Doppler ultrasound 
suggest that remodelling of the uterine artery is normal in Pabp4-/- dams (Figure 5.12) and this 
is further supported by normal blood flow and RI of the umbilical cord (Figure 5.13) as during 
hypoxia the fetus directs blood supply to the brain which results in reduced flow and increased 
vascular resistance in the umbilical artery. Therefore, both normal uterine artery remodelling 
is also consistent with the symmetrical IUGR of fetuses in Pabp4-/- dams.  We were unable to 
quantify uterine artery blood flow velocity as the small size of the uterine artery and its 
curvatures, together with the limitations of the greyscale Doppler, prevented us from accurately 
determining the direction of blood flow: this requires the angle between the ultrasound beam 
and the direction of blood flow to be known and as close as possible to 0° (Qu, 2014). Another 
limitation of using greyscale Doppler is that locating the uterine artery is more difficult and 
less certain. Other arteries are located in the vicinity of the uterine artery and have relatively 
similar Doppler waveforms and blood velocities to the uterine artery including the femoral 
artery, middle caudal artery, cranial vesical artery and the hypogastric trunk (Qu, 2014) In an 
attempt to avoid mistaking these arteries for the uterine artery a consistent anatomical location 
(bottom left or bottom right of the bladder, close to the utero-cervical junction) was chosen 
when being located. Doppler measurements of the uterine artery in non-pregnant females were 
not determined as the uterine artery is even smaller in non-pregnancy and we were not able to 
locate it. Fetal umbilical arteries on the other hand are easily located and the direction of blood 
flow is unambiguous. Abnormal umbilical artery Doppler is a marker of haemodynamic 
uteroplacental insufficiency and fetal distress and is defined by increased RI values resulting 
from reduced end diastolic flow which may become completely absent and eventually reverse 
(Maulik et al., 2010). At least three umbilical arteries of three different fetuses within each 
litter where assessed in each mother, providing more statistical power than for the 
measurements of the uterine artery. Considering that, similarly to the uterine artery, the 
umbilical RI index was no different in KO and WT females this is strongly indicative of normal 
uterine artery remodelling and adequate blood flow provided to the uteroplacental unit. 
Furthermore, adequate decidual spiral artery remodelling as indicated by the absence of smooth 
muscle actin (Figure 5.14).   
Intriguingly, the RI of the common carotid artery is increased in pregnancy when compared to 
non-pregnancy (Figure 5.10 C, D) as its elasticity declines towards the end of pregnancy 
(Karkkainen et al., 2014). Although initially measured as a control, an apparent genotype 
specific difference in this artery was noted during pregnancy. The physiological relevance of 
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this remains unclear since hypertension is mainly associated with stiffness in smaller vessels 
and we have no evidence of hypertension in Pabp4-/- mice, although tail plethysmography to 
examine their blood pressure would more direct inform on this point. 
Interestingly, maternal non-fasted circulating glucose levels of Pabp4-/- dams are equivalent to 
WT females at both e15.5 and e18.5 (Figure 5.16), yet fetal glucose levels of fetuses from 
Pabp4-/- dams have significantly lower blood glucose levels in comparison to fetuses from 
Pabp4+/+ dams (Figure 5.15). Suboptimal glucose and/or amino acid delivery to the fetus due 
to absence of maternal Pabp4 would be predicted to retard growth e.g. dysregulated fetal 
glucose homeostasis due to an absent/aberrant signal from the Pabp4-/- dam to its fetuses.  
Whilst it is unclear whether these reduced glucose levels are causal or a consequence of an 
alternative lesion, Glut-1 and Glut-3 expression is unaltered at e15.5 (Figure 5.17) but 
upregulated at e18.5 (Figure 5.18), a time at which Snat2 an amino acid transporter is also 
upregulated (Figure 5.20), suggestive of a potential compensatory change in expression. 
Although these results are interesting it is important to consider that the qPCR data of glucose 
and amino acid transporters presented in this thesis was normalised using only one reference 
gene. Normalisation is a critical step in the qPCR assay because it controls for variations in 
extraction yield, reverse-transcription yield, and efficiency of amplification and therefore 
enables the comparison of mRNA concentrations between samples (Bustin et al., 2009). There 
are a number of important criteria that a reference gene should fulfil including most importantly 
no change in expression levels in response to experimental factors, minimal variability in its 
expression between tissues and shows a similar threshold cycle with gene of interest (Kozera 
and Rapacz, 2013). Normalisation against a single reference gene is considered not be 
acceptable without confirmation of its invariant expression under the experimental conditions 
used (Bustin et al., 2009) and although this was confirmed to be the case for Sdha that was used 
for normalisation, it is strongly suggested that more than one stably expressed reference gene 
should be used to prevent misinterpretation of expression data (Chervoneva et al., 2010; 
Vandesompele et al., 2002). There is evidence that normalisation to a single housekeeping gene 
can lead to erroneous normalisation due to inherent noisy oscillations in expression levels of 
control genes (Vandesompele et al., 2002) and in the  light of this at least three proper control 
genes are recommended to be used and a geometric average of these obtained to determine a 
suitable normalisation factor. Therefore, in the future this experiment should be ideally 
repeated with the suitable number of reference genes.  
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Additionally, it remains to be confirmed whether any transporter changes are also present at 
the protein level.  Hormone assays (e.g. insulin) and metabolite (eg. cholesterol) analysis may 
be useful in further understanding the metabolic state of the mother and amino acid and glucose 
transport assays in vivo/ex vivo could be carried out to determine the transport capacity of the 
placenta (see chapter 7).   
 
This chapter provides the first insights into the underlying changes that are present in Pabp4-/- 
mice that may lead to phenotype development. These include changes in placental morphology 
i.e. reduced junctional zone and increased decidua basalis. Furthermore fetal but not maternal 
glucose was reduced and an increase in mRNA levels for nutrient transporters that reside in the 




















Pabp4-/- females, mated with a male of any genotype, give rise to IUGR fetuses which have an 
increased incidence of late gestational lethality between e18.5 and birth. Thus this model is 
useful for understanding a spectrum of closely related pregnancy disorders which encompasses 
IUGR and stillbirth. The placentas of fetuses from Pabp4-/- dams were found to be abnormal; 
having reciprocally altered volumetric proportions of two of the three main constituent layers. 
Specifically, the decidua basalis is increased in volume whereas the junctional zone is 
decreased, whilst the labyrinth remains unaltered. Whilst these changes may contribute or 
underlie the observed phenotypes, the placenta is largely fetal in origin but its formation and 
function rely on a complex feto-maternal dialogue, and its function is important for maternal 
pregnancy adaptation. Thus we hypothesis that defects in the materno-fetal dialogue or 
maternal adaptations may represent the primary defect, although their complex intertwined 
relationship makes it challenging to identify which phenotypic alterations, resulting from 
PABP4 loss, are causal as opposed to effect. Here we investigate aspects of maternal 
physiological adaptation to pregnancy including changes in body and organ weight, maternal 
haematology and hormonal and metabolic profile. In so doing we also examine these 
parameters in non-pregnant females allowing identification of pre-existing changes in maternal 
physiology which may contribute to IUGR-stillbirth. All parameters were compared to a 
control group of Pabp4+/+ dams. To inform these investigations, the expression patterns of 
mammalian PABP4 and PABP1 proteins in maternal organs were addressed as such 






6.2 Results  
 
The expression of PABP4 and PABP1 was examined in a number of key maternal organs 
including the liver, pancreas, spleen and kidney to identify organs and cell types which may be 
affected by loss the of PABP4 and cannot adequately adapt to pregnancy. PABP1 expression 
was also examined to determine organs/cells types in which PABP1 is relatively poorly 
expressed and which may therefore be more dependent on PABP4 function, and/or in which 
compensatory changes may take place. Expression was investigated in non-pregnant and 
pregnant e18.5 Pabp4+/+ and Pabp4-/- females. All the immunohistochemical analysis 
consisted of at least 3 biological and two technical replicates. In addition to an IgG negative 
control included in each immunohistochemistry run, the specificity of the PABP4 antibody was 
further probed by the use of tissue from Pabp4-/- females.  In all cases, Pabp4+/+ and Pabp4-/- 
non-pregnant and pregnant tissues were run on separate slides therefore it is not possible to 
draw inference from any intensity differences between these states. Thus Western blotting was 
also done to accompany the IHC as it is more likely to reveal changes in protein levels when 
in the linear range. The IHC being very informative, nonetheless, with respect to determining 












Figure 6.1. PABP4 and PABP1 expression in the adult non-pregnant and pregnant liver. 
Immunohistochemical analysis of PABP4 and PABP1 expression in non-pregnant (A, B) Pabp4+/+ and (C, D) 
Pabp4-/- liver and in the liver from e18.5 of gestation of (E, F) Pabp4+/+ and (G, H) Pabp4-/- females. Rabbit IgG 
control (insert in G and H). NP: non-pregnant. Antibody details: PABP4 (Sigma) used at 1/1000, PABP1 (in 




Figure 6.2. Western blot of PABP4 and PABP1 in Pabp4+/+ non-pregnant and pregnant liver. 
10µg of whole cell liver extract of non-pregnant and pregnant females at e18.5 gestation western blotted with anti-
PABP4 (in house; 1/1000), PABP1 (in house; 1/5000) and GAPDH (Sigma; 1/10,000). NP, non-pregnant; kDA,  
kilo Daltons.  
 
The liver is the largest solid organ with multiple functions including glycolytic metabolism and 
blood detoxification. Thus in pregnancy enhanced liver function is essential for meeting the 
energy demands of the fetus and for detoxification of fetal metabolites. This occurs via a 
combination of increased hepatocyte proliferation and cell size (Dai et al., 2011; Milona et al., 
2010). Immunohistochemical analysis revealed that PABP4 was detectable in the majority of 
hepatocytes, the predominant cell type of the liver, in the Pabp4+/+ non-pregnant liver (Figure 
6.1 A), and in e18.5 pregnant liver (Figure 6.1 E). The observed pattern in non-pregnant 
females is consistent with data in a male mouse from another researcher in the lab using a 
different PABP4 antibody, although detection was stronger in that case (H. Burgess, pers. 
comm.). It appears likely that the non-pregnant tissue here may be under-stained as the stronger 
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detection noted by H. Burgess is more consistent with the multi-tissue western blot (Figure 
1.15) and with the Western blot here (Figure 6.2), which shows that PABP4 protein is present 
at similar levels in non-pregnant and pregnant liver, although a shorter exposure may unmask 
differences. PABP4 was absent Pabp4-/- liver, confirming antibody specificity (Figure 6.1 C, 
G). PABP1 was also found to be expressed in hepatocytes with no difference in expression 
pattern of between non-pregnant Pabp4+/+ and Pabp4-/- liver (Figure 6.1. B, D), although 
western blots, indicated that PABP1 levels were diminished during pregnancy. Interestingly, 
at e18.5, PABP1 did show altered pattern of expression between wild-type and Pabp4-/- livers, 
where some hepatocytes showed more intense immunoreactivity (Figure 6.1  F, H), suggesting 
potentially compensatory changes in PABP1 expression. In this regard it is interesting to note 
that not all hepatocytes are functionally identical and that the liver also contains hepatic oval 
cells, a small subpopulation of intra-hepatic stem cells induced by injury or inhibited 
proliferation (Fausto and Campbell, 2003; Petersen et al., 1998). Therefore the use of markers 








Figure 6.3. PABP4 and PABP1 expression in the adult non-pregnant and pregnant pancreas. 
Immunohistochemical analysis of PABP4 and PABP1 expression in non-pregnant (A, B) Pabp4+/+ and (C, D) 
Pabp4-/- pancreas and that from e18.5 of gestation (E, F) Pabp4+/+ and (G, H) Pabp4-/- females. Rabbit IgG control 
(insert in G and H). NP: non-pregnant. Antibody details: PABP4 (Sigma) used at 1/1000, PABP1 (in house) used 
at 1/3500. x20 magnifications and 50 µm scale bars are shown. 
 
The pancreas is an important exocrine and endocrine organ and in pregnancy pancreatic -cells 
in the islets of Langerhans become increasingly sensitive and hyperfunctional, producing more 
insulin to combat the insulin resistance which manifests in the second half of gestation 
(reviewed by (Ernst et al., 2011; Sorenson and Brelje, 1997). Failing to do so can lead to 
development of gestational diabetes mellitus which increases the risk of fetal mortality and 
morbidity (Devlieger et al., 2008). Interestingly, immunohistochemical analysis revealed that 
PABP4 and PABP1 show largely reciprocal expression in the endocrine and exocrine cells of 
the Pabp4+/+ pancreas (Compare Figure 6.3. A and B). Specifically, PABP4 was found to be 
easily detectable in the exocrine acinar cells of the Pabp4+/+ pancreas which synthesize, store 
and secrete digestive enzymes, and barely detectable in the islets of Langerhans. In contrast, 
PABP1 showed barely detectable expression in the acinar cells but stronger expression in the 
islets of Langerhans (Figure 6.3. A, B). This expression pattern has been independently 
confirmed in male mice (H. Burgess and J. Scanlon, pers. comm). No difference in the 
expression pattern of PABP4 was observed between the non-pregnant and e18.5 Pabp4+/+ 
pancreas (Figure 6.3. A, E). The weak PABP4 staining in the islet of Langerhans in e18.5 
Pabp4-/- pancreas (Figure 6.3. G) is also present in the negative control (Figure 6.3. insert in 
G), suggesting a degree of non-specific binding to this region of the pancreas. Intriguingly, the 
relative staining of PABP1 in the exocrine cells in Pabp4-/- females (Figure 6.3 B) suggests 
that it may be upregulated in the exocrine tissue in the absence of PABP4. Similar observations 







Figure 6.4. PABP4 and PABP1 expression in the adult non-pregnant and pregnant spleen.  
Immunohistochemical analysis of PABP4 and PABP1 expression in non-pregnant (A, B) Pabp4+/+ and (C, D) 
Pabp4-/- spleen and in the spleen from e18.5 of gestation of (E, F) Pabp4+/+ and (G, H) Pabp4-/- females. Rabbit 
IgG control (insert in G and H). NP: non-pregnant; WPMZ: white pulp marginal zone. Antibody details: PABP4 
(Sigma) used at 1/1000, PABP1 (in house) used at 1/3500. x20 magnifications and 50 µm scale bars are shown. 
 
 
Figure 6.5. Western blot of PABP4 and PABP1 in Pabp4+/+ non-pregnant and pregnant spleen. 
10µg of whole cell spleen extract of non-pregnant and pregnant females at e18.5 gestation western blotted with 
anti-PABP4 (in house; 1/1000), PABP1 (in house; 1/5000) and GAPDH (Sigma; 1/10,000). NP – non-pregnant; 
kDA – kilo Daltons.  
 
The spleen is the body’s largest lymphatic organ and its functions include the production of 
antibodies, storing platelets, recycling iron, filtering foreign material, old/damaged red blood 
cells and platelets from blood and inducing adaptive immune responses (reviewed by (Mebius 
and Kraal, 2005). In both human and mice the spleen acts as a second site of red blood cell 
production in pregnancy (Fowler and Nash, 1968; Nakada et al., 2014). Immunohistochemical 
staining revealed that in the Pabp4+/+ non-pregnant spleen, PABP4 was expressed in specific 
cell types within the red pulp, the region of the spleen which acts to store iron, erythrocytes 
and platelets and is where blood filtration and haematopoiesis takes place. The cells expressing 
PABP4 in the red pulp may be macrophages, based on morphology and location, but this 
remains to be confirmed using dual labelling with a macrophage specific marker and PABP4. 
More limited expression in sporadic cells is seen within the white pulp, which is involved in 
responding to blood-borne antigens (Figure 6.4. A). The expression pattern of PABP4 did not 
appear to dramatically change upon pregnancy (Figure 6.4. G), nor did its levels (Figure 6.5). 
However, the western blot showed a high degree of variability in PABP4 between biological 
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replicates (Figure 6.5). PABP4 was absent in the non-pregnant and pregnant Pabp4-/- spleen, 
as expected (Figure 6.4. C, G). PABP1 appeared to be absent in the non-pregnant Pabp4+/+ 
and Pabp4-/- spleen (Figure 6.4. B, D), however this result is inconsistent both with the multi-
tissue Western blot (Figure 1.15) and with the Western analysis here, which shows that PABP1 
is present in equal amounts in Pabp4+/+ spleen from non-pregnant and pregnant females (). 
Moreover, it is inconsistent with PABP1 IHC in male mice using the same antibody (H. 
Burgess pers. Comm.) which revealed PABP1 expression throughout the different zones 
including the white pulp, white pulp marginal zone and red pulp of the spleen similar to females 
at e18.5 of gestation (Figure 6.4. F, H). Thus the weight of evidence suggests that the absence 
of PABP1 in non-pregnant spleen is due to a technical failure, although this remains to be 










Figure 6.6. PABP4 and PABP1 expression in the adult non-pregnant and pregnant kidney.  
Immunohistochemical analysis of PABP4 and PABP1 expression in non-pregnant (A, B) Pabp4+/+ and (C, D) 
Pabp4-/- kidney and in the kidney from e18.5 of gestation of (E, F) Pabp4+/+ and (G, H) Pabp4-/- females. Rabbit 
IgG control (insert in G and H). NP: non-pregnant; WPMZ: white pulp marginal zone. X40 magnifications are 
shown Antibody details: PABP4 (Sigma) used at 1/1000, PABP1 (in house) used at 1/3500. X40 magnifications 
and 50 µm scale bars are shown. 
 
The kidney is an important organ for the excretion of specific waste products, the regulation of 
water and solute excretion, secretion of hormones whilst also playing a role in haemodynamics, 
red blood cell production and bone metabolism (Adamson, 1996; Fukagawa et al., 2006). 
Although the initial multi-tissue panel (Figure 1.15, n=1 mouse), suggested that PABP1 and 
PABP4 were not expressed in kidney, subsequent western analysis on additional mice has 
detected their expression within kidney (M. Brook, pers comm.). In the Pabp4+/+ non-pregnant 
kidney, PABP4 was present in glomeruli and tubules appearing more pronounced in distal 
compared to proximal tubules (Figure 6.6. A), although markers are required to confirm the 
identity of proximal versus distal tubules, PABP expressing cell types within glomeruli (e.g. 
glomerular epithelium or mesangium) or structures such as Bowman’s capsule. This expression 
pattern did not appear to change upon pregnancy (Figure 6.6. E) and PABP4 expression was 
absent in Pabp4-/- kidneys, confirming specificity (Figure 6.6. C, G). PABP1 expression pattern 
was similar to that of PABP4 in both non-pregnancy and pregnancy (Figure 6.6. B,) and no 
changes were observed upon the KO of PABP4 (Figure 6.6. D, H).  
Although further work is required to validate and complete this dataset (see discussion), it 
nonetheless confirms the presence of PABP4 and PABP1 in these organs and provides a first 
insight into their distribution in non-pregnant females and at e18.5 of pregnancy. Importantly, 
as each of these organs undergo changes integral to the maternal adaptation response and 
adaptation in one or more of these organs could be compromised in Pabp4-/- females leading 
or contributing to the observed phenotypes.  
 
Maternal adaptation of the organs frequently includes changes in their weight, which tends to 
be normalised to body weight. Moreover, low female bodyweight prior to pregnancy and 
inadequate weight gain during pregnancy are associated with poor pregnancy outcome. This is 
often caused by low maternal circulating nutrients (Frederick et al., 2008; Mathews et al., 
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2004). Thus both non-pregnant and pregnant body weight was examined to enable 
normalisation for organ size but also to investigate whether Pabp4-/- dams have reduced 
bodyweight prior to pregnancy or exhibit altered weight gain during pregnancy that may 
contribute to the observed phenotypes. To this end, the weights of non-pregnant females and 
mated females (presumed pregnant) at the time of detection of a copulatory plug were recorded 
and normalised to age. The weight of females at plugging is comparable to that of non-pregnant 
females, therefore, data collected for these two groups was combined, providing the necessary 
power. Bodyweights of the mated females were also recorded at the three collection time-points 
including mid- (e13.5), mid-late (e15.5) and late pregnancy (e18.5), to address weight gain. No 
differences were found in age to weight ratios between Pabp4-/- and Pabp4+/+ females to/at the 
start of pregnancy (Figure 6.7), apparently ruling out low body weight prior to pregnancy as a 
causative factor for the poor pregnancy outcome. 
A sizeable component in maternal weight gain is due to growing fetuses and their associated 
placentas, which will differ between Pabp4+/+ and Pabp4-/- females due to IUGR and litter size, 
as gestation proceeds. Thus maternal body weight was measured post hysterectomy at e13.5, 
e15.5 and e18.5. Interestingly, at e13.5 maternal weight gain (calculated as a percentage of 
body weight gain) was significantly lower in Pabp4-/- dams compared to Pabp4+/+ dams but at 
later time-points (e15.5 and e18.5) were indistinguishable (Figure 6.8 A, B, C).  As stands, the 
data suggest that Pabp4-/- dams initially gain less weight but appear to catch-up by mid-late 
pregnancy, however the n numbers need to be increased to confirm this finding. Such initial 
low weight gain followed by catch up later in pregnancy, may reflect an altered lipid 
metabolism in Pabp4-/- dams which could in turn have a detrimental impact on fetal growth. 
Lipids stores put on by the dam in early pregnancy are utilised for maternal energy output in 
late gestation whilst the majority of glucose intake is directed to the fetus. If this maternal 
adaptation is disrupted an adequate supply of glucose to enable exponential fetal growth in late 
gestation may not be available. In support of this, fetuses in Pabp4-/- females have reduced 
glucose levels at e15.5 and e18.5 (Figure 5.15, Chapter 5).  However, this may be the result of 
aberrant glucose transport across the placenta rather than altered lipid/glucose metabolism. 
Levels of cholesterol and free fatty acids (FFA) and hormones associated with glucose 
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Figure 6.7. Age to body weight ratio of Pabp4-/- females is comparable to that of Pabp4+/+ females prior to 
pregnancy. 
The age of Pabp4+/+ (WT, green dots; n = 60) and Pabp4-/- (KO, red dots; n = 39) females divided by weight at 
the time of plugging. Data are shown as shown as box and whisker plots with the median (long line) and mean 
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Figure 6.8. Percentage weight gain of Pabp4-/- dams may be compromised in early pregnancy. 
Weight gain expressed as a percentage calculated from maternal bodyweight at the time of plugging and 
hysterectomised bodyweight at collection. Percentage weight gain of Pabp4+/+ females (green dots): e13.5 (n = 
6), e15.5 (n = 19), e18.5 (n=22). Percentage weight gain of Pabp4-/- females (red squares): e13.5 (n = 3), e15.5 (n 
= 8), e18.5 (n=5). Data shown as individual data points with means connected on an XY graph. Significance was 





















































Figure 6.9. Differences in maternal age at the time of plugging of females subsequently collected at e13.5, 
e15.5 and e18.5. 
Maternal age at the time of plugging of Pabp4 +/+ females (green dots) and Pabp4 -/- females (red dots) 
subsequently collected at (A) e13.5 (Pabp4 +/+ n = 7; Pabp4 -/- n = 6); (B) e15.5 (Pabp4 +/+ n = 25; Pabp4 -/- n = 
13) (C) e18.5 (Pabp4 +/+ n = 30; Pabp4 -/- n = 19). Data are shown as shown as box and whisker plots with the 
median (long line) and mean (cross) indicated. Significance was analysed by student’s T-test. * p =   0.05; ** p 
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Figure 6.10. Age has no bearing on the bodyweight of Pabp4+/+ and Pabp4-/- females plugged in the age 
window of 8-12 weeks however the KO cohort had a lower non-pregnant bodyweight. 
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Bodyweight versus age at the time of plugging of (A) Pabp4+/+ females (n = 40) and (B) Pabp4-/- females (n = 
30). Data is presented on X/Y scatterplot with mean (full line), 5 and 95% percentiles (dotted lines) indicated. The 
relationship between X and Y was determined by calculating R square (R2) and a P value was calculated from an 
F test to determine the probability that a randomly selected point would result in an R2 value as high as  the one 
observed. (C) Non-pregnant bodyweight of Pabp4+/+ females (n = 40) and Pabp4-/- females (n = 30). Data are 
shown as shown as box and whisker plots with the median (long line) and mean (cross) indicated. Significance 
was analysed by student’s T-test.  *** p =   0.001. 
 
Remarkably, all maternal organ systems undergo physiological changes to adapt to pregnancy, 
with the expression of PABP4 in key organs leading us to hypothesise that maternal organs 
may not adequately adapt leading to adverse pregnancy outcome. To this end, maternal organ 
weights, including the liver, kidney, spleen and heart, were examined prior to and at e13.5, 
e15.5 and e18.5 of gestation. In collecting this data and taking into account the data from 
Figures Figure 6.7 and Figure 6.8, it became clear that it was important to establish whether 
age differences between some of the cohorts (Figure 6.9) had the potential to confound the 
analysis of organ size: although all females were between 8-12 weeks in age, the Pabp4-/- 
pregnant females collected at e15.5 were significantly younger within the given age-frame (WT 
age mean = 75.17 days ± 1.618; KO age mean = 66.31 ± 2.246) whereas at e18.5 they were 
significantly older (WT age mean = 67.67 days ± 1.395; KO age mean = 73.71 ± 1.1968) 
(Figure 6.9. A, B, C).  This difference was mainly the result of the low number of Pabp4-/- mice 
by weaning, therefore Pabp4-/- mice tended to be plugged as soon as sexually mature (approx. 
8 weeks) whereas Pabp4+/+ mice were more readily available and random sampling 
inadvertently led to a skew in ages). This may be the reason why overall Pabp4-/- females had 
a lower bodyweight prior to pregnancy (Figure 6.10, C) as when the bodyweight of females 
was corrected for age no difference was found between Pabp4+/+ and Pabp4-/- females (Figure 
6.7) which implies that it is not a genotype dependent effect. However, if Pabp4-/- females do 
truly have reduced bodyweights as a failure to catch up postnatally this would imply growth 
restriction in utero not only due to an adverse maternal environment but also due to a 
pathological process in Pabp4-/- fetuses and therefore should be investigated further. A 
correlation coefficient, R square (R2), was calculated for age and maternal bodyweight 
recorded at the time of plugging for both Pabp4+/+ and Pabp4-/- females to determine whether 
age is indeed a confounding factor (Figure 8 focused on genotypic influence and was age 
corrected). Furthermore a P value was calculated from an F test to determine the probability 
that a randomly selected point would result in an R2 value as high as the one observed. This 
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analysis revealed that age in the window of 8-12 weeks at the time of plugging does not 
correlate with maternal bodyweight of Pabp4+/+ or Pabp4-/- females (Figure 6.10 A, B) and 
therefore is not a confounding factor in interpreting differences in organ weights. Using the 
same analysis it was found that organ weights, similarly to bodyweight, do not correlate with 
age. Additionally, the relationship with other potential confounding factors such as maternal 
bodyweight prior to pregnancy (at plugging) and at the time of collection were also analysed 
for each organ (for full analysis of all organs see Appendix; Figure 8.1, Figure 8.2, Figure 8.3, 
Figure 8.4). Resultantly, Pabp4-/- and Pabp4+/+ organ weights were compared as raw organ 
weights but also in cases where bodyweight, at the time of plugging or at the time of collection, 
were found to be a confounding factor (liver, kidney, heart) were also normalised. This is 
demonstrated for liver and kidney; kidney weight strongly correlates with maternal weight at 
the time of plugging for both genotypes (Figure 6.11 A, B), whereas liver weight only strongly 
correlates with maternal Pabp4-/- bodyweight (Figure 6.11 C, D). It is possible that the genotype 
dependent confounding factors for some of the organs may be a part of the Pabp4-/- phenotype 
and therefore should be taken into consideration, thus where appropriate the data is provided 
























Deviation from zero? Not Significant




















Deviation from zero? Significant






















Deviation from zero? Significant



























Figure 6.11. Liver weight is positively correlated with maternal bodyweight at collection in Pabp4-/-, but not 
Pabp4+/+, females whereas the weight of the kidney is positively correlated with maternal bodyweight prior 
to pregnancy independent of genotype. 
The weight of the liver collected at e15.5 plotted against the maternal hysterectomised bodyweight at e15.5 of (A) 
Pabp4+/+ females (n =11) and (B) Pabp4-/- females (n =8). The weight of the kidney collected at e15.5 plotted 
against the maternal hysterectomised bodyweight when a plug was found of (C) Pabp4+/+ females (n = 25) and 
(D) Pabp4-/- females (n =14). Data is presented on X/Y scatterplot with mean (full line) 5 and 95% percentiles 
(dotted lines) indicated. The relationship between X and Y was determined by calculating R square (R2) and a P 
value was calculated from an F test to determine the probability that a randomly selected point would result in an 
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Figure 6.12. Raw spleen weight changes during pregnancy. 
Raw spleen weights from non-pregnant (NP) females and females at day e13.5, e15.5 and e18.5 of gestation. 
Spleen weights from Pabp4+/+ females (green dots): (NP n = 25; e13.5 n = 8; e15.5 n = 24; e18.5 n = 18); from 
Pabp4-/- females (red squares): (NP n = 12; e13.5 n = 8; e15.5 n = 15; e18.5 n = 15). Data are shown as means 
with standard deviation (SD) indicated as error bars. Significance was analysed at each time-point by student’s T-
test. ns p = ≥ 0.05; * p =  0.05;  ** p =   0.01. 
 
Raw spleen weights were found not to be correlated with maternal age or bodyweight and 
therefore normalisation was not required. Splenic adaptations to pregnancy include an increase 
in size, associated with the expansion of red pulp which becomes an important secondary site 
of erythropoiesis (Fowler and Nash, 1968; Mattsson et al., 1984; Nakada et al., 2014). This 
contributes to the increase in RBC mass that is observed during pregnancy and enables the 
spleen to cope with the need to filter an increased blood volume. In Pabp4+/+ dams, spleen 
weights increased significantly between non-pregnancy and e13.5 but returned to its original 
weight by late gestation at e18.5 (Figure 6.12) as previously reported (Bustamante et al., 2008). 
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The spleen of  Pabp4-/- dams followed the same trajectory but failed to reach the same increase 
in weight at e13.5 and e15.5 (Figure 6.12) suggesting that the red pulp does not increase in size 
to the same extent as in Pabp4+/+ dams suggesting that splenic erythropoiesis may be negatively 
impacted, potentially resulting in a reduced haematocrit. Blood composition is investigated 
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Figure 6.13. Raw and normalised liver weight changes during pregnancy. 
(A) Raw liver weights from non-pregnant (NP) females and females at day e13.5, e15.5 and e18.5 of gestation 
and (B) liver weights normalised to maternal weight at collection from (NP) females and females at day e15.5 of 
gestation. Liver weights from Pabp4+/+ females (green dots): (NP n = 20; e13.5 n = 7; e15.5 n = 22; e18.5 n = 20); 
from Pabp4-/- females (red squares): (NP n = 13; e13.5 n = 6; e15.5 n = 14; e18.5 n = 18). Data are shown as 
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means with standard deviation (SD) indicated as error bars. Significance was analysed at each time-point by 
student’s T-test. ns p = ≥ 0.05; ** p =   0.01. 
 
Due to the potentially confounding effect of body weight, analysis of organ weights hereafter 
are presented as raw and normalized. The liver of the mouse adapts to the demands of 
pregnancy by increasing in size as a result of hepatocyte hyperplasia and hypertrophy (Dai et 
al., 2011; Milona et al., 2010). The increase in size is evident by e13, peaks at e18 and returns 
to a pre-pregnancy weight by day 10 postpartum (Dai et al., 2011). Enhanced liver metabolism 
is essential to accommodate the increase demand for energy from the developing fetus and the 
detoxification of fetal metabolites. Raw liver weights of Pabp4+/+ females increased in weight 
from a non-pregnant state to e13.5 and remained heavier beyond this time-point but did not 
significantly increase in later pregnancy (Figure 6.13 A). Raw liver weights of Pabp4-/- females 
also increased by e13.5 but not to the same extent as in Pabp4+/+ females (Pabp4+/+ mean = 
1.65±0.03512; Pabp4-/- mean = 1.42±0.04459) suggesting that the Pabp4-/- liver may not adapt 
to pregnancy to the same extent as the Pabp4+/+ liver (Figure 6.13 A). Beyond e13.5 there was 
no statistically significant difference in non-normalised liver weight between Pabp4-/- and 
Pabp4+/+ females (Figure 6.13. A). However, following normalisation, no differences in liver 
weight were found between the genotypes prior to pregnancy or at e15.5 (Figure 6.13 B). 
Insufficient maternal bodyweight information was collected at e13.5 and e18.5 to normalise at 
these time-points (Figure 6.13 B). Whilst it is tempting to speculate that the Pabp4-/- liver is 
transiently smaller at e13.5, suggestive of a suboptimal or delayed adaptation, the absence of 
normalised data for this time-point make any conclusion premature. 
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Figure 6.14. Raw and normalised kidney weight changes during pregnancy. 
(A) Raw kidney weights and (B) kidney weights normalised to maternal weight at plugging a proxy for non-
pregnant (NP) females and females at day e13.5, e15.5 and e18.5 of gestation. Left kidney weights from Pabp4+/+ 
females (green dots): raw (NP n = 26; e13.5 n = 8; e15.5 n = 25; e18.5 n = 20); normalised (NP n = 26; e13.5 n = 
6; e15.5 n = 21; e18.5 n = 20). Left kidney weights from Pabp4-/- females (red squares): raw (NP n = 13; e13.5 n 
= 8; e15.5 n = 15; e18.5 n = 18); normalised (NP n = 11; e13.5 n = 3; e15.5 n = 14; e18.5 n = 11). Data are shown 
as means with standard deviation (SD) indicated as error bars. Significance was analysed at each time-point by 
student’s T-test. ns p = ≥ 0.05; ** p =   0.01; **** p =  0.0001. 
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In Pabp4+/+ dams the kidney increased in weight from prior to pregnancy to e13.5, fell back to 
a lower weight at e15.5 and increased again by e18.5 (Figure 6.14 A). This pattern is disparate 
to that reported in literature where the kidney has been reported to progressively increase in 
size/weight during pregnancy as a result of the dilatation of the collecting system including the 
renal pelvis (funnel for urine flowing to the ureter) and the ureter (duct for urine passing from 
kidney to bladder). This unexpected weight trajectory of the Pabp4+/+ kidney is most likely due 
to a small n number at the e13.5 time-point and should be increased. The weight of Pabp4-/- 
kidneys increased throughout gestation and was equivalent to that of Pabp4+/+ kidneys apart 
from e13.5 when it was significantly smaller. This may be due to the e13.5 collection time-
point being underpowered, resulting in an unusual peak in kidney size in Pabp4+/+ mice (Figure 
6.14  A). Normalised Pabp4-/- kidney weights were comparable to Pabp4+/+ prior to pregnancy, 
at e13.5 and e18.5 but significantly greater at e15.5 (Figure 6.14 B). Thus, similarly to the liver 
data, the method of analysis impacts the outcome and interpretation (e.g. Pabp4-/- kidneys both 
with respect to the timing and whether Pabp4-/- kidneys are larger or smaller. This discrepancy 
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Figure 6.15. Raw and normalised heart weight changes during pregnancy. 
(A) Raw heart weights and (B) heart weights normalised to maternal weight at plugging from non-pregnant (NP) 
females and females at day e13.5, e15.5 and e18.5 of gestation. Heart weights from Pabp4+/+ females (green dots): 
raw (NP n = 25; e13.5 n = 8; e15.5 n = 23; e18.5 n = 21); normalised (NP n = 17; e13.5 n = 6; e15.5 n = 23; e18.5 
n = 29). Heart weights from Pabp4-/- females (red squares): raw (NP n = 13; e13.5 n = 8; e15.5 n = 15; e18.5 n = 
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18); normalised (NP n = 11; e13.5 n = 3; e15.5 n = 14; e18.5 n = 11). Data are shown as means with standard 
deviation (SD) indicated as error bars. Significance was analysed at each time-point by student’s T-test. ns p = ≥ 
0.05; ** p =   0.01. 
 
Similarly to the other organs, the heart also undergoes physiological changes during pregnancy, 
primarily due to the increase in blood volume and resultant cardiac volume (reviewed by 
(Chung and Leinwand, 2014). These changes result in cardiac hypertrophy whereby the heart 
muscle gains mass and an increase in chamber dimension which may be associated with wall 
thickness. The maternal raw heart weights of Pabp4+/+ females increased from a non-pregnant 
state to e13.5 and, similarly to the liver, remained heavier beyond this point until late gestation 
(Figure 6.15 A) (Chung and Leinwand, 2014). These weight changes were paralleled by Pabp4-
/- heart weights (Figure 6.15 A). Pabp4+/+and Pabp4-/- heart weights were also equivalent 
following normalisation except for e15.5 when Pabp4-/- heart weights were significantly 
heavier (Figure 6.15 B). An increase in heart weight in Pabp4-/- dams at e15.5 may be 
suggestive of pathological rather than physiological hypertrophy however the disparity 




Table 6.1. Summary of organ weight changes and PABP4 expression. 
 
In summary, with the exception of spleen, the data on organ weight in Pabp4-/- dams are 
affected by whether they are considered as raw or normalised weights (summarised in Table 
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6.1). When considered as raw weights the liver, kidney and the spleen, but not the heart, are 
significantly reduced at e13.5 and may potentially explain the significantly reduced maternal 
weight gain also observed at e13.5 (Figure 6.8.).  When the organ weights are normalised this 
weight reduction is lost and the weight for some organs is increased (kidney, heart) at e15.5 
(both normalised to maternal weight at plugging) (summarised in Table 6.1). , It remains to be 
determined which analysis method is most appropriate and normalisation to brain weight, as 
often done in toxicology studies may prove useful as it is not affected by bodyweight, correlates 
with age and importantly does not change with pregnancy. Unfortunately, brain weights were 
not obtained at the time of collections and therefore this normalisation cannot be done with the 
current dataset. Another frequently used method that may have utility is tibia length. However, 
our data with spleen suggest that at least one aspect of maternal adaptation deviates from that 
seen in Pabp4 +/+ mice.  
 
Many of the physiologic changes that occur in pregnancy are the result of an interplay between 
hormones, growth factors and cytokines produced by the placenta and maternal organs. 
Therefore the levels of several factors in maternal plasma were examined to test the hypothesis 
that the circulating levels of one or more of these factors may be altered in the Pabp4-/- mouse 
due to dysregulated production. The ovarian hormones, estradiol and progesterone, are 
essential for the establishment (Adams and DeMayo, 2015), maintenance (Beagley and Gockel, 
2003) and initiation of parturition of pregnancy but also contribute to maternal adaptations e.g. 
heart (Chung and Leinwand, 2014) and haematopoietic system (Nakada et al., 2014). Chung 
and Leinwand (2014) grouped serum progesterone and estradiol levels of rodents from 
previous reports to show that serum progesterone increases in early pregnancy, peaks at e15-
16 of pregnancy and significantly decreases by e18 (Chung and Leinwand, 2014). In contrast 
to this human serum progesterone concentration rises in a linear fashion up until term 
(Johansson, 1969; Tulchinsky et al., 1972) and unlike in rodents and some other species there 
is no dramatic drop in human progesterone prior to parturition (Tulchinsky et al., 1972). There 
is a lack of data regarding serum estradiol changes from non-pregnant into and throughout 
pregnancy in mouse, but it has been reported to peak on e18-19 and decrease 0-1 days post-
partum (dpp) (Chung and Leinwand, 2014). In humans, similarly to progesterone, estradiol 
concentrations increase as pregnancy progresses (Levitz and Young, 1977; Lindberg et al., 
1974; Tulchinsky et al., 1972). To test whether Pabp4-/- females present with a hormonal 
imbalance plasma estradiol and progesterone levels were quantified using ELISA at e18.5, a 
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time-point by which IUGR is well established and just prior to the major decrease in litter size. 
Interestingly, maternal plasma estradiol was significantly decreased in Pabp4-/- compared to 
Pabp4+/+ females (Figure 6.16. A), whereas progesterone was significantly increased (Figure 
6.16. B). Despite the absence of defects in implantation rates in Pabp4-/- mice, the role of these 
sex steroids in pregnancy maintenance means that alterations in their levels, particularly 






































Figure 6.16. Pabp4-/- dams have an imbalance of estradiol, progesterone at e18.5. 
Maternal blood plasma of Pabp4+/+ (WT; green dots) and Pabp4-/- females (KO; red dots) collected at e18.5 
analysed using competitive time resolved fluorescence immunoassay (TRFIA) to determine levels of (A) estradiol 
(WT n = 10; KO n = 12), (B) progesterone (WT n = 8; KO n = 12). Data are shown as shown as box and whisker 
plots with the median (long line) and mean (cross) indicated. Significance was analysed by student’s T-test. ** p 
= ≤ 0.01. 
 
In addition to the classic sex steroid hormones, other growth factors, hormones and metabolites 
in the maternal circulation are also key in fetal growth and survival. IGF-1 and IGF-2 are both 
important determinants of fetal growth (Baker et al., 1993; DeChiara et al., 1990; Liu et al., 
1993) and placentation (Holmes et al., 1998; Qiu et al., 2005) but exert their effects by different 
mechanisms. IGF-1 acts by directly affecting fetal growth and diverting maternal adipose stores 
to the fetus in late pregnancy (Sferruzzi-Perri et al., 2006). IGF-2 on the other hand alters 
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placental development to favour fetal growth (Sferruzzi-Perri et al., 2006). Therefore, IGF-1 
maternal plasma levels were investigated at e15.5, at which point IUGR is apparent, and at 
e18.5, prior to increased incidence of fetal death. However, neither of these time-points showed 
difference in maternal plasma levels of IGF-1 between Pabp4-/- and Pabp4+/+ female (Figure 
6.17 A, B), suggesting that aberrant maternal adaptation due to changed IGF-1 levels are not 


































Figure 6.17.Maternal plasma IGF-1 levels are comparable in Pabp4-/- and Pabp4+/+ dams at both e15.5 and 
e18.5. 
Maternal plasma IGF-1 levels measured using ELISA immunoassay from Pabp4+/+ (WT; green dots) and Pabp4-
/- (KO; red dots) females collected at (A) e15.5 (WT n = 10; KO n = 9) and at (B) e18.5 (WT n = 4; KO females n 
= 12). Data are shown as shown as box and whisker plots with the median (long line) and mean (cross) indicated. 
Significance was analysed by student’s T-test. ns p = ≥0.05. 
 
As discussed, fetal growth is sensitive to the nutritional status of the mother and as a result of 
needing to balance the demands of the fetus with that of the mother, many changes in maternal 
metabolic and even behaviour (e.g. appetite) occur during pregnancy. Lipid metabolism alters 
in pregnancy to increase fat storage in early gestation and enhance lipid catabolism in late 
gestation providing an alternative maternal energy source to carbohydrates enabling the 
nutritional demands of the growing fetus to be met (Alvarez et al., 1996; Lopez-Luna et al., 
1991; Montelongo et al., 1992). The switch from maternal carbohydrate to fat utilization, 
partitioning glucose for the feto-placental unit whose energy demands are particularly high in 
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late gestation is the result of progressive insulin resistance (Butte, 2000). Insulin levels rise to 
partly overcome the resistance and prevent gestation diabetes mellitus developing (Brelje et 
al., 1994; Parsons et al., 1992). Concurrently, there is a rise in leptin levels, an adipocytokine 
associated with insulin resistance and the switch in metabolism (Fasshauer and Paschke, 2003; 
Weyer et al., 2001). Maternal hyperleptinemia, isolated from maternal obesity or diabetes, has 
been shown to result in reduced fetal birthweight (Makarova et al., 2013; Yamashita et al., 
2001). To investigate this, non-fasted maternal insulin and leptin plasma levels were measured 
at e18.5 to discern whether Pabp4-/- females have comparable levels to those of Pabp4+/+ 
females. Maternal plasma insulin was found to be comparable between the genotypes, however, 
intriguingly, maternal leptin was found to be significantly increased in Pabp4-/- females (Figure 
6.19 A, B). It is important to note that plasma levels do not inform on the maternal sensitivity 
to insulin and leptin, which would require tolerance testing. These would be useful in 
determining whether a disrupted response to insulin and/or leptin may be implicated in the 
development of the phenotype. However, the increased levels of leptin suggest that lipid 
metabolism may be disrupted which has the potential to be a contributing causal factor to the 
phenotype. In keeping with this idea, abnormal cholesterol and FFA levels have been reported 
for Pabp4-/- mice in the EUKOMM pipeline which are on high fat diet 
(http://www.mousephenotype.org/data/experiments?geneAccession=MGI:2385206&mpTerm
Id=MP:0005376&mpTermId=MP:0005375). However, no data on mice maintained on normal 
diet or when pregnant is available.   
It is known that low-density lipoprotein cholesterol (LDLc) and triglycerides (TGs) increase 
progressively in gestation (Belo et al., 2002; Serdar et al., 2003) whereas high-density 
cholesterol (HDLc) begins to decrease post midgestation (Belo et al., 2002). Dyslipidemia is 
associated with pregnancy complications such as pre-eclampsia where an increase in LDLc, 
TG levels and a decrease HDLc levels have been observed (Belo et al., 2002; Var et al., 2003). 
This increased hyperlipidemic state may lead to atherosis, atherosclerosis-like" lesions, in 
maternal decidual vessels and reduced placental perfusion which may result in altered placental 
transfer of nutrients (Catarino et al., 2008). To test whether Pabp4-/- females have altered lipid 
profiles, non-fasted maternal plasma HDLc and LDLc and FFA were determined but were 
found to be comparable in Pabp4-/- and Pabp4+/+ females at e18.5 (Figure 6.18 A, B, C). The 
power of the Pabp4+/+ female cohort for LDLc was very low and therefore additional numbers 
would therefore strengthen this tentative conclusion. This result is, however, in line with the 
229 
 
Doppler results in chapter 5, which showed normal resistance index suggesting that the 
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Figure 6.18.Maternal plasma levels of high-density and low density lipoprotein cholesterol and free fatty 
acid are comparable in Pabp4-/- and Pabp4+/+ dams at e18.5. 
Maternal blood plasma of Pabp4+/+ (WT; green dots) and Pabp4-/- females (KO; red dots) collected at e18.5 
analysed using Randox colourimetric assay to determine levels of (A) high-density lipoprotein (HDL)  (WT n = 
9; KO n = 12), (B) low-density lipoprotein (LDL) cholesterol (WT n = 10; KO n = 12) and a half micro test kit to 
determine (C) free fatty acids (FFA). Data are shown as shown as box and whisker plots with the median (long 
line) and mean (cross) indicated. Significance was analysed by student’s T-test. ns p = ≥ 0.05. 
 
Finally, plasma levels of maternal corticosterone were examined. Corticosterone has been 
shown to have an important role in regulating nutrient allocation between the mother and the 
feto-placental unit during periods of stress such as food restriction whereby it limits fetal 
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growth by reducing the amino acid supply and density of blood vessels in the placenta 
(Vaughan et al., 2012). Interestingly comparisons of plasma from Pabp4+/+ and Pabp4-/- 
females, revealed that maternal corticosterone was significantly decreased in Pabp4-/- females 
(Figure 6.19 C) which has the potential to also be important in the phenotype and therefore this 
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Figure 6.19. Pabp4-/- dams have normal plasma insulin levels, increased leptin levels and reduce 
corticosterone levels at e18.5. 
Maternal blood plasma of Pabp4+/+ (WT; green dots) and Pabp4-/- females (KO; red dots) collected at e18.5 
analysed using electrochemical luminescence immunoassay to determine levels of (A) insulin (WT n = 9; KO n = 
12), (B) leptin (WT n = 10; KO n = 12),  and a competitive enzyme immunoassay (EIA) to determine (C) 
corticosterone (WT n = 10; KO n = 10). Data are shown as shown as box and whisker plots with the median (long 




Similarly to other systems, the haematological system also undergoes changes to adapt to 
pregnancy and to accommodate the fetoplacental unit. The levels of both white and red cells 
are critical in pregnancy and the spleen which becomes a site of red cell production was 
comparatively reduced in size during mid-pregnancy in Pabp4-/- females (Figure 6.12). As a 
first step towards determining if Pabp4-/- females have a maladapted haematological system, I 
examined their haematological state in non-pregnancy, as timing constraints did not allow for 
the necessary breeding cohorts to be set up for equivalent pregnancy based studies. To this end, 
we conducted a haematological investigation a of red blood cells, white blood cells and platelet 
in whole blood from non-pregnant Pabp4-/- and Pabp4+/+females. This revealed that platelet 
and white blood cell count (the number of cells in a given volume of blood) were normal, with 
equivalent numbers of neutrophils, lymphocytes, monocytes and eosinophils (see Appendix 
Figure 8.5, Figure 8.6). Red blood cell (RBC) counts also showed no significant difference. 
Additional red blood cell characteristics were also examined. Importantly the haematocrit 
(HCT) which is the measure of volume of red blood cells as a percentage of whole blood was 
decreased. Whilst this is not due to a decrease in red cell number (1.21 A), or red blood cell 
distribution width (RDW) (1.21 F), the mean cell volume (MCV) (the average size of red blood 
cells) was decreased (1.21 D). Consistent with a reduced MCV, haemoglobin (Hb) 
(concentration measurement of total haemoglobin per volume of whole blood) was reduced 
(Figure 6.20C.) although mean cell haemoglobin (MCHC) (haemoglobin concentration divided 
by haematocrit) was not (Figure 6.20D.).  
This data indicate that the red blood cells in non-pregnant Pabp4-/- mice are reduced in volume 
(microcytic) and contain less haemoglobin, hinting at a possible pre-existing condition, and 
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Figure 6.20.Red blood cell count and red blood cell indices analysis-of non-pregnant Pabp4+/+ and Pabp4-/- 
females. 
Analysis of non-pregnant (NP) Pabp4+/+ (WT; green dots; n = 10) and Pabp4-/- female blood (KO; red dots; n = 
6) using an automated flow cytometer-based haematological analyser. (A) Red blood cell count and (B) 
haematocrit (HCT), (C) red blood cell haemoglobin (Hb), (D) mean cell haemoglobin concentration (MCHC), 
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(E) mean cell volume (MCV), (F) red cell distribution width (RDW). Data are shown as shown as box and whisker 
plots with the median (long line) and mean (cross) indicated. Significance was analysed by student’s T-test. ns p 






The aim of this chapter was to shed light on the potential role of maternal physiology and 
adaptations to pregnancy in Pabp4-/- females. Whilst the genetics show that the primary defect 
is maternal in nature, they do not clarify whether the phenotype arises as a result of a pre-
existing, but perhaps subtle, deficit in maternal physiology that becomes “functionally 
relevant” during pregnancy or one that is unique to the pregnant state. Furthermore, the 
placenta changes observed in Chapter 5 raise the possibility that rather than the maternal 
systems being unable to respond and adapt to the correct signals from the placenta, any mal-
adaptation could arise from signalling from the placenta itself being compromised. In the latter 
case, the phenotype may arise from an early failure in materno-fetal communication where a 
deficit in one or more maternal cell type results in incorrect placentation, which in turn leads 
to maternal mal-adaptation. Whilst this is a complex problem, my data sheds some important 
light.  
Firstly, by exploring the expression pattern of PABP4 (and PABP1), we expand upon published 
northern blot data ((Wilkie et al., 2005), to establish that both are expressed in a wide variety 
of tissues (i.e. kidney, liver, pancreas): in some cases showing highly similar (e.g. kidney) and 
others reciprocal expression patterns (e.g. pancreas). Therefore whilst the phenotypes are 
reproductive, the maternal defect may lie, or involve tissues, outside the reproductive tract. 
Confirming these patterns requires further work due to technical issues, a second PABP1 
antibody (or PABP1-/- mouse tissue) to further control for its specificity and a more quantitative 
analysis of cell type specific changes in expression (e.g. immunofluorescence). Moreover 
markers are required to further inform which cells (e.g. in the red pulp of the spleen) are PABP 
expressing to relate these further to our other observations (e.g. genotype-dependent reduction 
in spleen; reduced haematocrit). Additionally, there are several limitations of the western blot 
data of which aimed to investigate whether there are any changes in the levels of PABP4 and/or 
PABP1 in maternal organs from non-pregnancy to pregnancy. Firstly, a negative control was 
not run alongside the samples such as a Papb4-/- sample to rule out any cross reaction, 
particularly with PABP1. Secondly, the signal in some cases varied substantially within a 
cohort of samples and therefore an n of 3 for each group is most likely insufficient to reveal 
any true differences in the levels of PABPs between non-pregnant and pregnant samples. 
Therefore an appropriate n number based on the variability of signal within a group should 
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have first been determined and subsequently used. Lastly, although the level of protein loaded 
per sample was the same, the levels of PABPs were not compared to that of the housekeeping 
gene used (GAPDH) which would have enabled a more quantitative interpretation of the 
results. Overall, these limitations of the western blot data hamper any interpretation of the 
results. However, in the future it would be worth repeating the experiment to accurately 
determine any changes in the levels of PABP4 with pregnancy as this may provide the basis of 
investigating specific organs in more detail as being implicated in the cause of the PABP4 
phenotype. Western blots of the pancreas and kidney were not included in the thesis as they 
technically failed and need to be repeated in the future. It would also be of great interest to 
expand analysis to other organs such as the pituitary, adrenal gland and adipose tissue whose 
function may be relevant to changes uncovered in this chapter and the described pregnancy 
phenotypes.  
Our analysis of PABP expression patterns, body weight and organ weights examined both 
pregnant and non-pregnant mice. Our data suggested that low pre-pregnancy weight was 
unlikely to be a cause of the phenotype, although weight gain was altered in pregnant mice. 
Similarly organ weight, both raw and normalised, argued against a pre-existing effect on their 
size in Pabp4-/- mice. Challenges posed in terms of the most appropriate method of 
normalisation precluded conclusions as to the changes in most organ sizes during pregnancy, 
since normalised and raw values lead to contradictory interpretations. However, spleen showed 
a pregnancy specific reduction in size compared to Pabp4+/+ mice during gestation (e13.5-
15.5), suggesting that this aspect of maternal adaptation has not proceeded normally. Detailed 
histological analysis of organs in which size (and/or functional, see below) genotype-dependent 
changes are present, combined with PABP expression patterns, may provide additional insight 
into their significance with respect to the observed phenotypes (e.g. in spleen does restricted 
expansion of the red pulp underlie the size difference?). Systematic histological analysis 
including use of appropriate markers and stains may also reveal genotype-dependent changes 
within these tissues that are not apparent at gross level (e.g. size). For instance several 
pregnancy specific diseases of the liver have been described (reviewed by (Hay, 2008), 
although they do not correlate well with our observations in Pabp4-/- mice.   
 
In contrast to changes in body weight and organ size that were only observed during pregnancy, 
haematocrit was reduced in non-pregnant Pabp4-/- mice, suggestive of a pre-existing condition 
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that may contribute to the phenotype, as severe anaemia  is associated with IUGR (Wollmann, 
1998). In contrast WBC and platelet counted appeared normal, although substantial further 
work would be needed to rule out a functional deficiency in these cells, with immune cells in 
particular playing important roles in pregnancy. The reduced haematocrit in Pabp4-/- mice 
manifested as a significant reduction in haemoglobin and mean cell volume (MCV) (Figure 
18.), which are features of microcytic anaemia (Massey, 1992), a condition often due to 
nutritional deficiencies or genetic mutations  . This observation is lent weight by recent studies 
that identified PABP4 as a potential regulator of erythroid differentiation in cell lines, as its 
knock-down blunted the terminal stages of differentiation and haemoglobin levels (Kini et al., 
2014). However, it is not yet clear whether abnormal erythropoiesis persists, is exacerbated or 
ameliorated during pregnancy. In non-pregnant adult mice, the bone marrow represents the 
primary site of erythropoiesis, emphasising a need to examine bone marrow and PABP4 
expression therein. However, the red pulp of the spleen represents a second site of 
erythropoiesis during pregnancy with PABP4 being expressed in one, or more, cell types within 
this compartment. Thus it will be of interest to determine whether the reduced expansion of the 
spleen during pregnancy in Pabp4-/- mice correlates with decreased RBC volume in splenic 
erythropoiesis.  
The work here also provides evidence for further work examining the metabolic changes that 
are necessary to meet the nutritional demands of the fetus. Pabp4-/- females show increased 
leptin, decreased corticosterone, decreased fetal blood glucose, and increased mRNA levels of 
glucose and amino acids transporter in the placenta. In contrast insulin, maternal blood glucose, 
cholesterol and FFA appeared within normal range, although further clarity with respect to 
cholesterol levels may be achieved with more animals and fasted glucose and insulin levels 
were not determined. Whilst a clear picture with respect to these metabolic changes is yet to 
emerge, these observations nonetheless inform on the potential origins of the phenotype.  
For instance, expression of PABP4 in the exocrine rather than endocrine, insulin producing, 
cells of the pancreas is consistent with the normal maternal insulin and glucose levels in Pabp4-
/- mice. The exocrine cells synthesize, store and secrete digestive enzymes which break down 
starch, protein and fat when secreted into the small intestine. Abnormal release of these 
hormones can lead to exocrine pancreatic insufficiency (EPI), characterised by an inability to 
properly digest food associated with growth failure, fat-soluble vitamin deficiencies decreased 
bone mineral density and kyphosis (Aris et al., 2005; Grey et al., 2008). Whilst a systemic 
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nutrient deficiency associated with poor nutrient uptake could explain poor fetal growth and 
upregulated placental transporters, Pabp4-/- females do not, for example, have low bodyweight 
prior to pregnancy; apparent concomitant up-regulation of PABP1 in these acinar exocrine 
cells, may therefore be able to partially or completely compensate for loss of Pabp4. As 
discussed earlier, other findings could also inform on the basis of the phenotype, for instance, 
studies of maternal hyperleptinemia (Yamashita et al., 2001) suggest that the observed increase 
in leptin in Pabp4-/- mice (Jansson et al., 2003) could contribute to the IUGR. Its contribution 
could be tested by the use of leptin agonists to reduce leptin levels in the Pabp4-/- mouse.  
Maternal adaptations are driven by multiple secreted factors which derive from both the 
placenta (e.g. placental lactogens) and maternal organs (e.g. oestrogen, progesterone, 
corticosterone) and can often affect multiple target tissues altering their gene expression 
programs to adapt their structure (e.g. size) and/or function. In this regards it was interesting 
that whilst IGF-1 and insulin levels were normal, estradiol, progesterone, leptin and 
corticosterone were all changed, as discussed above. The results of such changes are likely to 
be complex, for instance, estradiol, has multiple adaptation roles meaning it is a candidate 
whose dysregulation could interplay with other changes observed here. For example, estradiol 
insufficiency caused by ovariectomy impairs central leptin sensitivity and increases circulating 
plasma leptin concentrations (Ainslie et al., 2001). Similarly, rising estradiol levels promote 
haematopoietic stem-cell division, frequency and erythropoiesis in the spleen during pregnancy 
(Nakada et al., 2014). Therefore it would be interesting to investigate whether normal leptin 
can be restored by exogenous estradiol or transplantation of wild-type ovaries (the source of 
estradiol), and whether erythropoiesis increases sub-optimally in pregnant Pabp4-/- dams. 
In summary, whilst not an exhaustive study, this work provides evidence that aspects of 
maternal physiology beyond the sites of development of the materno-fetal units in the uterus, 
can influence their growth and survival. Future work (see chapter 7) will be aimed at adding to 
these snapshots to enable a clearer picture to emerge with the ultimate aim of identifying which, 
if any of these changes, are causative.  
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Chapter 7 – Final Discussion 
 
The aim of this thesis was to establish the phenotypic consequences of the loss of PABP4 
function in mammals, extending our previous knowledge of its function in non-mammalian 
vertebrates, and providing the first insight into the role of a non-germ cell specific PABP in 
mammals. In contrast to non-mammalian vertebrates, PABP4 was found not to be essential for 
embryogenesis in mice. Furthermore, the phenotype resulting from the loss of PABP4 differed 
from the phenotypes observed with loss of ePABP in X. laevis and mammals, as it was not 
required for oocyte development, despite being expressed small growing oocytes and granulosa 
cells (Chapter 3). Importantly though, it nonetheless impacted female fecundity as litter size 
was found to be reduced in late gestation and even more so by birth. Critically, this phenotype 
was dependent solely on the maternal genotype with paternal and fetal genotype having no 
impact (Chapter 3). Longitudinal analysis showed that implantation rates were not significantly 
altered but that fetal death was occurring primarily in late gestation (Chapter 3). In association 
with the maternally-dependent reduced litter size, fetuses of Pabp4-/- dams also presented with 
symmetrical IUGR which established prior to the most dramatic reduction in litter size; 
between e18.5 and birth (Chapter 4). However, the time-point at which IUGR becomes first 
apparent still needs to be determined, as the current dataset of the earliest time-point 
investigated (e13.5) is inconclusive. Together, these data provide evidence that Pabp4-/- dams 
offer an attractive, if not unique, opportunity for studying the maternal contribution to related 










Figure 7.1 Similarities between human clinical settings and the Pabp4-/- pregnancy mouse model of IUGR 
and miscarriage/stillbirth. 
In humans, not all pregnancies complicated by IUGR result in miscarriage or stillbirth and not all babies which 
are a ‘normal’ size survive with the underlying causes often unknown. Similarly in the Pabp4-/- mouse model of 
pregnancy, a range of growth restriction is present accompanied by late gestational lethality of a proportion of 
pups, with some more profoundly growth restricted pups born live, showing that the IUGR, does not a priori 
result in fetal death.     
 
Despite the parallels between our model and human pregnancy disorders, it is often difficult to 
know how to relate IUGR datasets in mouse to that in human. In mouse, the genetic potential 
for growth can be relatively easily established, aiding the identification of IUGR. In humans 
SGA is defined as a birth weight below the 10th percentile for gestational age but does not 
distinguish between infants that are constitutionally small due to factors such as maternal 
weight or height, ethnicity or parity, and those that are small as a result of maternal, 
fetal/placental abnormalities and/or environmental factors. According to the World Health 
Organisation (WHO), birthweight below the 10th percentile of the recommended gender-
specific birthweight for gestational age reference curves are considered as IUGR. Using the 
10th percentile as a standard results in over diagnosis and therefore some have suggested using 
the 5th percentile to define IUGR infants (Bernstein, 1996).  
In order to define IUGR observed in Pabp4-/- dams in a similar way to that used clinically in 
humans, we constructed frequency distribution curves, as described previously (Dilworth et al., 
2011), of Pabp4+/+ fetal weights at e18.5 from wild-type crosses and used these to calculated 
the 5th and 10th centiles as well as 25th and 75th centiles. These curves where then used to 
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determine which weights, specific to our wild-type population, represent IUGR versus AGA 
(Figure 7.2). 25% of Pabp4+/- fetuses from Pabp4-/- dams were found below the 10th percentile 
(<1035 mg) and 13.4% were below the 5th (<994.4 mg) in comparison to 25% of fetuses from 
Pabp4-/- dams were below the 10th percentile (<1035 mg) and 13.4% were below the 5th (<994.4 
mg) in comparison to 5.2% and 1.97% from the WT cross, and 1.8% and 0.68% in the 
reciprocal cross.  
 
 
Figure 7.2 Frequency distribution curves for fetal weights from Pabp4-/- and Pabp4+/+ dams at e18.5 shows 
that a higher percentage of fetuses from Pabp4-/- dams are growth restricted and small for their gestational 
age.  
♂ WT x ♀ WT n =134; ♂ WT x ♀ KO n = 117; ♂ KO x ♀ WT n = 83.  5th percentile = 994.4 mg; 10th percentile 
= 1035 mg; 25th percentile = 1101.2 mg ; 75th percentile = 1249.7 mg. Intrauterine growth restriction, IUGR; 
Appropriate for gestational age, AGA; percentile, %tile. 
 
This depiction of results, illustrate that fetal weights in litters from Pabp4-/- females show a 
relatively broad range when compared to other fetal genotype-dependent IUGR models such 
as the P0 mouse, which shows a smaller variation in size and weight reduction (Dilworth et al., 
2011). Importantly it also illustrates not only that are litters in Pabp4-/- females smaller than in 
the WT cross, but also that they are smaller than those in the reciprocal cross, which share 
equivalent genetic background and heterozygosity for Pabp4, showing that those developing 
within a Pabp4-/- in utero environment have not reached their genetic growth potential and are 
growth restricted.  
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Whilst the interpretation that our mice have maternally derived mid-late gestational lethality 
accompanied by stillbirth is fully consistent with the data at hand, several pieces of additional 
evidence would further strengthen these conclusions. Firstly, it is difficult to definitively prove 
that mortality occurred before or during birth rather than immediately after. Cameras for 
filming birth proved ineffective at providing the required level of resolution to distinguish 
between dead and alive newborn fetuses. Secondly, a direct demonstration that Mendelian 
ratios are present at birth would strengthen the conclusion that increased loss of Pabp4-/- pups 
only occurs after birth, as, due to cannibalism of the carcasses, material is seldom available for 
genotyping of pups from inter-crosses that fail to survive. Thirdly, the use of embryo transfers 
in which Pabp4+/+ embryos are transferred into Pabp4-/-recipients and vice versa would further 
provide further insight into the maternal nature of the phenotype. The initial design was to use 
our existing mouse strain. However, the very low success rate of even Pabp4+/+ embryo 
transfers into wild-type C57BL/6 recipients precluded this approach (M. Brook, pers. Comm.). 
Therefore, a hybrid Pabp4+/+ CD1 strain has been created using the breeding strategy in Figure 
7.3 to generate recipients that should enable good embryo transfer, as CD1 females are 
excellent recipients (Pomp et al., 1989). It is important to note that CD1 animals are an outbred 
stock and therefore genetically undefined and exhibit hybrid vigor including early fertility, 
large and frequent litters, low neonatal mortality and rapid growth and these characteristics as 
well as the genomic heterozygosity of these mice may impact the results obtained from the 
embryo transfer experiment and should be considered in interpretation. As discussed earlier, it 
will not be possible to assess effects on litter size using this approach, due to the inherent 
variability of embryo transfer rates, but measures of embryo weight, crown-rump length, 
placenta size and diameter at e18.5 will allow for investigation of the fetal/oocyte contribution 
to IUGR. This experiment is currently ongoing with the prediction that if the IUGR phenotype 
is related to the maternal ability to support pregnancy, but not fetal genotype, Pabp4+/+ embryos 
should present with IUGR in Pabp4-/- dams (as seen with Pabp4+/- fetuses, Chapter 4) and 
Pabp4-/- fetuses in Pabp4+/+ dams should present with normal weight and size. So far no 
differences were found between fetal or placental measurements when Pabp4+/+ and Pabp4-/- 







Figure 7.3 Strategy and design of embryo transfer experiment. 
As C57BL/6 (NTP4) female mice are poor embryo recipients with a very low success rate of implantation, a 
hybrid strain created by crossing of NTP4 and CD1 mice, referred to as NTCD,  was created as outlined above. 




































































































































































Figure 7.4 Weight and size of Pabp4+/+ and Pabp4-/- fetuses and placentas at e18.5 which where 
transferred into Pabp4+/+ NTCD females at the morula stage. (courtesy of Matt Brook) 
Data are shown as box and whisker plots with median (long line) and mean (cross) indicated. Significance was 
analysed by Student’s t-test. ns = > 0.05; * p = ≤ 0.05; ** p = ≤ 0.01; *** p = ≤ 0.001; **** p = ≤ 0.0001. 
 




Insights into the potential underlying cause of the IUGR and mid-late gestational mortality 
have been gained from combined analysis of placentation/placenta as well as maternal 
physiology and adaptation to pregnancy in Pabp4-/- mice (Chapters 5 and 6). In mid-late 
gestation (e15.5 and e18.5) alterations in F:P ratios were detected which were solely due to the 
reduced fetal size with no contribution from changes in placental weight or diameter (Chapter 
4). Volumetric analysis of the placenta did, however, reveal morphological changes in the 
relative volumes of the functional layers. In contrast to many IUGR models, the volume of the 
labyrinth was not altered but reciprocal changes in junctional zone and decidua basalis volumes 
were observed (Chapter 5). Interestingly, several lines of evidence pointed to a possible 
nutritional or metabolic component to the phenotype. For instance, reduced fetal glucose levels 
and potentially compensatory increases in levels of glucose and also amino acid transporter 
mRNAs (Chapter 5) were observed. An attractive hypothesis to explain these findings is that 
the smaller junctional zone compromises maternal adaptation and affects the circulating 
nutrient levels available for transfer. A smaller junctional zone could for example produce for 
example reduced levels of placental lactogen II which has lypolytic properties, promotes the 
expansion of pancreatic B cells and higher insulin levels which help shunt glucose to the fetus. 
Placental lactogens have also been shown to regulate maternal appetite via interaction with 
leptin and adipose tissue (Ben-Jonathan et al., 2006; Ladyman et al., 2010). Therefore it is 
plausible that a smaller junctional may negatively impact maternal metabolic adaptations to 
pregnancy and reduce the availability of both glucose and amino acids.  However maternal 
blood glucose levels were not reduced. This raises the possibility that despite the absence of 
volumetric differences in the labyrinth, its function (e.g. nutrient transport) may be suboptimal 
leading to an attempt to compensate. Plasma analysis revealed that circulating levels of factors 
involved in driving maternal adaptation e.g. metabolism/nutrients were altered, namely leptin, 
corticosterone, estradiol and progesterone (Chapter 6). As these hormonal circuits do not 
operate in isolation but are often interconnected, the possible downstream effects of this are 
complex e.g. estradiol deficiency affects central leptin sensitivity and blood concentration 
(Ainslie et al., 2001). Finally, evidence of a pre-existing reduction in haematocrit (reduced red 
blood cell volume and haemoglobin) and reduced expansion of the spleen during pregnancy 
were obtained (Chapter 6), phenotypes that may be linked. Taken together these results provide 
many avenues for future research into the underlying causes of these pregnancy complications 






Figure 7.5 The underlying cause of the Pabp4-/- phenotype are currently unknown with interplay between 
different observations likely.  
 
 
In interpreting how these data may result in the development of IUGR and/or stillbirth, it is 
important to bear in mind, as detailed in the discussion of chapter 6, the maternal genetics and 
the importance of the materno-fetal dialogue in placentation, and conversely the role of the 
placenta in adapting the maternal physiology. However, many pieces of the puzzle that could 
help to focus future research effort are missing. Notably, we need to know whether the 
morphological and functional placental changes detected thus far, are recapitulated in those 
from the paternal KO (reciprocal) cross, and what changes in cellular composition are present 
(e.g. investigation of cell specific markers). Further functional measures of the placenta at e18.5 
are also required, for instance, to determine whether nutrient transport and/or 
paracrine/endocrine signalling are impacted, and whether glycogen stores are normal. 
Understanding nutrient transfer across the placenta can be gained by confirmation of current 
results at the protein level and similar studies of other transporters, but ultimately functional 
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transport assays should be used. These can examine passive/facilitated diffusion and active 
transport that are involved in nutrient supply/removal of metabolites (e.g. by infusing 
radioactive compounds such as 14C-methyl-D-glucose). Since our data do not point towards a 
defect in fetal vasculature and maternal blood spaces, high-resolution resin cast stereology to 
examine the architecture and to quantify interhaemal distance, the determinant of efficient 
materno-fetal gas exchange, do not appear a priority. Paracrine and endocrine signalling are 
associated with the decidua basalis and junctional zone and any perturbations due to changes 
in their relative volume can be detected by standard approaches such a qRT-PCR, ELISA, and 
radio-immune assays. Endocrine signalling to the corpus luteum of the ovary, for instance, is 
important for regulating estradiol (reduced in Pabp4-/- females) which in turns acts as a signal 
for many aspects of maternal adaptation (e.g. enlargement of spleen, which is blunted in Pabp4-
/- females). To date we have no data implicating alterations in glycogen cells, but glycogen is 
used as a source for energy late in gestation and this involves movement of these cells from the 
junctional zone to the decidua basalis, and can be easily examining using glycogen assays (Lo 
et al., 1970). 
Moreover we need to fill in many more “black boxes”, for example, with respect to events at 
the maternal fetal interface prior to e18.5. Some snapshots are available at e5.5, e8.5 and e15.5 
but events prior to e5.5 or between e5.5 and 8.5, when changes in implantation site shape are 
observed, and whether/how such changes lead to the morphological and functional changes 
observed at e18.5 is unknown. Whilst early events such as decidualisation and the control of 
trophoblast invasion are undoubtedly important questions and link to the maternality of the 
phenotype, arguably more direction may be gained by initially focusing on events between 
e8.5-e18.5, when differences may be more overt. Currently, we have no insight with respect to 
when, and where, PABP4 and PABP1 are expressed at the materno-fetal interface in this 
timeframe, which spans many important milestones in the development of the placenta (e.g. 
gains partial function at e10.5). Moreover, morphological and functional data for placentas 
from Pabp4-/- females at these milestones need to be obtained, applying information and 
approaches from studies at e18.5. This will help build a picture of the how and when changes 
observed at e18.5 may arise: the alterations in implantation site shape observed at e8.5 may be 
the first piece in this puzzle. Correlating the onset of morphological and functional placental 
changes in the initial onset of IUGR is important, and also will require the latter to be 
determined. This correlative information may provide insight into their likely involvement in 
the phenotypes e.g. changes arising after a phenotype is established are likely to be an effect 
(potentially compensatory) rather than a cause. 
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As the genetics point to a primary maternal defect and the placenta plays a major role in 
directing maternal adaptation, it is also important to examine maternal physiology outside of 
the immediate physical materno-fetal interface. To date, our data point to a pre-existing 
difference in red blood cells (microcytic), a change in the relative size of at least one organ 
(spleen) during pregnancy and differences in estradiol, progesterone, leptin and corticosterone 
at e18.5. Prior to pregnancy, red blood cells are normally synthesised in the bone marrow, 
which expresses PABP4 (Figure 1.15, 1.5 Work leading up to PhD project), with the red pulp 
of the spleen acting as a second site of erythropoiesis during pregnancy. Interestingly, the 
relative increase in spleen size during pregnancy is smaller in Pabp4-/-females. Thus it is 
important to determine whether Pabp4-/- mice are also microcytic during pregnancy, whether 
the reduced weight of the spleen is due to a change in the red pulp and whether this is related 
to the reduced red cell volume. Support for a potential role of PABP4 in erythropoiesis comes 
from recent studies in cell lines (Kini et al., 2014). Dependent on outcome, the contribution of 
this pre-existing condition to the phenotype could be further investigated by taking advantage 
of the availability of a second Pabp4 mouse containing the conditional ready allele (with both 
loxP sites intact and functional). For instance this could be bred to locally available VavCre 
mice (Georgiades et al., 2002b), removing Pabp4 from hematopoietic lineages (also some germ 
and endothelial cell expression). Normal pregnancy in these mice would suggest that the 
observed microcytic phenotype does not account for the phenotype. Since this would also target 
myeloid and lymphocyte lineages, this result would also provide additional information on the 
role, or lack thereof, of immune cell populations, which have key reproductive roles. 
Conversely, a recapitulation of the phenotype would imply a causative role, with more refined 
targeting with additional Cre lines allowing insight into the respective roles of different cell 
types. In contrast to data on RBCs, our results argue against low bodyweight prior to pregnancy 
as a pre-existing factor that contributes to the phenotype. However, weight gain is reduced 
during early pregnancy in Pabp4-/- mice, and levels of several hormones related to 
nutrients/metabolism and mRNA levels of placental nutrient transporters altered late in 
pregnancy. Thus the sensitivity of the phenotype to dietary manipulations may be informative 
with respect to whether further work into their nutritional status is warranted.  
Currently, whilst intriguing, information on the hormonal status of Pabp4-/- mice is only 
available at e18.5, making it is unclear when these changes arise. In particular it would be 
informative to link this to the temporal analysis of placental endocrine function (e.g. placental 
lactogen, prolactin levels), placental morphology and IUGR onset. Whilst levels also need to 
be established in non-pregnant mice, their ability to maintain normal implantations rates, argue 
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that at least some of their levels were within a physiological range, prior to and during early 
pregnancy, which is compatible with ovulation and implantation. Determining the temporality 
of these events will shed light on whether these changes are downstream consequences of 
altered maternal adaptation (i.e. due to reduced hormone levels from the junctional zone) that 
nonetheless contribute to the phenotype due to their roles in maternal adaptation. For instance, 
in the redirecting maternal metabolism to meet nutritional needs. As discussed in chapter 6, 
modulation of these circulatory hormones to investigate their roles in phenotype development 
can be achieved by achieved without further genetic manipulation by exogenous 
supplementation, use of antagonists, and if warranted ovarian transplant (to restore estradiol 
and progesterone levels).  
In addition to these “leads”, many aspects of pregnant physiology in the Pabp4-/- mice have not 
yet been established, for instance, interpretable data on organ size was only achieved for spleen, 
and future analysis will include additional measures that can be utilised for normalisation e.g. 
tibia length, brain weight. Moreover, given the abundant evidence for changes in maternal 
adaptation, my data argue for a complete histopathological and body composition work up (e.g 
by TD-NMR time dependent-nuclear magnetic resonance) of pregnant Pabp4-/- mice to provide 
an overview of their health and maternal adaptation status. It is possible that the range of 
changes observed in the maternal environment may point towards a syndrome in which IUGR 
is one consequence and which may be caused by several different factors. There are currently 
no reports a syndrome in humans which matches our observations however anaemia is a known 
maternal factor associated with IUGR and high leptin levels have been reported in women with 
established IUGR (Savvidou et al., 2008).  
In summary, we have only scratched the surface of understanding how Pabp4 loss results in 
these phenotypes, but the above examples illustrate some of the important questions, avenues 
and tools that can be used to advance our knowledge. Whilst work in the shorter term should 
focus on gaining a complete picture of the pathophysiology of IUGR and stillbirth in these 
mice, a clear challenge is to utilise this information to track back to the primary defect. Clearly, 
in the long term, gaining a more cellular and molecular understanding of the phenotype will 
require identification of mis-regulated pathways and mRNAs (e.g. translational profiling 
combined with RNA-Seq), only then will we understand how and why this RNA-binding 
protein is necessary to support normal fetal growth and survival. Although it remains to be 
determined what the underlying cause of IUGR and late fetal death is, the likelihood of it being 
informative on human IUGR and stillbirth is likely  because although differences between the 
two species exists in terms of pregnancy there are many similarities at the level of maternal 
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adaptation to pregnancy such as expansion of blood volume, increase in RBC number and 
insulin resistance as well as similarities at the level placental morphology and function such as 
production of placental lactogens by trophoblast cells which drive maternal adaptation. This 
model recapitulates many of the features associated with the spectrum of pregnancy disorders 
seen in humans, therefore the opportunities offered by it to understand specifically the maternal 
causes of IUGR and stillbirth argue strongly for pursing this challenging goal.  
To date, little insight into the maternal genetic risk factors of IUGR and stillbirth (with the 
exception of genetic factors involving uterine natural killer cells and the remodelling of 
maternal vasculature) is available, meaning there is a lack of information on loci associated 
with these pregnancy complications. At present, it is too premature to look for PABP4 
mutations in women whom have had one, or more, growth restricted and or stillborn fetuses, 
and more information would be required to stratify patients for further study. However, at least 
in non-pregnant human endometrium, the expression patterns observed in mouse for PABP1 
and PABP4 (Chapter 5) were broadly conserved, suggesting that it is present at the site at which 
the materno-fetal interface will subsequently develop. Moreover, translation of our findings is 
not dependent on the identification of patients containing PABP4 mutations, as study of the 
PABP4 mouse will reveal insight into maternal pathways which are important in pregnancy. 
Therefore, this work lays the foundation for disease causing mutations to be identified in these 
pathways, in addition to PABP4 itself.  
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Figure 8.1 Liver weight at e15.5 of Pabp4-/- but not Pabp4+/+ dams correlates with maternal 
weight at collection.  
The weight of Pabp4+/+ (n =11) and Pabp4-/- (n =8) liver collected at e15.5 plotted against (A, B) age, 
(C, D) maternal hysterectomised bodyweight at collection and (E, F) maternal bodyweight when plug 
was found. Data is presented on X/Y scatterplot with mean (full line) 5 and 95% percentiles (dotted 
lines) indicated. The relationship between X and Y was determined by calculating R square (R2) and a 
P value was calculated from an F test to determine the probability that a randomly selected point would 
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Figure 8.2 Kidney weight at e15.5 of Pabp4-/- and Pabp4+/+ dams correlates with weight when 
plug was found.  
The weight of Pabp4+/+ (n =11) and Pabp4-/- (n =8) kidney collected at e15.5 plotted against (A, B) age, 
(C, D) maternal hysterectomised bodyweight at collection and (E, F) maternal bodyweight when plug 
was found. Data is presented on X/Y scatterplot with mean (full line) 5 and 95% percentiles (dotted 
lines) indicated. The relationship between X and Y was determined by calculating R square (R2) and a 
P value was calculated from an F test to determine the probability that a randomly selected point would 
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Figure 8.3  Heart weight at e15.5 of Pabp4-/- but not Pabp4+/+ dams correlates with weight when 
plug was found.  
The weight of Pabp4+/+ (n =11) and Pabp4-/- (n =8) heart collected at e15.5 plotted against (A, B) age, 
(C, D) maternal hysterectomised bodyweight at collection and (E, F) maternal bodyweight when plug 
was found. Data is presented on X/Y scatterplot with mean (full line) 5 and 95% percentiles (dotted 
lines) indicated. The relationship between X and Y was determined by calculating R square (R2) and a 
P value was calculated from an F test to determine the probability that a randomly selected point would 


















































Deviation from zero? Not Significant






















Deviation from zero? Not Significant






















Deviation from zero? Not Significant






















Deviation from zero? Not Significant






























Figure 8.4 Spleen weight at e15.5 of Pabp4-/- and Pabp4+/+ dams do not correlate with age, 
maternal bodyweight or weight when plug found  
The weight of Pabp4+/+ (n =11) and Pabp4-/- (n =8) spleen collected at e15.5 plotted against (A, B) age, 
(C, D) maternal hysterectomised bodyweight at collection and (E, F) maternal bodyweight when plug 
was found. Data is presented on X/Y scatterplot with mean (full line) 5 and 95% percentiles (dotted 
lines) indicated. The relationship between X and Y was determined by calculating R square (R2) and a 
P value was calculated from an F test to determine the probability that a randomly selected point would 
result in an R2 value as high as  the one observed. 
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Figure 8.5 Platelet count is unaltered in Pabp4-/- non-pregnant females. 
Platelet count using an automated flow cytometer-based haematological analyser of non-pregnant 
Pabp4+/+ (green dots; n = 10) and Pabp4-/- females (red dots; n = 7). Data are shown as shown as box 
and whisker plots with the median (long line) and mean (cross) indicated. Significance was analysed by 


















































































































































































Figure 8.6 White blood cell count and differential white blood cell count of non-pregnant 
Pabp4+/+ and Pabp4-/- females. 
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Analysis of non-pregnant Pabp4+/+ (WT; green dots; n = 10) and Pabp4-/- female blood (KO; red dots; 
n = 7) using an automated flow cytometer-based haematological analyser. (A) White blood cell count 
and differential count analysis; (B) neutrophils (segmented), (C) lymphocytes, (D) monocytes, (E) 
eosinophils. Data are shown as shown as box and whisker plots with the median (long line) and mean 
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